-1 	|BT| (NP (NP (NN BACKGROUND/AIMS)) (: :) (NP (NP (JJ Several) (NN study)) (VP (VBD reported) (NP (NP (NP (NP (NP (NN efficacy) (NN combination) (NN therapy) (NN interferon)) (PRN (-LRB- -LRB-) (NP (NN IFN)) (-RRB- -RRB-))) (NN alpha) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 617:D12.644.276.374.440 618:E02.186|ES| 10:1 14:1 19:1 104:1 130:1 131:1 303:1 304:1 441:1 530:1 993:1 1836:1 2302:1 2303:1 2304:1 2305:1 2306:1 2307:1 2308:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND/AIMS)) (: :) (NP (NP (DT The) (NN success) (NN sorafenib) (NN treatment)) (VP (VBD advanced) (SBAR (S (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBD focused) (NP (NN interest) (NN role) (NN Ras) (NN signaling) (NN malignancy))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 52:E02 69:G02.111.087.800 104:C04.557.470.200.025.255|ES| 10:1 14:1 19:1 31:1 49:1 104:1 195:1 303:1 304:1 441:1 546:1 691:1 997:1 1775:1 2063:1 2302:1 2309:1 2310:1 2311:1
-1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (NP (NNP Magnolol) (, ,) (NN plant) (NN lignan)) (NP (VBN isolated) (NN bark) (NN seed) (NN cone) (NN Magnolia) (NN officinalis)) (, ,) (VP (VBN shown) (NP (JJ chemopreventive) (NN effect) (JJ chemically-induced) (NN skin) (NN cancer) (NN development))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 328:B01.650 619:D02.455.426.559.847.117.159.205 620:B01.650.940.800.575.100.680.500 621:D02.455.426.559.389.140.450 622:A08.675.650.850.625.670.100 623:A08.186.211.730.885.287.500 624:D27.505.696.706.018 625:A06.407.071.140 626:A05.810.453.324 627:A18.024.500.750|ES| 2:1 18:1 19:1 35:1 75:1 104:1 237:1 1046:1 1098:1 1653:1 1946:1 2233:1 2312:1 2313:1 2314:1 2315:1 2316:1 2317:1 2318:1 2319:1
-1 	|BT| (NP (NP (NP (NNP Brucine) (NN alkaloid) (VBN derived) (NN seed) (NNS Strychnos)) (NP (JJ nux-vomica) (NNP Linn)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 629:E02.190.488 630:Z01.252.474.164 631:D03.132|ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 1721:1 2315:1 2320:1 2321:1 2322:1 2323:1 2324:1 2325:1 2326:1 2327:1 2328:1
-1 	|BT| (S (S (NP (NP (NP (JJ Caffeic) (NN acid) (NN phenethyl) (NN ester)) (PRN (-LRB- -LRB-) (NP (NN CAPE)) (-RRB- -RRB-))) (, ,) (NP (JJ natural) (NN component)) (NP (NN propolis)) (, ,)) (VP (VBP show) (S (NP (JJ anticarcinogenic) (NN property)) (VP (NP (VBN modified) (JJ resistant) (NN hepatocyte) (NN model)) (S (NP (VBN administered) (NN initiation) (NN promotion) (NN hepatocarcinogenesis) (NN process))))))) (: ;) (RB however) (, ,) (NP (NP (NN information) (NN mechanism)) (VP (VBG underlying) (S (NP (NN chemoprotection)) (ADJP (VBN limited)))))) |ET| |BS|262:A11.436.348 632:D05.750.078.840.762|ES| 2:1 10:1 14:1 19:1 72:1 162:1 217:1 333:1 427:1 429:1 435:1 637:1 638:1 841:1 900:1 1021:1 1275:1 1387:1 1909:1 2131:1 2329:1 2330:1 2331:1 2332:1 2333:1 2334:1 2335:1 2336:1 2337:1 2338:1 2339:1
-1 	|BT| (S (NP (NP (NP (JJ Epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN tyrosine) (NN kinase) (NN inhibitor) (NN erlotinib)) (VP (VBP show) (SBAR (S (NP (JJ potent) (NP (NP (NN antitumor) (NN activity) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD approved) (NP (NNP Food) (NNP Drug) (NNP Administration) (JJ second) (JJ third) (NN line) (NN treatment) (NN NSCLC))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1
-1 	|BT| (NP (NN Hepatocyte) (NP (NP (CD I) (NN kappaB) (NN kinase) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN IKK) (NN beta)) (-RRB- -RRB-))) (VBZ inhibits) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG suppressing) (NP (NP (NP (NN accumulation) (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))) (NN liver) (NN damage)))) (, ,) (SBAR (IN whereas) (S (NP (NN JNK1) (NN activation)) (VP (VBZ promotes) (NP (NP (NN ROS) (NN accumulation)) (, ,) (NP (NN liver) (NN damage)) (, ,) (NP (NN carcinogenesis))))))) |ET| |BS|33:C04.697.098 122:C14.280.383 242:A03.620 262:A11.436.348 635:D08.811.913.696.620.682.700.494 636:D01.339.431|ES| 2:1 10:1 14:1 19:1 207:1 225:1 298:1 372:1 470:1 615:1 836:1 900:1 1848:1 1972:1 2120:1 2250:1 2349:1 2350:1 2351:1 2352:1 2353:1 2354:1 2355:1 2356:1 2357:1
-1 	|BT| (NP (NP (NN PURPOSE)) (: :) (S (NP (JJ Recent) (NN study)) (VP (VBD revealed) (S (NP (NP (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VB reduce) (NP (NP (NP (NN development) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient) (NN obesity) (NN hepatitis) (NN C) (NN virus) (NN infection) (S (VP (VBG improving) (NP (NP (NN insulin) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NN IR)) (-RRB- -RRB-))))))))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 550:B04.450.410 564:C18.654.726.500 637:D06.472.699.587.200.500.625 638:C02.440.440 639:D12.125.070|ES| 10:1 14:1 19:1 35:1 104:1 120:1 131:1 275:1 303:1 304:1 441:1 687:1 1094:1 1275:1 1422:1 1955:1 2010:1 2048:1 2189:1 2358:1 2359:1 2360:1 2361:1 2362:1 2363:1 2364:1 2365:1
-1 	|BT| (NP (NP (NP (NN Tamoxifen) (JJ non-steroidal) (JJ anti-estrogenic) (NN drug)) (NP (ADJP (RB widely) (JJ used)) (NN treatment) (NN prevention) (NN breast) (NN cancer) (NN woman))) (: ;) (FRAG (ADVP (RB however)) (, ,) (NP (NP (NN evidence) (NN tamoxifen) (JJ hepatocarcinogenic) (NN rat)) (, ,) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 67:D26 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900 641:D27.505.696.399.472.277.540 642:M01.975|ES| 2:1 18:1 19:1 23:1 38:1 52:1 191:1 217:1 476:1 546:1 849:1 1387:1 1474:1 2366:1 2367:1 2368:1 2369:1 2370:1 2371:1 2372:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN inflexinol)) (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN growth)) (PP (IN via) (NP (NP (NN induction)) (NP (NP (JJ apoptotic) (NN cell) (NN death) (NN inactivation) (NN NF-kappaB)) (NP (NP (JJ direct) (NN modification) (NN cysteine) (NN residue)) (NP (NN p50) (NN subunit) (NN NF-kappaB)))))))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383 210:D12.776.260.600 583:D12.776.813 643:D02.886.030.230|ES| 18:1 19:1 94:1 101:1 102:1 113:1 411:1 596:1 615:1 714:1 736:1 792:1 796:1 1314:1 1891:1 2110:1 2223:1 2373:1 2374:1 2375:1 2376:1 2377:1
-1 	|BT| (S (NP (DT This) (NN research)) (VP (VBZ provides) (NP (NN evidence) (NN tea)) (, ,) (NP (ADVP (RB particularly)) (NP (VBN administered) (NN combination) (NN sulindac)) (, ,) (NP (PP (ADJP (RB highly) (JJ effective)) (S (VP (VBG inhibiting) (NP (NP (NP (JJ intestinal) (NN neoplasia) (NN male) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN min)) (-RRB- -RRB-))) (NN mouse)) (PP (IN via) (NP (JJ direct) (JJ indirect) (NN effect) (NN beta-catenin/APC) (NN pathway)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 102:C04.588.274.476.411 122:C14.280.383 251:D02.455.426.559.847.486.875 644:H01.770.644 645:H01.770.644|ES| 2:1 10:1 14:1 19:1 38:1 52:1 75:1 109:1 280:1 383:1 530:1 596:1 626:1 640:1 807:1 815:1 869:1 880:1 1402:1 1639:1 1891:1 2336:1 2378:1 2379:1 2380:1 2381:1 2382:1 2383:1
-1 	|BT| (S (NP (NP (NNP UNLABELLED)) (: :) (S (NP (JJ Epidemiological) (NNS data)) (VP (VBP associate) (NP (NP (NN coffee) (NN consumption)) (NP (JJR lower) (NN prevalence) (JJ chronic) (NN liver) (NN disease))) (VP (VBD reduced) (NP (NP (NN risk) (JJ elevated) (NN liver) (NN enzyme) (NN level)) (PRN (-LRB- -LRB-) (NP (NN gamma) (NN glutamyl) (NN transpeptidase) (NN alanine) (NN aminotransferase)) (-RRB- -RRB-)))))) (, ,)) (VP (VBD advanced) (NP (NP (NN liver) (NN disease) (NN complication)) (, ,) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|60:E05.318.308.985.525.750 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 648:D08.811.913.050.200.500 649:E01.370.225.124.200 650:C06.552 651:H02.403.720.500 652:D20.215.784.249|ES| 2:1 10:1 14:1 19:1 104:1 117:1 171:1 179:1 249:1 303:1 304:1 452:1 756:1 793:1 836:1 997:1 998:1 1790:1 2266:1 2384:1 2385:1 2386:1 2387:1 2388:1 2389:1 2390:1 2391:1 2392:1 2393:1 2394:1
-1 	|BT| (S (NP (NN 5-aza-dC) (NN treatment)) (ADVP (RB markedly)) (VP (VBD decreased) (NP (NP (NN atherosclerosis) (NN development) (NN Ldlr)) (-LRB- -LRB-) (PRN (: -) (: /) (: -)) (-RRB- -RRB-) (NN mouse)) (NP (PP (IN without) (NP (NN change) (NN body) (NN weight))) (, ,) (NP (NN plasma) (NN lipid) (NN profile)) (, ,) (NP (NN macrophage) (NN cholesterol) (NN level) (NN plaque) (NN lipid) (NN content))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821 653:C23.888.144 654:D02.145.150 655:D04.808.247.222.284 656:C07.793.208.377 657:A12.207.152.693 658:A11.329.372 659:D10|ES| 2:1 10:1 14:1 19:1 35:1 45:1 52:1 200:1 202:1 249:1 546:1 1195:1 1711:1 1794:1 1804:1 1981:1 2395:1 2396:1 2397:1 2398:1 2399:1 2400:1 2401:1 2402:1 2403:1
-1 	|BT| (NP (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (CD one) (JJ common) (JJ chemotherapeutic) (NN agent)) (VP (VBN used) (NP (NP (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 655:1 728:1 1010:1 1762:1 2308:1 2404:1
-1 	|BT| (NP (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (CD one) (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN agent) (NN colon) (NN cancer) (NN treatment)) (, ,) (NP (JJ narrow) (JJ therapeutic) (NN index) (JJ limited) (NN toxicity))))) |ET| |BS|46:A03.556.124.526.356 52:E02 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 2:1 10:1 14:1 15:1 18:1 19:1 113:1 476:1 541:1 546:1 721:1 728:1 1010:1 1762:1 2131:1 2308:1 2404:1 2405:1 2406:1
-1 	|BT| (S (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ common) (JJ chemotherapeutic) (NN agent)) (VP (VBN used) (NP (NP (NP (NN treatment) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (JJ inadequate) (NN response) (NN rate)) (: ;) (VP (VBG highlighting) (NP (NN need) (NN novel))))))) (VP (VBD improved) (NP (NN treatment) (NNS regimen) (NN patient)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 259:D12.776.395.240.150.500 284:N03.349.380.420 532:E02.183 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 2:1 10:1 14:1 17:1 18:1 19:1 41:1 120:1 217:1 245:1 476:1 494:1 546:1 655:1 728:1 891:1 1762:1 1881:1 2308:1 2404:1 2407:1 2408:1 2409:1 2410:1
-1 	|BT| (S (NP (NNP Administration) (NNP SP600125) (NN acetaminophen)) (VP (VBD protected) (NP (NP (NP (NN Jnk)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN control) (NN mouse) (NN liver) (NN injury)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 661:D02.065.199.092.040|ES| 10:1 14:1 19:1 52:1 289:1 836:1 2346:1 2411:1 2412:1 2413:1 2414:1 2415:1 2416:1
-1 	|BT| (S (NP (NNP Administration) (NN HMGB1) (NN release) (NN inhibitor) (NN ethyl) (NN pyruvate)) (, ,) (VP (VBP affect) (NP (NP (JJ p53-mediated) (JJ hepatic) (NN apoptosis)) (, ,) (VP (ADVP (RB substantially)) (VBD prevented) (NP (JJ carcinogen-induced) (NN cirrhosis) (NN tumorigenesis) (NN rat) (NN liver)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 357:C06.552.630 433:F01.470.047 585:D12.644.276.087.371 589:E02.204.125 662:C23.550.355|ES| 2:1 19:1 78:1 89:1 380:1 836:1 838:1 849:1 1199:1 1486:1 1944:1 2164:1 2165:1 2346:1 2417:1 2418:1 2419:1 2420:1 2421:1
-1 	|BT| (S (NP (NNP Aliskiren)) (VP (VBZ attenuates) (NP (NN steatohepatitis) (NN increase) (NN turnover) (JJ hepatic) (JJ fat) (NN mouse) (NN fed) (NN methionine) (NN choline) (JJ deficient) (NN diet)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676 665:N04.452.677.680|ES| 19:1 40:1 52:1 838:1 1504:1 1791:1 2050:1 2191:1 2422:1 2423:1 2424:1 2425:1 2426:1 2427:1
-1 	|BT| (S (NP (DT All) (NN result)) (VP (VBD revealed) (NP (NP (NN pterostilbene) (JJ effective) (NN antitumor) (NN agent)) (NP (RB well) (NP (JJ inhibitory) (NN effect) (NN down-regulation) (JJ inflammatory) (NN iNOS) (NN COX-2) (NN gene)) (NN expression) (NN up-regulation) (NN apoptosis) (NN mouse) (NN colon))) (, ,) (S (VP (VBG suggesting) (NP (NP (NP (NN pterostilbene)) (JJ novel) (JJ functional) (NN agent)) (ADJP (JJ capable) (S (VP (VBG preventing) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248|ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1
-1 	|BT| (S (NP (NP (NNP Alternol)) (, ,) (NP (JJ natural) (NN compound)) (, ,)) (VP (VBZ exerts) (NP (NP (JJ anti-tumour) (NN effect) (NN osteosarcoma)) (VP (VBG modulating) (NP (NN STAT3) (NN ROS/MAPK) (NN signalling) (NN pathway)))))) |ET| |BS|12:Z01.542.049 38:Z01.058.290.120.180 40:Z01.542.248.700 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650 666:G02.111.087.800.560|ES| 2:1 19:1 75:1 251:1 383:1 1562:1 1977:1 2333:1 2432:1 2433:1 2434:1 2435:1 2436:1 2437:1
-1 	|BT| (S (NP (JJ Anthocyanin-containing) (JJ purple-fleshed) (NN potato)) (VP (VBP suppress) (NP (NP (NN colon) (NN tumorigenesis)) (PP (IN via) (NP (NN elimination) (NN colon) (NN cancer) (NN stem) (NN cell)))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 308:A11.872 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087|ES| 18:1 19:1 78:1 94:1 113:1 156:1 596:1 1106:1 2438:1 2439:1 2440:1 2441:1
-1 	|BT| (FRAG (NP (NP (JJ Anti-tumor) (NN effect)) (VBN pegylated) (NN interferon) (NN rat) (NN hepatocarcinogenesis) (NN model))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 617:D12.644.276.374.440|ES| 19:1 72:1 75:1 849:1 900:1 2305:1 2442:1 2443:1
-1 	|BT| (SINV (PP (IN As) (NP (NN wogonin) (ADJP (JJ effective) (ADVP (FW vitro) (FW vivo))))) (, ,) (NP (JJ novel) (S (VP (VBG finding) (S (NP (JJ open) (NN possibility) (NN wogonin) (JJ effective) (ADJP (ADJP (JJ therapeutic)) (CC and/or) (ADJP (JJ chemopreventive))) (NN agent)) (ADJP (JJ ER-positive))) (: -) (NP (NP (JJ negative) (NN breast) (NN cancer)) (, ,) (NP (RB particularly) (JJ aggressive) (JJ hormonal) (JJ therapy-resistant) (JJ ER-negative) (NN type))))))) |ET| |BS|52:E02 162:F01.145.126.125 259:D12.776.395.240.150.500|ES| 2:1 18:1 19:1 23:1 149:1 168:1 216:1 343:1 378:1 538:1 541:1 543:1 728:1 891:1 927:1 1045:1 1639:1 1654:1 1946:1 2380:1 2444:1 2445:1 2446:1 2447:1 2448:1
-1 	|BT| (NP (NP (NP (NP (NN Aspirin)) (PRN (-LRB- -LSB-) (NP (NP (JJ acetylsalicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN ASA)) (-RRB- -RRB-))) (-RRB- -RSB-))) (VP (VBN shown) (VP (VBP prevent) (NP (NN CRC))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ epigenetic) (NN mechanism) (NN action)) (VP (VBP remain) (ADJP (JJ unknown))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203|ES| 2:1 10:1 14:1 19:1 162:1 217:1 237:1 245:1 733:1 1275:1 1373:1 1378:1 1387:1 1603:1 2013:1 2181:1 2182:1 2449:1 2450:1 2451:1
-1 	|BT| (S (NP (NN AZD6244) (NN doxorubicin)) (VP (VBP induce) (NP (NN growth) (NN suppression) (NN apoptosis) (NN mouse) (NN model) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 45:G07.700.320.249 104:C04.557.470.200.025.255 136:D02.455.426.559.847.562.050.200.175|ES| 19:1 52:1 72:1 89:1 102:1 243:1 303:1 304:1 599:1 2452:1 2453:1
-1 	|BT| (NP (NP (NP (NN Beta-ionone)) (, ,) (NP (JJ end-ring) (NN analogue) (NN beta-carotenoid)) (, ,) (NP (NN constituent) (NN vegetable) (NN fruit)) (, ,)) (NP (VBN analyzed) (NN colon) (NN cancer) (NN chemoprevention) (NN treatment))) |ET| |BS|12:Z01.542.049 52:E02 253:E02.319.162 672:D02.455.326.271.665.202 673:A18.024.500 674:B01.650.510.956|ES| 2:1 18:1 19:1 113:1 546:1 870:1 1168:1 1380:1 2454:1 2455:1 2456:1 2457:1 2458:1 2459:1
-1 	|BT| (S (NP (NNP Bortezomib)) (ADVP (RB also)) (VP (VBD prevented) (SBAR (S (NP (NN activation) (JJ hepatic) (JJ stellate) (NN cell)) (VP (VBD inhibited) (NP (NN liver) (NN fibrosis) (NN DEN/CDAA) (NN model))))))) |ET| |BS|122:C14.280.383 675:D01.029.260.110.500 676:C06.552.630 677:A11.561|ES| 5:1 19:1 72:1 94:1 225:1 365:1 836:1 838:1 949:1 1944:1 2460:1 2461:1 2462:1
-1 	|BT| (S (NP (NN Bortezomib)) (VP (VBZ induces) (SBAR (S (NP (NP (JJ tumor-specific) (NN cell) (NN death)) (NN growth) (NN inhibition) (JJ hepatocellular) (NN carcinoma)) (VP (VBZ improves) (NP (NN liver) (NN fibrosis))))))) |ET| |BS|8:C04 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 134:G04.299.139 675:D01.029.260.110.500 676:C06.552.630|ES| 19:1 94:1 102:1 103:1 214:1 303:1 304:1 411:1 836:1 949:1 2460:1 2463:1 2464:1
-1 	|BT| (S (NP (JJ Branched-chain) (NN amino) (NN acid) (-LRB- -LRB-) (NN BCAA) (-RRB- -RRB-)) (, ,) (S (VP (VB improve) (NP (NN insulin) (NN resistance)))) (, ,) (VP (VBD inhibited) (NP (NP (JJ obesity-related) (NN colon) (NN carcinogenesis) (JJ rodent) (NN model)) (, ,) (S (ADVP (RB also)) (VP (VBD reduced) (NP (NN incidence) (JJ hepatocellular) (NN carcinoma) (JJ obese) (NN patient) (NN liver) (NN cirrhosis))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 50:M01.643 104:C04.557.470.200.025.255 122:C14.280.383 357:C06.552.630 434:E05.318.308.985.525.375 514:B01.050.150.900.649.865 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 5:1 10:1 14:1 19:1 72:1 113:1 120:1 207:1 303:1 304:1 365:1 452:1 836:1 1094:1 1199:1 1275:1 1511:1 2173:1 2189:1 2360:1 2364:1 2465:1 2466:1 2467:1 2468:1
-1 	|BT| (S (NP (JJ Bromelain-containing) (NN food) (CC and/or) (NN bromelain)) (VP (MD may) (VP (VB represent) (NP (JJ good) (NN candidate) (JJ colorectal) (NN cancer) (NN chemoprevention))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 253:E02.319.162 679:D08.811.277.656.262.500.096 680:G07.203.300|ES| 17:1 18:1 19:1 149:1 491:1 799:1 870:1 1243:1 1318:1 2469:1 2470:1 2471:1
-1 	|BT| (S (NP (NP (NNP Brucine)) (, ,) (NP (NN alkaloid) (NN seed))) (VP (VBZ Strychnos) (NP (JJ nux-vomica) (NNP Linn)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 631:D03.132 681:G04.299.283 682:D12.776.260.103.625|ES| 2:1 19:1 31:1 63:1 94:1 98:1 104:1 185:1 303:1 304:1 383:1 514:1 806:1 2315:1 2320:1 2321:1 2322:1 2323:1 2472:1 2473:1 2474:1
-1 	|BT| (S (NP (NP (NNP Celecoxib)) (, ,) (NP (NP (JJ selective) (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NP (NN inhibitor)) (, ,)) (NP (JJ effective) (JJ chemopreventive) (NN colon) (NN cancer) (JJ nonsteoroidal) (JJ antiinflammatory) (NN drug)) (VP (VBD approved) (NP (NP (NNP FDA) (JJ adjuvant) (NN therapy) (NN patient)) (JJ familial) (JJ adenomatous) (NN polyposis)))) |ET| |BS|3:C04.557.470.035.215.100 50:M01.643 52:E02 349:D27.505.519.389.310.500 633:I01.409.418.750.600.650.760 683:D27.505.519.389.310 684:D02.065.884.247 685:D27.505.696.477.067 686:D27.505.954.158 687:D26.650.064|ES| 2:1 10:1 14:1 18:1 19:1 57:1 58:1 61:1 76:1 113:1 120:1 130:1 191:1 380:1 854:1 1639:1 1749:1 1946:1 2343:1 2475:1 2476:1 2477:1 2478:1 2479:1
-1 	|BT| (S (NP (NNP Coffee)) (VP (VBZ reduces) (NP (NP (NN liver) (NN damage) (NN rat) (NN model) (NN steatohepatitis)) (: :) (NP (VBG underlying) (NN mechanism) (NN role) (NNS polyphenols) (NNS melanoidins))))) |ET| |BS|15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249|ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1
-1 	|BT| (S (NP (NN Colon) (NN cancer) (NN cell) (JJ treated) (NNS SDs)) (VP (VBD exhibited) (NP (VBN reduced) (NN Wnt) (JJ transcriptional) (NN activity)) (, ,) (VP (ADVP (RB well)) (VBN reduced)) (NP (JJ nuclear) (NN beta-catenin) (NN localization) (JJ subsequent) (NN reduction) (NN active-beta-catenin) (NN level)))) |ET| |BS|23:D12.776.091.249 41:A11 52:E02 175:J01.897.280.500.269 209:G02.111.087.847|ES| 2:1 18:1 19:1 60:1 94:1 249:1 370:1 399:1 452:1 559:1 609:1 787:1 877:1 1099:1 1256:1 1319:1 2482:1 2483:1 2484:1 2485:1
-1 	|BT| (S (NP (NN Combination) (NN aspirin) (NN sorafenib)) (VP (MD may) (NP (JJ effective) (NN regimen) (NN treat) (NN HCC) (NN colon) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 532:E02.183 670:D02.455.426.559.389.657.410.595.176|ES| 18:1 19:1 113:1 441:1 491:1 1090:1 1639:1 1881:1 2063:1 2486:1 2487:1
-1 	|BT| (S (NP (NP (JJ Combined) (NN treatment) (NN EPLE) (NN 5-fluorouracil)) (, ,) (NP (JJ first-line) (NN chemotherapy) (NN CRC) (NN patient)) (, ,)) (VP (VBD achieved) (NP (JJ synergistic) (NN effect)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 151:E02.319 560:D03.383.742.698.875.404 618:E02.186|ES| 2:1 19:1 75:1 120:1 245:1 495:1 546:1 2012:1 2307:1 2488:1 2489:1 2490:1 2491:1
-1 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
-1 	|BT| (S (NP (NN Compound) (NN Astragalus)) (NP (FW Salvia) (FW miltiorrhiza) (NN extract)) (VP (VBZ suppresses) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN progression)) (VP (VBG inhibiting) (NP (NN fibrosis) (NN PAI-1) (NN mRNA) (NN transcription)))))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 111:D13.444.735.544 122:C14.280.383 209:G02.111.087.847 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 690:D12.644.861.695.500 691:C23.550.355|ES| 19:1 48:1 303:1 304:1 325:1 487:1 686:1 880:1 949:1 2492:1 2493:1 2494:1 2495:1 2496:1 2497:1
-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN curcumin)) (VP (VBZ potentiates) (NP (NP (JJ antitumor) (NN effect) (NN radiation) (NN therapy)) (JJ colorectal) (NN cancer) (VBG suppressing) (NP (NN NF-kappaB) (JJ NF-kappaB-regulated) (NN gene) (NN product))) (, ,) (NP (VBG leading) (NN inhibition) (NN proliferation) (NN angiogenesis))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745|ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1
-1 	|BT| (S (NP (NN CONCLUSION) (: :)) (PP (IN In) (NP (NN summary))) (, ,) (S (VP (VBG finding) (VP (VB provide) (NP (NP (JJ preclinical) (NN evidence)) (VP (VBG supporting) (NP (NN evaluation) (NN agent) (NN DMAPT) (NN gemcitabine) (NN prevention) (NN treatment) (JJ pancreatic) (NN cancer)))))))) |ET| |BS|52:E02 225:E05.337|ES| 2:1 18:1 19:1 38:1 104:1 244:1 467:1 490:1 546:1 711:1 728:1 927:1 1472:1 1474:1 1494:1 1882:1 2503:1 2504:1 2505:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (SBAR (S (NP (NN coffee) (NN consumption)) (VP (VBZ protects) (SBAR (S (NP (NN liver) (NN damage)) (VP (VBD caused) (NP (JJ high-fat) (NN diet))))))))))) |ET| |BS|242:A03.620 652:D20.215.784.249 694:G07.203.650.240.267|ES| 19:1 104:1 502:1 658:1 793:1 836:1 1848:1 1863:1 1882:1 2191:1 2386:1 2387:1 2506:1 2507:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (NP (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis) (JJ colorectal) (NN cancer)) (VP (VBD associated) (NP (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (JJ overall) (NN mortality)) (, ,) (PP (ADVP (RB especially)) (IN among) (NP (JJ individual) (NN tumor)))) (S (VP (VBP overexpress) (NP (NN COX-2))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 493:M01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 696:V02.270.500|ES| 2:1 7:1 17:1 18:1 19:1 76:1 104:1 117:1 169:1 171:1 345:1 1037:1 1372:1 1659:1 1882:1 2487:1 2508:1 2509:1 2510:1 2511:1 2512:1 2513:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (DT The) (JJ present) (NN work)) (VP (VBZ provides) (NP (NP (JJ novel) (NNS data)) (PP (VBG concerning) (NP (JJ preventive) (NN action) (NN glycerol) (NN development) (NN liver) (NN cancer)))))) (VP (VBZ represents) (NP (ADJP (RB economically) (JJ feasible)) (NN intervention) (NN treat) (JJ high-risk) (NN individual))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 61:E05.318.740.600.800 259:D12.776.395.240.150.500 445:I03.946 493:M01 697:D02.033.800.421 698:I01.261|ES| 18:1 19:1 35:1 104:1 106:1 691:1 793:1 815:1 836:1 891:1 1090:1 1307:1 1546:1 1645:1 1882:1 1883:1 2013:1 2512:1 2514:1 2515:1 2516:1 2517:1 2518:1
-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (NP (DT These) (VBP result) (NP (VBN suggested) (NN TFA) (VBD protected) (ADJP (NN mouse) (JJ CCl4-induced) (ADJP (NN liver) (NN injury) (JJ antioxidant)) (NN stress) (JJ antiinflammatory)) (NN effect)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217|ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1
-1 	|BT| (FRAG (NP (NN CONCLUSION)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NN evidence) (NN saffron)) (VP (VBZ exerts) (NP (JJ significant) (JJ chemopreventive) (NN effect) (NN liver) (NN cancer) (NN inhibition) (NN cell) (NN proliferation) (NN induction) (NN apoptosis)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 624:D27.505.696.706.018 701:B01.650.940.800.575.100.549.500|ES| 18:1 19:1 38:1 75:1 89:1 94:1 103:1 104:1 131:1 135:1 299:1 736:1 807:1 815:1 836:1 1882:1 1946:1 1977:1 2523:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (NP (NNP Aliskiren)) (VP (VBZ attenuates) (NP (NN steatohepatitis) (NN fibrosis) (NN mouse) (NN fed) (NN MCD) (NN diet)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 691:C23.550.355|ES| 19:1 52:1 104:1 239:1 949:1 1791:1 2191:1 2422:1 2423:1 2426:1 2524:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Magnolol) (NNS pretreatments)) (VP (VBP prevent) (S (NP (JJ UVB-induced) (NN skin) (NN cancer) (NN development)) (VP (VBG enhancing) (NP (NN apoptosis)) (, ,) (S (VP (VBG causing) (NP (NN cell) (NN cycle) (NN arrest) (NN G2/M) (NN phase)))))) (, ,) (S (VP (VBG affecting) (NP (JJ various) (NN signaling) (NN pathway))))))) |ET| |BS|39:G04.299.139.160 126:G02.111.087.800 702:G04.299.134.109.750|ES| 2:1 18:1 19:1 35:1 89:1 94:1 104:1 195:1 239:1 383:1 601:1 602:1 733:1 1096:1 1491:1 2312:1 2319:1 2525:1 2526:1 2527:1 2528:1 2529:1 2530:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NN Silibinin) (NN target) (NN beta-catenin) (NN IGF-1Rbeta) (NN pathway) (JJ chemopreventive) (NN efficacy) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937|ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN Since) (NP (NN lymph) (NN node) (NN involvement) (JJ important) (JJ prognostic) (NN factor) (NN breast) (NN cancer) (NN patient))) (, ,) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin)) (VP (VBD detected) (NP (NP (JJ mammary) (NN cancer)) (VP (VBG carrying) (NP (NN p53) (NN mutation) (JJ present) (NN study)))) (VP (MD may) (NP (JJ specific) (JJ clinical) (NN application))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 50:M01.643 247:G01.374.676.530 703:A10.549.400|ES| 2:1 12:1 18:1 19:1 23:1 34:1 84:1 104:1 120:1 131:1 165:1 185:1 239:1 399:1 491:1 540:1 636:1 850:1 884:1 902:1 1007:1 1307:1 2245:1 2246:1 2248:1 2535:1 2536:1 2537:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (VP (VBN Taken) (ADVP (RB together)) (, ,) (S (VP (VBG finding) (VP (VB identify) (S (NP (NN mechanism) (NN ABT-100) (NN function)) (VP (VBP show) (NP (NP (NN efficacy) (NN ABT-100) (JJ chemopreventive) (NN agent)) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|104:C04.557.470.200.025.255 375:Z01.639.100|ES| 2:1 19:1 33:1 104:1 162:1 239:1 303:1 304:1 429:1 728:1 832:1 927:1 1537:1 1538:1 1946:1 2304:1 2538:1
-1 	|BT| (FRAG (NP (NNS CONCLUSIONS) (: :)) (PP (DT These) (S (VP (VBG finding) (S (VP (VBP suggest) (NP (NP (NN MPT0E028) (NN combination) (NN sorafenib) (JJ significant) (JJ anti-hepatocellular) (NN carcinoma) (NN activity) (JJ preclinical) (NN model)) (, ,) (S (ADVP (RB potentially)) (VP (VBG suggesting) (SBAR (S (NP (JJ novel) (JJ therapeutic) (NN strategy) (NN patient)) (VP (VBD advanced) (NP (JJ hepatocellular) (NN carcinoma)))))))))))))) |ET| |BS|50:M01.643 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 19:1 72:1 104:1 120:1 135:1 239:1 303:1 304:1 399:1 530:1 541:1 773:1 792:1 796:1 891:1 927:1 997:1 1009:1 1114:1 1494:1 2063:1 2539:1 2540:1
-1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (NP (JJ synergistic) (NN antitumor) (NN activity) (NN combination) (NN dovitinib) (NN oxaliplatin) (NN colon) (NN cancer) (JJ different) (NN RAS-RAF) (NN status))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550|ES| 18:1 19:1 104:1 113:1 131:1 239:1 399:1 414:1 416:1 530:1 807:1 2012:1 2244:1 2541:1 2542:1 2543:1 2544:1
-1 	|BT| (NP (NP (NP (NN Connexin) (CD 32) (NN luteolin) (NN play) (JJ protective) (NN role)) (JJ non-alcoholic) (NN steatohepatitis) (NN development) (JJ related) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 509:C06.552.241.519 704:D03.383.663.283.266.450.260.555|ES| 19:1 31:1 35:1 238:1 419:1 493:1 849:1 900:1 1791:1 2069:1 2545:1 2546:1 2547:1
-1 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
-1 	|BT| (S (NP (NN Cytochrome) (NN P450) (NN 1A2)) (VP (VBZ Metabolizes) (S (NP (NN 17beta-Estradiol)) (VP (VB Suppress) (NP (JJ Hepatocellular) (NN Carcinoma)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 705:D08.244.453.040.443 706:D04.808.365.415.248|ES| 19:1 1241:1 2151:1 2548:1 2549:1 2550:1 2551:1 2552:1 2553:1
-1 	|BT| (S (NP (NP (NNS Data)) (VP (VBN obtained))) (VP (VBP suggest) (S (NP (NN contribution) (NN SphK/S1P) (NN system)) (NP (JJ related) (NN signaling) (NN pathway) (JJ protective) (NN effect) (NN melatonin) (NN hepatocarcinogenesis))))) |ET| |BS|126:G02.111.087.800 707:D03.438.473.914.481|ES| 19:1 75:1 195:1 383:1 419:1 493:1 593:1 796:1 900:1 1224:1 1360:1 2554:1 2555:1 2556:1
-1 	|BT| (NP (NP (NP (JJ Decorin-mediated) (NN inhibition) (JJ colorectal) (NN cancer) (NN growth) (NN migration)) (NP (VBN associated) (NN E-cadherin) (NN vitro) (NN mouse)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625|ES| 17:1 18:1 19:1 52:1 102:1 103:1 169:1 216:1 514:1 2267:1 2557:1
-1 	|BT| (S (PP (IN Despite) (NP (JJ recent) (JJ therapeutic) (NN advance))) (, ,) (NP (NP (NN response) (NN rate) (NN chemotherapy) (NN patient)) (JJ metastatic) (NN colon) (NN cancer)) (VP (VBP remain) (NP (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (NP (NN fluoropyrimidine))) (, ,) (NP (NN 5-fluorouracil) (-LRB- -LRB-) (NN 5-FU) (-RRB- -RRB-))) (, ,) (S (VP (VBG continuing) (VP (VB serve) (NP (NN foundation) (JJ chemotherapeutic) (NN agent) (NN treatment) (NN disease))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 50:M01.643 52:E02 113:C04.697.650 151:E02.319 288:C23.550.288 560:D03.383.742.698.875.404 660:D27.505.954.248 709:N03.219.483.311|ES| 2:1 10:1 14:1 18:1 19:1 41:1 113:1 120:1 337:1 368:1 369:1 494:1 495:1 532:1 541:1 546:1 550:1 659:1 728:1 998:1 1762:1 1843:1 2181:1 2307:1 2308:1 2558:1 2559:1 2560:1 2561:1
-1 	|BT| (S (NP (NP (JJ Dietary) (NN intake) (NN pterostilbene)) (, ,) (NP (NN constituent) (NN blueberry)) (, ,)) (VP (VBZ inhibits) (NP (NN beta-catenin/p65) (JJ downstream) (NN signaling) (NN pathway) (NN colon) (NN carcinogenesis) (NN rat)))) |ET| |BS|23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249|ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1
-1 	|BT| (S (NP (JJ Dietary) (NN lycopene) (NN tomato) (NN extract) (NN supplementation)) (VP (VBP inhibit) (NP (JJ nonalcoholic) (JJ steatohepatitis-promoted) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 509:C06.552.241.519 595:G07.203.650.240|ES| 19:1 849:1 900:1 1097:1 1370:1 1796:1 2496:1 2562:1 2566:1 2567:1 2568:1
-1 	|BT| (S (S (NP (JJ Diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (VP (VBD suppressed) (NP (NN lecithin)))) (: :) (S (NP (NN retinol) (JJ acyltransferase-deficient) (NN mouse)) (ADVP (RB primarily)) (NP (NP (JJ retinoid) (NN action)) (NP (ADVP (RB immediately)) (NP (NN carcinogen) (NN administration)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 554:D02.654.442.200 711:D02.455.326.271.665.202.495|ES| 19:1 52:1 104:1 307:1 900:1 1970:1 2013:1 2125:1 2569:1 2570:1 2571:1 2572:1 2573:1 2574:1 2575:1
-1 	|BT| (S (VP (NP (NNP Digital)) (VBG karyotyping) (VP (VBZ identifies) (NP (NN thymidylate) (NN synthase) (NN amplification) (NN mechanism) (NN resistance) (NN 5-fluorouracil) (JJ metastatic) (JJ colorectal) (NN cancer) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430|ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1
-1 	|BT| (S (NP (NNP Diosmin)) (VP (VBZ abrogates) (VP (ADVP (RB chemically)) (VBN induced) (NN hepatocarcinogenesis) (PP (IN via) (NP (NP (NN alleviation) (JJ oxidative) (NN stress)) (, ,) (NP (JJ hyperproliferative) (JJ inflammatory) (NN marker) (JJ murine) (NN model))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 158:D23.101 715:D03.383.663.283.266.450.260.222 716:G03.495.710|ES| 2:1 19:1 72:1 412:1 534:1 596:1 627:1 900:1 2430:1 2522:1 2579:1 2580:1 2581:1 2582:1 2583:1 2584:1
-1 	|BT| (S (NP (NP (NN DNA) (NN microarray) (NN analysis)) (VP (VBN used))) (VP (VBP analyze) (NP (NP (JJ transcriptional) (NN profile) (NN HCT116) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBN treated) (NP (NP (NP (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NN oxaliplatin) (VBN selected) (NN resistance) (NN agent)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 198:D13.444.308 209:G02.111.087.847 560:D03.383.742.698.875.404 717:A11.251.210.190.380 718:E05.588.570|ES| 10:1 14:1 17:1 18:1 19:1 94:1 476:1 559:1 566:1 661:1 666:1 728:1 913:1 1094:1 1099:1 1711:1 2307:1 2308:1 2543:1 2585:1 2586:1
-1 	|BT| (S (NP (NN Embelin)) (VP (VBZ inhibits) (NP (NP (NN chemical) (JJ carcinogen-induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (NP (NN effect)) (ADJP (RB partially) (JJ dependent)) (NN presence) (JJ functional) (NN PPARgamma)) (, ,) (NP (NP (VBG indicating) (NN PPARgamma) (JJ necessary) (NN signaling) (NN pathway)) (VBN involved) (NN antitumor) (NN activity) (JJ normal) (NN organism))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 279:D27.888.569.100 719:D12.776.826.239.588|ES| 2:1 19:1 75:1 113:1 118:1 195:1 207:1 321:1 346:1 383:1 399:1 415:1 615:1 774:1 1351:1 2124:1 2236:1 2244:1 2421:1 2587:1 2588:1 2589:1 2590:1
-1 	|BT| (S (NP (JJ Epidemiological) (NN evidence)) (VP (VBZ suggests) (S (NP (NN vitamin) (NN D)) (VP (MD may) (VP (VB play) (NP (NP (NN role)) (VP (VBG inhibiting) (NP (NN development) (NN colon) (NN prostate) (NN cancer))))))))) |ET| |BS|15:F01.829.316.616 46:A03.556.124.526.356 79:I03.450.642.693 122:C14.280.383 651:H02.403.720.500 720:D04.808.247.222.474 721:D04.808.812.768|ES| 18:1 19:1 31:1 35:1 38:1 77:1 113:1 238:1 331:1 491:1 880:1 2384:1 2591:1 2592:1
-1 	|BT| (S (NP (JJ Epidemiological) (NN study)) (VP (VBP indicate) (NP (JJ adequate) (JJ dietary) (NN folate) (JJ protective) (NN colon) (NN cancer)) (, ,) (SBAR (IN although) (S (NP (NN mechanism)) (VP (VBP remain) (ADJP (RB largely) (JJ elusive))))))) |ET| |BS|224:D03.438.733.631.400 595:G07.203.650.240 722:E05.318.760.500|ES| 2:1 18:1 19:1 113:1 131:1 162:1 493:1 777:1 778:1 1479:1 1592:1 2181:1 2384:1 2593:1 2594:1 2595:1
-1 	|BT| (S (NP (NNP Erlotinib)) (ADVP (RB also)) (VP (VBD decreased) (NP (NN hepatocyte) (NN proliferation) (NN liver) (NN injury)))) |ET| |BS|242:A03.620 262:A11.436.348|ES| 5:1 19:1 202:1 299:1 836:1 1909:1 2416:1 2596:1
-1 	|BT| (S (NP (NN ESE-1) (: /) (NN EGR-1) (NN pathway)) (VP (VBP play) (NP (NN role)) (NP (ADJP (JJ tolfenamic) (JJ acid-induced)) (NP (NN apoptosis) (JJ colorectal) (NN cancer) (NN cell))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 39:G04.299.139.160 41:A11 79:I03.450.642.693|ES| 17:1 18:1 19:1 31:1 89:1 94:1 238:1 383:1 2597:1 2598:1 2599:1
-1 	|BT| (NP (NP (NP (NN Evaluation) (JJ chemopreventive) (NN effect)) (NP (NNP Fumaria) (NN indica) (NN N-nitrosodiethylamine) (JJ CCl4-induced) (JJ hepatocellular) (NN carcinoma) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750|ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1
-1 	|BT| (NP (NP (NP (NN Exenatide)) (PRN (-LRB- -LRB-) (NP (NN Ex-4)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ potent) (NN diabetes) (NN drug)) (VP (VBG targeting) (NP (NP (JJ glucagon-like) (NN peptide-1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GLP-1R)) (-RRB- -RRB-))))) (, ,) (NP (NP (JJ protective) (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN NAFLD)) (-RRB- -RRB-)))) |ET| |BS|369:E02.319.300 577:C06.552.241.519 725:D12.776.543.750.100.021.500 726:C18.452.394.750|ES| 2:1 10:1 14:1 19:1 22:1 186:1 191:1 493:1 616:1 836:1 998:1 2009:1 2069:1 2070:1 2604:1 2605:1 2606:1 2607:1 2608:1 2609:1
-1 	|BT| (SINV (ADVP (RB Furthermore)) (, ,) (NP (NN exposure) (JJ colorectal) (NN cancer) (NN cell) (JJ anti-periostin) (NN antibody)) (VP (VBZ activates) (NP (NN apoptosis))) (VP (VBZ potentiates) (NP (NN effect) (NN 5-fluorouracil) (NN chemotherapy)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 151:E02.319 560:D03.383.742.698.875.404 727:D12.776.124.486.485.114.071|ES| 2:1 17:1 18:1 19:1 75:1 89:1 94:1 301:1 334:1 495:1 1953:1 2307:1 2499:1 2610:1 2611:1
-1 	|BT| (S (NP (NNP Garcinol)) (VP (VBZ suppresses) (NP (JJ inflammation-associated) (NN colon) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 53:C06.405.205.265|ES| 19:1 52:1 113:1 207:1 686:1 1849:1 2612:1
-1 	|BT| (S (NP (JJ Garlic) (NN oil)) (VP (VBD attenuated) (NP (NP (JJ nitrosodiethylamine-induced) (NN hepatocarcinogenesis)) (VP (VBG modulating) (NP (JJ metabolic) (NN activation) (NN detoxification) (NN enzyme)))))) |ET| |BS|554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811|ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1
-1 	|BT| (NP (NP (NP (NNP Gemcitabine)) (, ,) (NP (JJ current) (JJ standard-of-care) (NN chemotherapy) (JJ pancreatic) (NN cancer)) (, ,) (NP (JJ limited) (JJ clinical) (NN benefit)))) |ET| |BS|151:E02.319|ES| 2:1 18:1 19:1 84:1 175:1 467:1 495:1 2131:1 2617:1 2618:1 2619:1
-1 	|BT| (S (NP (NNS Glucans) (JJ edible) (NN mushroom) (NN Pleurotus) (NN pulmonarius)) (VP (VBP inhibit) (NP (JJ colitis-associated) (NN colon) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 731:B01.300.179.100.650 732:D05.750.078.562 733:B01.300.179.100|ES| 19:1 52:1 113:1 207:1 410:1 1370:1 2620:1 2621:1 2622:1 2623:1 2624:1
-1 	|BT| (NP (NP (NP (JJ Glycyrrhizic) (NN Acid)) (NP (VBN used) (NN treat) (JJ chronic) (NN hepatitis))) (, ,) (S (VP (VBG inhibiting) (NP (NN penetration) (NN hepatitis) (NN A) (NN virus) (NNS hepatocytes))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 122:C14.280.383 262:A11.436.348 734:D02.455.849.919.530.466 735:B04.450.420.410 736:C06.552.380.350|ES| 2:1 19:1 69:1 476:1 880:1 894:1 1090:1 1422:1 1790:1 2048:1 2625:1 2626:1 2627:1
-1 	|BT| (S (NP (JJ Great) (NN interest)) (VP (VBD focused) (NP (NN chemoprevention) (JJ colonic) (NN carcinogenesis) (JJ oral) (NN administration)) (NP (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (NN administration)) (VP (ADVP (RB reportedly)) (VBZ reduces) (NP (NN incidence) (NN colon) (NN cancer) (NN animal) (NN experiment))))) |ET| |BS|33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 253:E02.319.162 434:E05.318.308.985.525.375 737:D04.808.105.225.272.962 738:E05.017 739:E02.319.267.100|ES| 10:1 14:1 18:1 19:1 46:1 113:1 142:1 207:1 677:1 870:1 1051:1 1275:1 1511:1 2310:1 2311:1 2575:1 2628:1 2629:1 2630:1 2631:1 2632:1
-1 	|BT| (SINV (ADVP (RB Here)) (VP (VBN aimed)) (VP (VBP determine) (NP (NP (NN mechanism) (NN action) (NN DHEA)) (, ,) (NP (NP (NN comparison) (NN vitamin) (NN E)) (, ,) (NP (JJ chemically-induced) (JJ hepatocellular) (NN carcinoma) (NN model) (NN rat)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 740:D04.808.054.079.429.625 741:D03.383.663.283.909 742:G03.787|ES| 2:1 19:1 72:1 74:1 162:1 303:1 304:1 400:1 844:1 849:1 2013:1 2085:1 2233:1 2591:1 2633:1 2634:1
-1 	|BT| (S (NP (ADVP (RB Herein)) (, ,) (JJ first) (NN time)) (, ,) (VP (VBP investigate) (NP (FW vivo) (NN efficacy) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910|ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1
-1 	|BT| (NP (NP (ADVP (RB However)) (, ,) (NP (NN investigation) (JJ protective) (NN effect) (NN betaine) (NN hepatocarcinogenesis)))) |ET| |BS|225:E05.337 743:D02.092.877.883.077|ES| 2:1 19:1 75:1 433:1 493:1 900:1 1497:1 2636:1
-1 	|BT| (S (NP (NN HTHQ)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN carcinogenesis) (CD two) (NN stage) (NN colon) (NN carcinogenesis) (NN model)) (S (VP (VBG using) (NP (NP (NP (NN 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-))) (NN initiator))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725|ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1
-1 	|BT| (S (NP (JJ Hyperactive) (NN EGFR) (NN signaling) (NN Stat3) (NN Jak-Stat3) (NN activity)) (ADVP (RB together)) (VP (VBP promote) (SBAR (S (NP (NP (JJ ovarian) (NN cancer) (NN progression) (NN cisplatin) (NN resistance)) (ADVP (RB therefore))) (VP (VBP represent) (NP (NP (NN target)) (VP (VBG preventing) (NP (NN development) (NN cisplatin) (NN resistance) (JJ recurrent) (NN disease) (NN cisplatin) (NN therapy) (JJ ovarian) (NN cancer))))))))) |ET| |BS|16:C23.550.291.656 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 288:C23.550.288 496:C23.550.291.937 498:D01.210.375 745:C10.597.350.350|ES| 18:1 19:1 35:1 48:1 130:1 160:1 187:1 195:1 218:1 399:1 679:1 799:1 998:1 1094:1 1538:1 1753:1 1761:1 1763:1 1937:1 2645:1 2646:1 2647:1
-1 	|BT| (FRAG (NP (NP (JJ Immunohistochemical) (NN analysis)) (JJ late) (NN stage) (NN tumor) (NN promotion) (NN oxfendazole) (NN rat) (NN hepatocarcinogenesis) (NN model))) |ET| |BS|8:C04 38:Z01.058.290.120.180 40:Z01.542.248.700 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 7:1 19:1 72:1 661:1 849:1 900:1 1129:1 2337:1 2648:1 2649:1 2650:1
-1 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN cotreatment) (JJ low) (NNS dos) (NP (NP (NNS oligoamines) (NN DNA) (NN methyltransferase) (NN inhibitor)) (ADVP (RB highly)))) (VP (VBZ induces) (SBAR (S (NP (NN reexpression)) (ADVP (RB aberrantly)) (VP (VBD silenced) (SBAR (S (NP (NN SFRP2) (NN gene)) (VP (VBP result) (NP (NP (JJ significant) (NN inhibition) (NN growth)) (VBN established) (NN tumor) (JJ human) (NN colon) (NN tumor) (NN model)) (FW vivo))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240|ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1
-1 	|BT| (S (PP (IN In) (NP (CD 2012) (NN case) (NN report))) (, ,) (VP (VBN described) (NP (NP (NN breakthrough)) (VP (VBG finding) (NP (NP (CD two) (JJ advanced) (NNP HCC) (NN patient)) (, ,) (NP (S (NP (CD one)) (VP (VBD achieved) (SBAR (S (NP (JJ complete) (NN remission) (NN liver) (NN tumor)) (VP (VBD normalized) (NP (NP (NN alpha-fetoprotein) (NN level)) (, ,) (PP (IN along) (NP (JJ complete) (NN remission) (NN lung) (NN metastasis))))))))) (, ,) (NP (JJ concomitant) (NN use) (NN thalidomide) (NN cyproheptadine)))))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 275:C23.888 405:V03.100 406:V03.100 515:C04.588.274.623 747:D02.455.426.559.847.181.384.340 748:D12.776.124.790.106.092 749:D02.241.223.805.810.800|ES| 2:1 7:1 19:1 120:1 172:1 244:1 249:1 328:1 417:1 441:1 634:1 806:1 836:1 927:1 933:1 934:1 997:1 1010:1 1659:1 1681:1 2491:1 2661:1 2662:1 2663:1 2664:1 2665:1 2666:1 2667:1 2668:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN alpha-mangostin)) (VP (MD may) (VP (VB chemopreventive) (NP (NP (NN benefit)) (CC and/or) (VP (VB prove) (NP (NP (JJ useful) (JJ adjuvant) (NN therapy)) (, ,) (NP (JJ complementary) (NN alternative) (NN medicine) (NN treatment) (NN breast) (NN cancer)))))))) |ET| |BS|52:E02 685:D27.505.696.477.067 687:D26.650.064 750:E02.190|ES| 2:1 18:1 19:1 23:1 130:1 149:1 244:1 468:1 491:1 546:1 1036:1 1946:1 2246:1 2327:1 2479:1 2619:1 2669:1 2670:1 2671:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (NN dioscin) (NN show) (JJ excellent) (JJ protective) (NN effect)) (JJ ethanol-induced) (NN liver) (NN injury)) (S (VP (VBG ameliorating) (NP (NP (JJ ethanol-induced) (JJ oxidative) (NN stress)) (, ,) (NP (JJ mitochondrial) (NN function)) (, ,)) (NP (NP (JJ inflammatory) (NP (NN cytokine)) (NN production)) (, ,) (NP (NN apoptosis) (NN liver) (NN steatosis)) (, ,))))) (VP (VBD developed) (NP (JJ new) (NN drug) (NN treatment) (JJ ethanol-induced) (NN liver) (NN injury) (NN future)))) |ET| |BS|39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241|ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN simvastatin)) (VP (VBD inhibited) (NP (NP (NN colon) (NN cancer) (NN development) (NN induction)) (NN apoptosis) (NN suppression) (NN angiogenesis)))) |ET| |BS|39:G04.299.139.160 122:C14.280.383 754:D02.455.426.559.847.638.400.900|ES| 2:1 18:1 19:1 35:1 89:1 113:1 244:1 365:1 736:1 1284:1 2453:1 2502:1 2679:1
-1 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (VP (VBP inhibit) (NP (NP (JJ colitis-related) (NN mouse) (NN colon) (NN carcinogenesis)) (VBN compared) (NN effect) (NN sulfasalazine))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 737:D04.808.105.225.272.962 755:D02.065.884.730|ES| 2:1 10:1 14:1 19:1 50:1 52:1 75:1 113:1 131:1 175:1 207:1 221:1 244:1 403:1 1275:1 1370:1 2630:1 2631:1 2680:1 2681:1
-1 	|BT| (FRAG (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBD investigated) (NP (JJ anticancer) (NN activity) (JJ tolfenamic) (NN acid) (JJ human) (JJ colorectal) (NN cancer) (NN cell)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 17:1 18:1 19:1 36:1 94:1 131:1 244:1 399:1 403:1 1275:1 1307:1 1880:1 2598:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN shown) (NP (NP (JJ myrtenal) (, ,) (JJ natural) (NN monoterpene)) (, ,) (NP (VP (VBP act) (SBAR (S (NP (JJ antineoplastic) (NN agent) (NN diethylnitrosamine)) (VP (VBD induced) (NP (JJ phenobarbital) (VBN promoted) (NP (JJ experimental) (JJ hepatocellular) (NN carcinoma))))))))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575|ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD demonstrated) (NP (NP (NN alantolactone)) (, ,) (NP (NN sesquiterpene) (NN lactone)) (, ,) (NP (NP (JJ potential) (NN activity) (JJ triple-negative) (NN breast) (NN cancer) (NN MDA-MB-231) (NN cell) (JJ suppressing) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN signaling) (NN pathway))))) |ET| |BS|41:A11 69:G02.111.087.800 160:C04.588.180.788 209:G02.111.087.847 250:E07.305.812 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 761:G02.111.087.800 762:D02.455.849.765 763:Z01.542.248.540 764:D02.540|ES| 2:1 10:1 14:1 18:1 19:1 23:1 26:1 94:1 131:1 195:1 244:1 251:1 383:1 399:1 487:1 827:1 859:1 860:1 861:1 862:1 1175:1 1307:1 2250:1 2686:1 2687:1 2688:1 2689:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN examined) (NN effect) (NN pitavastatin) (: -) (NN drug)) (VP (VBD used) (S (NP (NN treatment) (NN hyperlipidemia)) (: -) (NP (NP (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (S (NP (NP (NN liver) (JJ preneoplastic) (NN lesion) (NN C57BL/KsJ-db/db)) (PRN (-LRB- -LRB-) (NP (NN db/db)) (-RRB- -RRB-))) (NP (JJ obese) (NN mouse))))))) |ET| |BS|52:E02 67:D26 242:A03.620 554:D02.654.442.200 593:B01.050.050.199.520.520.420 765:B01.050.150.900.649.865.635.505.500.550.530 766:C18.452.584.500.500|ES| 2:1 10:1 14:1 19:1 35:1 52:1 75:1 131:1 191:1 244:1 324:1 409:1 476:1 546:1 836:1 1131:1 1307:1 1438:1 1875:1 1952:1 2468:1 2690:1 2691:1 2692:1 2693:1 2694:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN shown) (NN diosmin)) (VP (VBZ attenuates) (SBAR (S (NP (NP (NN 2-AAF)) (VP (VBD induced) (NP (NP (NP (JJ hepatic) (NN toxicity) (JJ early) (NN tumor) (NN promotion) (NN marker)) (PRN (-LRB- -LRB-) (NP (NP (NN ODC)) (, ,) (NP (NN PCNA) (NN Ki67))) (-RRB- -RRB-))) (, ,) (NP (JJ chemopreventive) (NN efficacy) (NN DEN))))) (VP (VBD initiated) (NP (JJ 2-AAF) (VBN promoted) (NN hyper-proliferation) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))))) |ET| |BS|376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740|ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1
-1 	|BT| (NP (NP (PP (IN In) (NP (NN study))) (, ,) (NP (NP (NP (NN report) (NN effect) (NN resveratrol) (JJ early) (JJ advanced) (NN stage) (NN hepatocarcinogenesis) (NN model) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VBN induced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ male) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 2:1 10:1 14:1 19:1 72:1 75:1 131:1 244:1 303:1 304:1 409:1 417:1 441:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1712:1 1875:1 2602:1 2603:1
-1 	|BT| (S (NP (NN Inflexinol)) (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN growth) (NN inhibition) (JJ nuclear) (NN factor-kappaB) (NN activity)) (PP (IN via) (NP (JJ direct) (NN interaction) (NN p50))))) |ET| |BS|41:A11 43:F01.145.544 45:G07.700.320.249 122:C14.280.383 210:D12.776.260.600|ES| 18:1 19:1 94:1 102:1 103:1 113:1 399:1 596:1 615:1 618:1 1256:1 1891:1 2377:1 2701:1 2702:1
-1 	|BT| (S (NP (NN Inhibition) (JJ retinoic) (NN acid) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NN N-nitrosomorpholine) (NN expression) (NN myc) (NN oncogene) (NN protein) (JJ Sprague-Dawley) (NN rat)))) |ET| |BS|43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500|ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1
-1 	|BT| (NP (NP (NN Inhibition) (NP (NN c-Jun) (JJ NH2-terminal) (NN kinase) (NN switch)) (NN Smad3) (NN signaling) (NN oncogenesis) (NN tumor)) (: -) (NP (NN suppression) (NN rat) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 43:F01.145.544 69:G02.111.087.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 771:D08.811.913.696.620.682.700.567.374|ES| 19:1 195:1 303:1 304:1 470:1 849:1 1686:1 2453:1 2703:1 2708:1 2709:1 2710:1 2711:1 2712:1
-1 	|BT| (NP (NP (NP (JJ Inhibitory) (NN effect) (JJ oleanolic) (NN acid) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (NP (JJ ERK-p53-mediated) (NN cell) (NN cycle) (NN arrest)) (NP (JJ mitochondrial-dependent) (NN apoptosis)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 772:D02.455.849.919.530.733 773:G04.299.134.109|ES| 19:1 75:1 89:1 94:1 303:1 304:1 596:1 601:1 602:1 1275:1 2713:1 2714:1 2715:1 2716:1
-1 	|BT| (NP (NP (JJ Inhibitory) (NN effect) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1
-1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
-1 	|BT| (S (NP (NP (JJ Kruppel-like) (NN factor) (CD 9)) (PRN (-LRB- -LRB-) (NP (NN KLF9)) (-RRB- -RRB-))) (VP (VBZ prevents) (NP (JJ colorectal) (NN cancer) (NN inhibition) (JJ interferon-related) (NN signaling)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 69:G02.111.087.800 617:D12.644.276.374.440 774:D12.776.124.125.375|ES| 10:1 14:1 17:1 18:1 19:1 103:1 185:1 195:1 318:1 703:1 2717:1 2718:1 2719:1
-1 	|BT| (S (NP (NN Latexin)) (VP (VBP exhibit) (NP (NN tumor) (NN suppressor) (JJ potential) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|104:C04.557.470.200.025.255 175:J01.897.280.500.269 206:G05.360.340.024.340.375.249|ES| 7:1 19:1 303:1 304:1 587:1 700:1 827:1 2720:1
-1 	|BT| (S (NP (NN Liver) (NN cell) (NN proliferation)) (VP (VBD increased) (ADVP (RB significantly)) (NP (NP (NN liver) (NN tumor) (JJ tamoxifen-treated) (NN rat)) (NP (ADJP (CD 12) (NN month)) (NN treatment) (NN recovery) (NN period))))) |ET| |BS|52:E02 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 775:E02.760.058 776:G01.910.645|ES| 7:1 19:1 47:1 94:1 124:1 299:1 546:1 836:1 849:1 1120:1 2721:1 2722:1 2723:1 2724:1 2725:1
-1 	|BT| (S (S (NP (JJ Liver-specific) (NN deletion) (NN prohibitin) (CD 1)) (VP (VBP result) (NP (JJ spontaneous) (NN liver) (NN injury)))) (, ,) (NP (NP (NN fibrosis)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 242:A03.620 306:G05.355.600.800 691:C23.550.355|ES| 2:1 19:1 52:1 98:1 101:1 283:1 303:1 304:1 836:1 949:1 1059:1 2416:1 2726:1 2727:1
-1 	|BT| (S (NP (NN Loss) (NN Dicer)) (ADVP (RB primarily)) (VP (VBZ impairs) (SBAR (S (NP (NN hepatocyte) (NN survival)) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN cooperation) (JJ additional) (JJ oncogenic) (NN stimulus))))))) |ET| |BS|96:I03.784 262:A11.436.348 279:D27.888.569.100|ES| 19:1 274:1 679:1 900:1 953:1 980:1 1788:1 1909:1 1960:1 1970:1 2728:1 2729:1 2730:1
-1 	|BT| (S (NP (NN Loss) (NN metallothionein)) (VP (VBZ predisposes) (NP (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (VBG activating) (NN NF-kappaB) (NN target) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670|ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1
-1 	|BT| (S (NP (NNP Lycopene) (JJ active) (JJ chemopreventive) (NN agent) (NN offer) (NN protection) (JJ DEN-induced) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (NN NF-kappaB) (NN mTOR) (NN pathway)))) |ET| |BS|122:C14.280.383 210:D12.776.260.600|ES| 19:1 197:1 383:1 714:1 728:1 880:1 900:1 1042:1 1946:1 2733:1 2734:1 2735:1 2736:1
-1 	|BT| (S (NP (NN Magnolol)) (VP (MD could) (ADVP (RB potentially)) (NP (JJ safe) (JJ potent) (JJ anticarcinogenic) (NN agent) (NN skin) (NN cancer)))) |ET| |BS|778:D27.505.954.444|ES| 18:1 19:1 22:1 333:1 728:1 773:1 908:1 2312:1 2319:1 2737:1
-1 	|BT| (S (NP (NN Melatonin)) (VP (VBD improved) (SBAR (S (NP (NN survival) (NN rate)) (VP (ADVP (RB successfully)) (VBD attenuated) (NP (NN liver) (NN injury))))) (, ,) (VP (VBN shown) (NP (NN histopathology))) (, ,) (VP (VBD decreased) (NP (NP (NN level) (NN serum) (NN transaminase)) (NP (VBN reduced) (NN expression) (JJ placental) (NN glutathione) (NN S-transferase)))))) |ET| |BS|242:A03.620 707:D03.438.473.914.481 779:E05.318.308.985.550.900 780:D08.811.913.225.500 781:D08.811.913.477.700 782:A12.207.152.846 783:A16.710|ES| 2:1 19:1 41:1 115:1 202:1 237:1 249:1 274:1 452:1 808:1 836:1 2410:1 2416:1 2738:1 2739:1 2740:1 2741:1 2742:1 2743:1 2744:1 2745:1
-1 	|BT| (S (NP (NN Metformin)) (VP (VBZ inhibits) (NP (JJ early) (NN stage) (JJ diethylnitrosamineinduced) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450|ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1
-1 	|BT| (NP (NP (NP (NN METHODOLOGY/PRINCIPAL) (NNS FINDINGS)) (: :) (NP (NP (JJ Pancreatic) (NN cancer) (NN cell) (NN line)) (VP (VBN treated) (NP (NN resveratrol)))))) |ET| |BS|52:E02 94:A11.251.210|ES| 18:1 19:1 94:1 104:1 264:1 1099:1 1213:1 1712:1 2748:1 2749:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (JJ UVB-induced) (NN skin) (NN carcinogenesis) (NN model) (NN SKH-1) (NN mouse)) (VP (VBN used) (S (VP (VBG determining) (NP (JJ preventive) (NN effect) (NN magnolol) (NN skin) (NN cancer) (NN development))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 168:E05.581 785:A17.815|ES| 18:1 19:1 35:1 52:1 72:1 75:1 104:1 207:1 476:1 565:1 1883:1 2319:1 2526:1 2750:1 2751:1 2752:1
-1 	|BT| (S (NP (NN Methyl) (NN antcinate) (NN A) (NN Antrodia) (NN camphorata)) (VP (VBZ induces) (NP (NP (NN apoptosis) (JJ human) (NN liver) (NN cancer) (NN cell) (JJ oxidant-mediated) (NN cofilin)) (: -) (NP (JJ Bax-triggered) (JJ mitochondrial) (NN pathway))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 342:D12.644.360.075.718.400 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 573:N05.715.350.200.650 786:B01.300.179.120.174.070 787:D27.720.642|ES| 18:1 19:1 36:1 69:1 89:1 94:1 214:1 383:1 836:1 2004:1 2753:1 2754:1 2755:1 2756:1 2757:1 2758:1 2759:1
-1 	|BT| (NP (NP (NN Modulation) (NN energy) (JJ metabolic) (NN enzyme) (NN expression) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (JJ Chinese) (NN herb)) (, ,) (NP (NNP Huqi) (NNP San))) |ET| |BS|554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500|ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1
-1 	|BT| (FRAG (ADVP (RBR More) (RB importantly)) (, ,) (NP (NP (NN EPLE)) (VBN hampered) (NN tumor) (NN development) (NN CRC) (NN xenograft) (NN model))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 92:E04.936.764 93:A01.941.875|ES| 2:1 7:1 19:1 35:1 72:1 245:1 265:1 2489:1 2767:1 2768:1 2769:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (S (VP (VBG using) (NP (NP (NN mouse) (NN xenograft) (NN model)) (, ,) (NP (NN show) (NN treatment) (JJ specific) (NNP PPOX) (NN inhibitor) (NN acifluorfen))))) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NP (NN growth) (CD three) (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 42.8) (NN %)) (-RRB- -RRB-))) (NN colon) (NN cancer) (NN line)) (NP (VBN investigated))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875|ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 102:1 113:1 124:1 264:1 265:1 350:1 369:1 380:1 403:1 429:1 452:1 482:1 540:1 546:1 622:1 1733:1 2770:1 2771:1 2772:1
-1 	|BT| (S (NP (NP (NNP Myrtenal)) (, ,) (NP (JJ natural) (NN monoterpene)) (, ,)) (VP (VBZ down-regulates) (SBAR (S (NP (NN TNF-alpha) (NN expression)) (VP (VBZ suppresses) (NP (JJ carcinogen-induced) (JJ hepatocellular) (NN carcinoma) (NN rat))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 351:A17.360 758:D02.455.849.575 789:D12.644.276.374.500.800 790:D12.644.276.374.750|ES| 2:1 19:1 115:1 303:1 304:1 686:1 849:1 2333:1 2421:1 2683:1 2773:1 2774:1 2775:1
-1 	|BT| (S (NP (NN N-acetyl-L-cysteine)) (VP (VBD blocked) (SBAR (S (NP (NN EGFR) (NN activation)) (VP (VBD reduced) (NP (JJ N-nitrosodiethylamine-initiated) (NN hepatocarcinogenesis) (NN level) (NNP Cre-Ctrl) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259|ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1
-1 	|BT| (S (NP (JJ Natural) (NNS polyphenols)) (VP (VBP facilitate) (NP (NP (NN elimination) (NN HT-29) (JJ colorectal) (NN cancer) (NN xenograft) (NN chemoradiotherapy)) (: :) (NP (NP (NN Bcl-2)) (: -) (NP (NN superoxide) (NN dismutase) (JJ 2-dependent) (NN mechanism)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 56:D02.455.426.559.389.657.715 59:E02.186.079 92:E04.936.764 93:A01.941.875 792:A11.251.210.190.475|ES| 17:1 18:1 19:1 104:1 146:1 147:1 154:1 156:1 162:1 265:1 1989:1 2780:1 2781:1 2782:1 2783:1 2784:1
-1 	|BT| (S (NP (JJ Natural) (NN product) (NN pectolinarigenin)) (VP (VBZ inhibits) (NP (NN osteosarcoma) (NN growth) (NN metastasis)) (PP (IN via) (NP (JJ SHP-1-mediated) (NN STAT3) (NN signaling) (NN inhibition))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383 447:C04.557.450.565.575.650 793:D20.215|ES| 19:1 102:1 103:1 195:1 251:1 596:1 615:1 675:1 806:1 1562:1 2780:1 2785:1 2786:1
-1 	|BT| (S (NP (NN Nitidine) (NN chloride)) (VP (VBZ inhibits) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN cell)) (NN growth)) (NP (FW vivo) (NN suppression) (NN JAK1/STAT3) (NN signaling) (NN pathway)))) |ET| |BS|41:A11 45:G07.700.320.249 69:G02.111.087.800 82:D12.644.360.024.342.300 104:C04.557.470.200.025.255 122:C14.280.383 126:G02.111.087.800 794:D08.811.913.696.620.682.725.124.100|ES| 19:1 94:1 102:1 195:1 303:1 304:1 378:1 383:1 615:1 2453:1 2787:1 2788:1 2789:1
-1 	|BT| (NP (NP (NP (JJ Nitric) (JJ oxide-releasing) (NN aspirin) (NN indomethacin) (JJ potent) (NN inhibitor) (NN colon) (NN cancer) (JJ azoxymethane-treated) (NN rat)) (: :) (NP (NN effect) (JJ molecular) (NN target)))) |ET| |BS|52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420|ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1
-1 	|BT| (NP (NP (JJ Non-steroidal) (JJ anti-inflammatory) (NN drug) (NN sulindac) (JJ promising) (NN chemoprevention) (NN agent) (NN colon) (NN cancer)) (, ,) (NP (JJ weak) (NN potency) (NN side) (NN effect) (NN limit) (NN use) (NN chemoprevention) (NN chemotherapy))) |ET| |BS|151:E02.319 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500|ES| 2:1 18:1 19:1 75:1 113:1 191:1 338:1 495:1 728:1 869:1 870:1 871:1 1517:1 1659:1 2794:1 2795:1 2796:1 2797:1
-1 	|BT| (S (S (ADVP (RB Notably)) (, ,) (NP (JJ adeno-XAF1) (NN treatment)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN tumor) (NN growth)) (, ,) (ADVP (NP (ADJP (RB strongly) (VBN enhanced)) (NN antitumor) (NN activity) (NN TRAIL) (JJ gastric) (NN cancer) (NN xenograft) (NN model)) (FW vivo)) (, ,) (NP (RB significantly) (JJ prolonged) (NN survival) (NN time) (JJ animal) (NN bearing) (NN tumor) (NN xenograft))))) |ET| |BS|8:C04 19:B01.050 45:G07.700.320.249 52:E02 92:E04.936.764 93:A01.941.875 96:I03.784 122:C14.280.383 322:G01.910 455:B01.050.150.900.649.147.890|ES| 2:1 7:1 18:1 19:1 46:1 72:1 86:1 102:1 124:1 265:1 274:1 365:1 378:1 385:1 399:1 546:1 635:1 1081:1 1584:1 1695:1 2244:1 2798:1 2799:1 2800:1
-1 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN colon) (NN tumor) (NN prevention) (NN activity) (NN sulindac)) (VP (VP (VBN accompanied) (NP (NP (JJ marked) (NN induction) (JJ lymphoid) (NN aggregate)) (NP (JJ proximal) (JJ colonic) (JJ inflammatory) (NN mass) (NN lesion)))) (, ,) (VP (S (NP (JJ side) (NN effect)) (VP (VBN seen) (NP (JJR lesser) (NN degree) (NN celecoxib)))) (, ,) (NP (NN aspirin))))) |ET| |BS|51:C04.588.274.476.411.307.180 213:F02.830.816.964 251:D02.455.426.559.847.486.875 670:D02.455.426.559.389.657.410.595.176 684:D02.065.884.247 797:A10.549.600|ES| 2:1 7:1 19:1 75:1 113:1 399:1 677:1 724:1 736:1 869:1 871:1 1070:1 1131:1 1474:1 1967:1 2430:1 2487:1 2798:1 2801:1 2802:1 2803:1 2804:1 2805:1 2806:1 2807:1
-1 	|BT| (S (NP (JJ Nuclear) (NN Maspin) (NN expression)) (NP (ADJP (RB highly) (JJ predictive)) (NN 5-FU) (NN chemotherapy) (NN response) (NN patient)) (VP (VBD advanced) (NP (NN stage) (NN colon) (NN cancer)))) |ET| |BS|50:M01.643 151:E02.319 560:D03.383.742.698.875.404|ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1
-1 	|BT| (FRAG (PP (IN On) (NP (NN basis) (NN finding) (, ,) (NN development) (NN 2-aryl) (NN benzimidazole) (NN derivative))) (, ,) (NP (NP (JJ new) (NN class) (JJ multitarget) (JJ anticancer) (NN agent)) (, ,) (VP (VBD warranted) (VP (VBZ represents) (NP (NP (JJ novel) (NN strategy)) (VP (VBG improving) (NP (NN breast) (NN cancer) (NN treatment)))))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 660:D27.505.954.248 798:D03.438.103|ES| 2:1 18:1 19:1 23:1 35:1 546:1 712:1 728:1 891:1 927:1 1114:1 1140:1 1880:1 2363:1 2516:1 2810:1 2811:1 2812:1 2813:1 2814:1 2815:1 2816:1
-1 	|BT| (S (NP (ADJP (RB Orally) (VBN administered)) (NN lycopene)) (VP (VBZ attenuates) (NP (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN rat)) (VP (VBG modulating) (NP (NP (NN Nrf-2)) (: /) (NP (NN HO-1) (NN Akt/mTOR) (NN pathway))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534|ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (SBAR (S (NP (NN nifuroxazide)) (VP (MD may) (ADVP (RB potentially)) (NP (JJ therapeutic) (NN agent) (NN growth) (NN metastasis) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 113:C04.697.650|ES| 18:1 19:1 23:1 102:1 491:1 541:1 658:1 728:1 773:1 793:1 806:1 1541:1 2820:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (VP (VBD indicated) (NP (NP (NN silymarin) (JJ therapeutic) (NN effect)) (NP (JJ early) (NN stage) (NN liver) (NN damage))) (, ,) (S (VP (VBG reversing) (NP (NP (JJ fatty) (NN change)) (VP (VBG recovering) (NP (NN liver) (NN histopathology) (JJ dose-dependent) (NN manner)))))))) |ET| |BS|242:A03.620 801:D03.383.663.283.266.450.268.777|ES| 2:1 19:1 75:1 200:1 541:1 658:1 793:1 836:1 1128:1 1129:1 1541:1 1668:1 1848:1 2070:1 2740:1 2821:1 2822:1 2823:1 2824:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB thus)) (VP (VBP establish) (SBAR (S (NP (NN EPLE) (JJ novel) (NN inhibitor) (NN Wnt) (NN signaling)) (VP (VBP hold) (NP (JJ great) (NN promise) (JJ potential) (NN candidate) (JJ preclinical) (NN evaluation) (NN CRC) (NN treatment))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 69:G02.111.087.800 225:E05.337 259:D12.776.395.240.150.500|ES| 19:1 195:1 220:1 245:1 380:1 546:1 658:1 793:1 827:1 877:1 891:1 1243:1 1334:1 1494:1 2489:1 2503:1 2825:1 2826:1 2827:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data) (NN pterostilbene)) (VP (VBG suppressing) (NP (NP (NN colon) (NN tumorigenesis)) (, ,) (NP (NN cell) (NN proliferation)) (NP (ADJP (RB well) (JJ key)) (JJ inflammatory) (NN marker))) (ADVP (FW vivo) (FW vitro)) (VP (VBP suggest) (NP (JJ potential) (NN use) (NN pterostilbene) (NN colon) (NN cancer) (NN prevention))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 158:D23.101 183:G04.299.233.750|ES| 2:1 18:1 19:1 78:1 94:1 113:1 159:1 216:1 299:1 378:1 534:1 658:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (ADVP (RB also)) (VP (VBD showed) (SBAR (S (NP (NP (JJ myrtenal) (NNS restrains) (NN liver) (NN cancer)) (VP (VBG preventing) (NP (NN DEN-PB)))) (VP (VBD induced) (NP (NN up-regulation) (NN TNF-alpha) (NN protein) (NN expression) (NN immunoblot))))))) |ET| |BS|7:D12.776 122:C14.280.383 142:I01.880.604 789:D12.644.276.374.500.800 790:D12.644.276.374.750 802:E05.478.566.320|ES| 4:1 5:1 18:1 19:1 115:1 132:1 412:1 658:1 836:1 896:1 927:1 1937:1 2682:1 2775:1 2828:1 2829:1 2830:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (NP (NN rimonabant) (ADJP (JJ able) (S (VP (VBP inhibit) (NP (NP (JJ colorectal) (NN cancer) (NN cell) (NN growth) (JJ different) (NN stage) (NN colon) (NN cancer) (NN pathogenesis)) (VP (VBG inducing) (NP (JJ mitotic) (NN catastrophe) (NN vitro)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 122:C14.280.383 385:F02.784.629.131|ES| 17:1 18:1 19:1 94:1 102:1 113:1 216:1 414:1 501:1 658:1 720:1 796:1 927:1 1129:1 1370:1 1864:1 2831:1 2832:1 2833:1
-1 	|BT| (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (VBP identify) (S (NP (NP (JJ chemopreventive) (JJ potential) (NN pterostilbene) (JJ colonic) (NN tumor) (NN formation)) (NN end) (NN point)) (VP (VB evaluate) (NP (JJ mechanistic) (NN action) (NN pterostilbene) (NN colon) (NN carcinogenesis)))))) |ET| |BS|20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 225:E05.337 742:G03.787|ES| 7:1 19:1 43:1 113:1 131:1 207:1 658:1 677:1 827:1 832:1 890:1 1307:1 1890:1 1946:1 2013:1 2121:1 2428:1 2834:1
-1 	|BT| (S (NP (PRP$ Our) (JJ previous) (NN study)) (VP (VBD demonstrated) (SBAR (S (NP (NP (JJ garlic) (NN oil)) (PRN (-LRB- -LRB-) (NP (NN GO)) (-RRB- -RRB-))) (VP (MD could) (VP (VB prevent) (NP (JJ NDEA-induced) (NN hepatocarcinogenesis) (NN rat)) (, ,) (NP (NP (VBG underlying) (NN mechanism)) (VP (ADVP (RB fully)) (VBN understood))))))))) |ET| |BS|239:F02.463.188.357 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 131:1 162:1 435:1 658:1 733:1 849:1 889:1 900:1 908:1 979:1 1175:1 1819:1 2614:1 2835:1 2836:1 2837:1
-1 	|BT| (S (PRP$ Our) (VP (VBP result) (ADVP (RB clearly)) (VP (VBP indicate) (SBAR (S (NP (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (VBD exert) (NP (JJ marked) (NN chemoprevention) (JJ DENA-initiated) (NN hepatocarcinogenesis) (NN inhibition) (JJ abnormal) (NN cell) (NN proliferation) (NN induction) (NN apoptosis)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 253:E02.319.162 554:D02.654.442.200 803:D01.248.497.158.845 804:D09.698|ES| 19:1 89:1 94:1 101:1 103:1 299:1 658:1 736:1 870:1 900:1 1229:1 1479:1 2802:1 2838:1 2839:1 2840:1 2841:1 2842:1 2843:1 2844:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP demonstrate)) (, ,) (NP (ADVP (JJ first) (NN time)) (, ,) (NP (NP (NP (ADJP (NN elaiophylin) (JJ novel)) (NN autophagy) (NN inhibitor)) (, ,) (NP (NP (JJ significant) (NN antitumor) (NN efficacy)) (JJ single) (NP (NN agent) (NN combination) (JJ human) (JJ ovarian) (NN cancer) (NN cell)))) (, ,) (VP (VBG establishing) (NP (JJ potential) (NN treatment) (JJ ovarian) (NN cancer) (NN compound)))))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 259:D12.776.395.240.150.500 322:G01.910 390:G04.299.139.399 660:D27.505.954.248 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725|ES| 2:1 18:1 19:1 36:1 94:1 101:1 135:1 380:1 502:1 530:1 546:1 658:1 728:1 816:1 827:1 891:1 1081:1 1317:1 1763:1 2244:1 2304:1 2433:1 2845:1 2846:1 2847:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NNP Lrat) (NNP KO) (NN mouse)) (NP (DT le) (JJ susceptible) (JJ DEN-induced) (NN hepatocarcinogenesis)) (ADVP (RB due)) (VP (VBD increased) (NP (ADJP (NP (NN retinoid) (NN signaling)) (JJR higher)) (NN expression) (NN p21)) (, ,) (SBAR (S (NP (NP (VBN accompanied) (JJ altered) (JJ hepatic) (NN level)) (JJ DEN-activating) (NN enzyme) (NNP MGMT) (NNP Lrat) (NNP KO) (NN mouse)) (ADVP (RB also)) (VP (VBP contribute) (SBAR (S (NP (VBN decreased) (NN cancer) (NN initiation)) (VP (VBD suppressed) (NP (NN liver) (NN tumor) (NN development))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 515:C04.588.274.623 649:E01.370.225.124.200 711:D02.455.326.271.665.202.495 807:D08.811.913.555.500.800.650|ES| 2:1 5:1 7:1 18:1 19:1 35:1 47:1 52:1 101:1 115:1 170:1 195:1 202:1 249:1 307:1 450:1 637:1 658:1 693:1 836:1 838:1 899:1 900:1 1135:1 1479:1 2388:1 2573:1 2735:1 2801:1 2848:1 2849:1 2850:1 2851:1 2852:1 2853:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (SBAR (S (NP (NP (NN administration) (NN resveratrol)) (UCP (CC either) (NP (JJ early) (JJ advanced) (NN stage) (NN hepatocarcinogenesis)) (ADJP (RB equally) (JJ effective)))) (VP (VBZ involves) (NP (NP (NN activation)) (NP (JJ apoptotic) (NN pathway) (NN male) (NNP Wistar) (NN rat)))))))) |ET| |BS|39:G04.299.139.160 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 39:1 101:1 225:1 383:1 658:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1479:1 1639:1 1673:1 1712:1 2223:1 2575:1 2603:1 2854:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (NP (NN show) (NN enzastaurin) (JJ effective) (JJ chemopreventive) (NN agent) (NN mouse) (NN model) (JJ sporadic) (NN colon) (NN cancer)) (SBAR (S (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (NN expression) (JJ proproliferative) (NN gene)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 16:C23.550.291.656 122:C14.280.383 155:G05.355.310|ES| 7:1 9:1 18:1 19:1 48:1 52:1 72:1 101:1 113:1 115:1 124:1 142:1 429:1 637:1 658:1 725:1 728:1 880:1 1639:1 1946:1 2855:1 2856:1
-1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (NP (NN cimetidine) (VBG inhibiting) (NN effect) (NN hepatocarcinogenesis)))) |ET| |BS|12:Z01.542.049 122:C14.280.383 808:D02.078.370.200|ES| 19:1 75:1 101:1 132:1 658:1 880:1 900:1 2857:1
-1 	|BT| (S (NP (PRP$ Our) (NN study)) (VP (VBZ demonstrates) (NP (NP (NN inhibition) (NN cell) (NN proliferation) (NN regulation)) (SBAR (S (NP (JJ inflammatory) (NN marker)) (VP (MD may) (, ,) (ADVP (JJS least) (NN part)) (, ,) (S (VP (VBG underlying) (NP (NN mechanism) (JJ related) (NN liver) (NN tumor) (NN inhibition) (NN diosmin)))))))))) |ET| |BS|41:A11 43:F01.145.544 85:G02.111.087.225 158:D23.101 183:G04.299.233.750 515:C04.588.274.623 715:D03.383.663.283.266.450.260.222|ES| 2:1 7:1 19:1 94:1 103:1 131:1 162:1 299:1 419:1 435:1 438:1 451:1 491:1 534:1 658:1 836:1 1331:1 2430:1 2541:1 2695:1
-1 	|BT| (S (NP (JJ Overall) (NN finding)) (VP (VBP substantiate) (SBAR (S (NP (NN artesunate)) (VP (VBZ promotes) (SBAR (S (NP (JJ anti-tumour) (, ,) (JJ anti-proliferation) (NN apoptosis) (NN nitrosodiethylamine)) (VP (VBD mediated) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500|ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1
-1 	|BT| (SINV (S (NP (JJ Overall) (NN analysis)) (VP (VBD indicated) (SBAR (S (NP (NN pterostilbene)) (VP (VBD reduced) (NP (NN colon) (NN tumor) (NN multiplicity) (JJ non-invasive) (NN adenocarcinoma))))))) (, ,) (VP (VBD lowered) (S (VP (VBG proliferating) (NP (NN cell) (JJ nuclear) (NN antigen))))) (VP (VBD downregulated) (NP (NN expression) (NN beta-catenin) (NN cyclin) (NN D1)))) |ET| |BS|23:D12.776.091.249 51:C04.588.274.476.411.307.180 84:C04.557.470.200.025 215:D12.644.360.262.150.100 696:V02.270.500 768:D12.776.660.740|ES| 2:1 7:1 19:1 60:1 94:1 113:1 115:1 255:1 426:1 452:1 661:1 743:1 744:1 1030:1 1256:1 1361:1 1541:1 2428:1 2858:1 2863:1 2864:1 2865:1
-1 	|BT| (S (ADVP (RB Overall)) (, ,) (VP (VBP result) (NP (NN support) (JJ translational) (JJ potential) (NN silibinin) (JJ colorectal) (NN cancer) (NN chemoprevention)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 145:G02.111.087.675.871 253:E02.319.162 696:V02.270.500 809:L01.178.682.920|ES| 2:1 17:1 18:1 19:1 101:1 827:1 870:1 1364:1 2635:1 2858:1 2866:1
-1 	|BT| (S (NP (NN Overexpression) (NN Klotho)) (VP (VBZ suppresses) (SBAR (S (NP (NN liver) (NN cancer) (NN progression)) (VP (VBZ induces) (S (NP (NN cell) (NN apoptosis)) (ADVP (RB negatively)) (VP (VBG regulating) (NP (JJ wnt/beta-catenin) (NN signaling) (NN pathway))))))))) |ET| |BS|16:C23.550.291.656 39:G04.299.139.160 41:A11 105:G02.149.115.800.925|ES| 18:1 19:1 48:1 89:1 94:1 195:1 214:1 383:1 668:1 686:1 836:1 2867:1 2868:1 2869:1 2870:1
-1 	|BT| (S (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma)) (VP (VBZ contributes) (NP (JJ inhibitory) (NN effect) (NN Embelin) (NN colon) (NN carcinogenesis)))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 719:D12.776.826.239.588|ES| 19:1 75:1 113:1 207:1 845:1 1800:1 1801:1 2429:1 2587:1 2871:1
-1 	|BT| (NP (NP (NP (JJ Pharmacogenetic) (NN approach) (NN capecitabine) (NN 5-fluorouracil) (NN selection)) (SBAR (S (NP (VBN combined) (NN oxaliplatin) (JJ first-line) (NN chemotherapy)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 151:E02.319 375:Z01.639.100 560:D03.383.742.698.875.404 810:D03.383.742.680.245.500.425 811:H01.158.273.343.750 812:G05.355.800|ES| 17:1 18:1 19:1 164:1 495:1 911:1 997:1 2307:1 2490:1 2543:1 2872:1 2873:1 2874:1
-1 	|BT| (S (NP (NN Phyllanthus) (NN urinaria)) (VP (VBZ ameliorates) (NP (NN severity) (JJ nutritional) (FW steatohepatitis) (FW vitro) (FW vivo)))) |ET| |BS|508:C06.552.241 813:B01.650.940.800.575.100.350.622|ES| 19:1 216:1 378:1 1473:1 1791:1 2875:1 2876:1 2877:1 2878:1
-1 	|BT| (S (NP (NN Polyenephosphatidylcholine)) (VP (VBZ prevents) (NP (NP (JJ alcoholic) (NN liver) (NN disease) (NN PPARalpha-null) (NN mouse) (NN attenuation) (NN increase)) (JJ oxidative) (NN stress)))) |ET| |BS|29:B01.050.050.136.500.500 536:D12.776.826.239.500 716:G03.495.710 814:C06.552.645|ES| 19:1 40:1 52:1 836:1 998:1 2522:1 2583:1 2718:1 2879:1 2880:1 2881:1 2882:1
-1 	|BT| (S (NP (NP (NP (JJ Polyinosinic-polycytidylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN Poly) (NN I) (: :) (NN C)) (-RRB- -RRB-))) (NN IFN-gamma) (NN treatment)) (VP (VBD inhibited) (NP (NN liver) (NN fibrosis) (JJ pair-fed) (JJ ethanol-fed) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 122:C14.280.383 663:C16.320.565.398.500.330.500 676:C06.552.630 751:D02.033.375 815:D13.695.578.550.560.600 816:G01.358.500.505.300|ES| 10:1 14:1 19:1 52:1 104:1 365:1 546:1 836:1 949:1 1275:1 1955:1 2350:1 2883:1 2884:1 2885:1 2886:1 2887:1
-1 	|BT| (NP (NP (NP (NP (NP (NP (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-) (NN mouse) (JJ susceptible) (JJ DMH-induced) (NN colon) (NN carcinogenesis) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NN mouse))) (, ,) (S (NP (NN embelin)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (NP (NN incidence) (NN colon) (NN cancer) (NN PPARgamma)) (PRN (-LRB- -LRB-) (NP (NP (CC +) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (: -))) (-RRB- -RRB-))) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 434:E05.318.308.985.525.375 719:D12.776.826.239.588|ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 124:1 207:1 452:1 899:1 1511:1 2588:1 2888:1 2889:1
-1 	|BT| (S (NP (NNP Pravastatin)) (VP (VBZ reduces) (NP (NN lung) (NN metastasis) (NN rat) (JJ hepatocellular) (NN carcinoma)) (PP (IN via) (NP (VBN coordinated) (NN decrease) (NN MMP) (NN expression) (NN activity))))) |ET| |BS|104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 817:D02.455.426.559.847.638.930 818:D08.811.277.656.300.480.525|ES| 19:1 115:1 142:1 295:1 303:1 304:1 328:1 399:1 596:1 806:1 849:1 2890:1 2891:1 2892:1
-1 	|BT| (S (NP (JJ Preclinical) (JJ clinical) (NN investigation)) (VP (VBP demonstrate) (SBAR (S (NP (NN aspirin)) (VP (VBP inhibit) (NP (NP (JJ several) (NN type) (NN cancer) (JJ colorectal) (NN adenoma) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))))) |ET| |BS|17:C04.557.470.035 104:C04.557.470.200.025.255 122:C14.280.383 225:E05.337 670:D02.455.426.559.389.657.410.595.176|ES| 10:1 14:1 17:1 18:1 19:1 42:1 84:1 262:1 303:1 304:1 441:1 502:1 543:1 1370:1 1497:1 2487:1 2893:1
-1 	|BT| (S (NP (NP (JJ Pre-operative) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (: -) (NP (VBN based) (NN chemoradiotherapy)) (ADVP (RB locally)) (VP (VBD advanced) (SBAR (S (NP (NP (JJ rectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN UICC-II/III)) (-RRB- -RRB-))) (VP (MD may) (ADVP (RB significantly)) (VP (VB reduce) (NP (JJ local) (NN tumour) (NN mass)))))))) |ET| |BS|8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404|ES| 10:1 14:1 18:1 19:1 124:1 491:1 997:1 1011:1 1985:1 1986:1 1989:1 2307:1 2308:1 2361:1 2804:1 2894:1 2895:1 2896:1 2897:1
-1 	|BT| (NP (NP (NNP Prevention) (NN rat) (NN liver) (NN fibrosis) (NN carcinogenesis) (NN coffee) (NN caffeine))) |ET| |BS|33:C04.697.098 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 652:D20.215.784.249 676:C06.552.630 819:D03.132.960.175|ES| 19:1 207:1 836:1 849:1 949:1 2386:1 2898:1 2899:1
-1 	|BT| (NP (NP (JJ Previous) (NN study)) (VP (VBN shown) (S (NP (NN decorin) (NN expression)) (VP (ADVP (RB significantly)) (VBD reduced) (NP (NP (JJ colorectal) (NN cancer) (NN tissue) (NN cancer) (NN cell)) (, ,) (NP (JJ genetic) (NN deletion) (NN decorin) (NN gene) (JJ sufficient) (NN cause) (JJ intestinal) (NN tumor) (NN formation) (NN mouse)) (, ,) (VP (VBG resulting) (NP (NN downregulation) (NN p21))) (, ,) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN kip1)) (-RRB- -RRB-))) (FRAG (NP (NN E-cadherin) (NN upregulation) (NN beta-catenin) (NN signaling)) (-LRB- -LSB-) (NP (NP (NN Bi)) (, ,) (NP (NN X))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 20:G03.495 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 69:G02.111.087.800 85:G02.111.087.225 98:A10 102:C04.588.274.476.411 249:G05.355.315.800 338:D12.644.360.225.600 339:G02.111.087.880 549:G05.355.600.800.320 708:D12.776.395.650.750.625 820:D12.776.395.550.200.200|ES| 2:1 7:1 9:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 60:1 94:1 109:1 115:1 124:1 131:1 195:1 237:1 242:1 272:1 384:1 452:1 595:1 864:1 929:1 1059:1 1124:1 1126:1 1135:1 1373:1 1779:1 2267:1 2900:1 2901:1 2902:1 2903:1
-1 	|BT| (S (S (NP (JJ Previous) (NN work)) (VP (VBD showed) (NP (NN loss) (NN TIP30)))) (, ,) (ADVP (RB also)) (VP (VBN called) (S (NP (NN CC3))) (, ,) (NP (NP (JJ putative) (NN tumor) (NN suppressor)) (, ,) (NP (VBD increased) (NN incidence) (JJ hepatocellular) (NN carcinoma) (NN mouse)) (, ,) (NP (JJ clinical) (NN sample) (JJ human) (NN HCC) (NN tissue) (JJ aberrant) (NN expression) (NN TIP30))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 98:A10 104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249 434:E05.318.308.985.525.375 445:I03.946|ES| 2:1 5:1 7:1 19:1 32:1 36:1 47:1 52:1 84:1 115:1 132:1 272:1 303:1 304:1 441:1 700:1 835:1 918:1 1511:1 1546:1 1547:1 1725:1 2900:1 2904:1 2905:1
-1 	|BT| (S (NP (NNP Progastrin) (VBG targeting) (NN strategy)) (VP (VBP provide) (NP (JJ exciting) (NN prospect) (NN differentiation) (NN therapy) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 52:E02 74:G04.299.151 821:E05.318.760.500.750.500|ES| 17:1 18:1 19:1 130:1 215:1 616:1 711:1 1114:1 2906:1 2907:1 2908:1
-1 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1
-1 	|BT| (NP (NP (NN Protein) (NN kinase) (JJ potential) (JJ chemotherapeutic) (NN target) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 151:E02.319 823:D08.811.913.696.620.682.700.150.125|ES| 17:1 18:1 19:1 160:1 470:1 827:1 1762:1 2911:1
-1 	|BT| (S (NP (NN Pterostilbene)) (VP (VBZ inhibits) (NP (NP (NP (JJ colorectal) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (NP (NN colon) (NN carcinogenesis)) (PP (IN via) (NP (NN suppression) (JJ multiple) (NN signal) (NN transduction) (NN pathway) (JJ azoxymethane-treated) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 52:E02 122:C14.280.383 126:G02.111.087.800 132:D02.172.080 824:C04.834.020|ES| 10:1 14:1 17:1 19:1 52:1 113:1 207:1 383:1 596:1 615:1 649:1 859:1 1431:1 1725:1 2453:1 2793:1 2912:1 2913:1 2914:1 2915:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (JJ objective)) (VP (VBP investigate) (SBAR (IN whether) (S (NP (NP (NN polymorphism) (JJ putative) (NN influence) (NN fluorouracil/oxaliplatin) (NN activity)) (VBN associated) (JJ clinical) (NN outcome) (NN patient)) (VP (VBD advanced) (NP (NP (JJ colorectal) (NN cancer)) (VP (VBN treated) (NP (NP (JJ first-line) (NN oxaliplatin)) (, ,) (NP (JJ folinic) (NN acid)) (, ,) (NP (NN fluorouracil) (JJ palliative) (NN chemotherapy)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 151:E02.319 307:G05.365.795 415:F01.658.500 560:D03.383.742.698.875.404 825:D03.438.733.631.400.800.350.450 826:F01.752.609|ES| 2:1 17:1 18:1 19:1 84:1 104:1 120:1 169:1 221:1 399:1 459:1 495:1 547:1 687:1 691:1 867:1 918:1 997:1 1060:1 1099:1 1275:1 2490:1 2543:1 2916:1 2917:1 2918:1 2919:1 2920:1
-1 	|BT| (NP (NP (NP (NN Ras) (NN pathway) (NN activation) (JJ hepatocellular) (NN carcinoma) (JJ anti-tumoral) (NN effect)) (NP (VBN combined) (JJ sorafenib) (NN rapamycin) (FW vivo)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 104:C04.557.470.200.025.255 827:D02.540.505.760|ES| 19:1 75:1 164:1 225:1 303:1 304:1 378:1 383:1 1775:1 2063:1 2921:1 2922:1
-1 	|BT| (S (S (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis)) (VP (VBD associated) (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (NN mortality)) (PP (IN among) (NP (NP (NN participant) (JJ primary) (NN tumor) (JJ overexpressed) (NN COX-2)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 0.39)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.20-0.76)))) (-RRB- -RRB-)))))) (, ,) (IN whereas) (S (NP (NN aspirin) (NN use)) (VP (VBD associated) (NP (JJR lower) (NN risk)) (PP (IN among) (NP (NP (JJ primary) (NN tumor) (JJ weak) (JJ absent) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (JJ multivariate) (NN HR)) (, ,) (NP (CD 1.22)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 0.36-4.18)))) (-RRB- -RRB-))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 828:Z01.107.757.235|ES| 2:1 7:1 10:1 14:1 17:1 19:1 25:1 76:1 115:1 117:1 169:1 171:1 217:1 338:1 344:1 367:1 369:1 372:1 374:1 1037:1 1372:1 1659:1 2487:1 2508:1 2509:1 2511:1 2923:1 2924:1 2925:1 2926:1 2927:1 2928:1 2929:1 2930:1
-1 	|BT| (S (NP (NNS Results)) (NP (ADJP (FW vitro) (FW vivo)) (NN bioassay)) (ADVP (RB clearly)) (VP (VBP suggest) (SBAR (S (NP (NN beta-ionone)) (VP (MD could) (VP (VBD developed) (NP (NN prevention) (NN treatment) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 106:E05.091|ES| 18:1 19:1 113:1 216:1 378:1 546:1 702:1 796:1 908:1 1165:1 1474:1 2838:1 2931:1 2932:1
-1 	|BT| (FRAG (NP (NNS RESULTS)) (: :) (NP (NP (NN Liver) (NN tumor) (NN mass)) (NP (NP (NP (JJR lower) (NN pravastatin) (NN group)) (PRN (-LRB- -LRB-) (NP (NN PG)) (-RRB- -RRB-))) (NP (NP (NP (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NN CG)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN estimated) (NN number) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NP (NN p)) (ADJP (JJR <) (NP (CD 0.004)))) (-RRB- -RRB-))) (NP (NP (NN liver) (NN weight/body) (NN weight) (NN ratio)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (NP (QP (JJR <) (CD 0.04)))) (-RRB- -RRB-))))))) |ET| |BS|242:A03.620 515:C04.588.274.623 616:E05.318.780.074 653:C23.888.144 817:D02.455.426.559.847.638.930 829:M01.686|ES| 2:1 7:1 10:1 14:1 19:1 104:1 117:1 289:1 312:1 646:1 710:1 836:1 2300:1 2399:1 2721:1 2804:1 2933:1 2934:1 2935:1 2936:1 2937:1 2938:1 2939:1 2940:1 2941:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1
-1 	|BT| (S (NP (NNP Resveratrol)) (VP (VBZ interferes) (NP (NP (JJ N-nitrosodiethylamine-induced) (JJ hepatocellular) (NN carcinoma)) (JJ early) (JJ advanced) (NN stage) (JJ male) (JJ Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 19:1 303:1 304:1 849:1 997:1 1128:1 1129:1 1402:1 2603:1 2946:1 2947:1 2948:1
-1 	|BT| (S (S (NP (NN Rimonabant)) (VP (VBZ inhibits) (NP (JJ human) (NN colon) (NN cancer) (NN cell) (NN growth)))) (VP (VBZ reduces) (NP (NN formation) (JJ precancerous) (NN lesion) (NN mouse) (NN colon)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 341:C04.834|ES| 18:1 19:1 36:1 43:1 52:1 94:1 102:1 113:1 142:1 615:1 1130:1 1131:1 2949:1
-1 	|BT| (NP (NP (NN Role) (NN Fas/FasL) (NN pathway) (NN combination) (NN therapy) (NN interferon-alpha) (NN fluorouracil) (JJ hepatocellular) (NN carcinoma) (NN vitro))) |ET| |BS|15:F01.829.316.616 104:C04.557.470.200.025.255 356:D12.644.276.374.440.890.250 560:D03.383.742.698.875.404 618:E02.186|ES| 19:1 130:1 216:1 303:1 304:1 383:1 530:1 1198:1 2187:1 2919:1 2950:1
-1 	|BT| (NP (NP (NNP Saffron)) (: :) (NP (JJ potential) (NN candidate) (JJ novel) (JJ anticancer) (NN drug) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|67:D26 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 701:B01.650.940.800.575.100.549.500|ES| 19:1 104:1 191:1 303:1 304:1 827:1 891:1 1243:1 1880:1 2951:1
-1 	|BT| (NP (NP (NNP Sesamin)) (, ,) (NP (JJ lipid-soluble) (NN lignan)) (, ,) (S (NP (CD one) (NN agent)) (VP (VBZ belongs) (NP (SBAR (S (NP (NP (NN class) (NNS phytoestrogens)) (, ,) (NP (NP (VBN isolated) (NN sesame)) (PRN (-LRB- -LRB-) (NP (NN Sesamum) (NN indicum)) (-RRB- -RRB-))) (, ,)) (VP (VBN linked) (NP (NN prevention) (NN hyperlipidemia))))) (, ,) (NP (NP (NN hypertension)) (, ,) (NP (NN carcinogenesis) (JJ unknown) (NN mechanism))))))) |ET| |BS|33:C04.697.098 621:D02.455.426.559.389.140.450 659:D10 766:C18.452.584.500.500 830:B01.650.940.800.575.100.583.690.750 831:D27.505.696.399.472.277.540.500 832:C14.907.489|ES| 2:1 10:1 14:1 19:1 162:1 207:1 728:1 1010:1 1363:1 1474:1 1653:1 2182:1 2313:1 2692:1 2814:1 2952:1 2953:1 2954:1 2955:1 2956:1 2957:1 2958:1 2959:1
-1 	|BT| (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (JJ molecular) (NN therapy) (JJ non-small-cell) (NN lung) (NN cancer))) |ET| |BS|52:E02 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 375:Z01.639.100|ES| 18:1 19:1 130:1 161:1 327:1 328:1 487:1 860:1 861:1 862:1 2960:1
-1 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1
-1 	|BT| (S (NP (NN Sodium) (NN alginate)) (VP (VBZ prevents) (NP (NN progression) (JJ non-alcoholic) (NN steatohepatitis) (NN liver) (NN carcinogenesis) (JJ obese) (JJ diabetic) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 33:C04.697.098 242:A03.620 509:C06.552.241.519 564:C18.654.726.500|ES| 19:1 48:1 52:1 207:1 836:1 1791:1 2069:1 2468:1 2718:1 2962:1 2963:1 2964:1
-1 	|BT| (S (NP (NN Sulindac) (NNS NSAIDs)) (VP (ADVP (RB widely)) (NP (VBN studied) (NP (JJ potential) (JJ chemopreventive) (NN agent) (NN colon) (NN cancer))))) |ET| |BS|251:D02.455.426.559.847.486.875 796:D27.505.696.663.850.014.040.500 833:D27.505.696.706.018|ES| 18:1 19:1 113:1 401:1 728:1 827:1 1946:1 2369:1 2965:1 2966:1
-1 	|BT| (S (NP (NP (NN Supplementation) (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VBZ reduces) (NP (NP (NN risk) (NN liver) (NN cancer) (JJ cirrhotic) (NN patient)) (NP (JJ obese) (, ,) (NP (JJ associated) (NN improvement) (NN insulin) (NN resistance)))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 10:1 14:1 18:1 19:1 120:1 142:1 169:1 171:1 836:1 1094:1 1275:1 2189:1 2359:1 2360:1 2364:1 2468:1 2967:1 2968:1 2969:1
-1 	|BT| (S (NP (NP (NP (NN Suppression) (JJ early) (NN stage) (JJ neoplastic) (NN transformation)) (JJ two-stage) (NN chemical) (NN hepatocarcinogenesis) (NN model)) (: :) (S (NP (NP (NN supplementation) (NN vanadium)) (, ,) (NP (JJ dietary) (NN micronutrient)) (, ,) (NP (NN limit) (NN cell) (NN proliferation))) (VP (VBZ inhibits) (NP (NP (NN formation) (NN 8-hydroxy-2)) ('' ')))) (: -)) (VP (NNS deoxyguanosines) (NP (NN DNA) (NNS strand-breaks) (NN liver) (JJ sprague-dawley) (NN rat)))) |ET| |BS|20:G03.495 32:C04.697.098.500 122:C14.280.383 183:G04.299.233.750 242:A03.620 595:G07.203.650.240 769:B01.050.150.900.649.865.635.505.700.750 834:D27.505.696.377.605.555 835:D27.505.696.377.605 836:G05.355.180.210 837:D01.268.556.920 838:E05.599.495|ES| 2:1 19:1 43:1 72:1 94:1 104:1 299:1 615:1 666:1 836:1 849:1 893:1 900:1 1128:1 1129:1 1384:1 2124:1 2567:1 2594:1 2797:1 2970:1 2971:1 2972:1 2973:1 2974:1 2975:1 2976:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (NP (VBN indicated) (NN nifuroxazide)) (VP (MD could) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN tumor) (NN metastasis)) (S (VP (VBG mediating) (NP (NP (NN Stat3)) (NN pathway))))))) (VP (MD might) (NP (JJ therapeutic) (JJ potential) (NN treatment) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 82:D12.644.360.024.342.300 113:C04.697.650 122:C14.280.383|ES| 2:1 7:1 19:1 101:1 245:1 383:1 541:1 546:1 761:1 798:1 806:1 827:1 908:1 1370:1 1537:1 1538:1 1541:1 2646:1 2820:1 2977:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP provide) (SBAR (S (NP (NP (NN evidence) (NN plant) (NN flavonoid) (NN fisetin)) (VP (VBP induce) (NP (NN apoptosis)))) (VP (VBP suppress) (NP (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN inhibition) (NN COX2)) (: -) (NP (NN Wnt/EGFR/NF-kappaB-signaling) (NN pathway)))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11 43:F01.145.544 45:G07.700.320.249 147:G02.149.115.800.925 210:D12.776.260.600 328:B01.650 534:D03.383.663.283.266.450|ES| 2:1 18:1 19:1 38:1 89:1 94:1 102:1 103:1 113:1 243:1 383:1 711:1 1098:1 1537:1 1538:1 1886:1 2441:1 2978:1 2979:1 2980:1
-1 	|BT| (S (NP (VBN Targeted) (NN disruption) (JJ Nemo-like) (NN kinase)) (VP (VBZ inhibits) (NP (NN tumor) (NN cell) (NN growth) (JJ simultaneous) (NN suppression) (NN cyclin) (NN D1) (NN CDK2) (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|8:C04 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 215:D12.644.360.262.150.100 469:D08.811.913.696|ES| 7:1 19:1 36:1 94:1 102:1 303:1 304:1 470:1 615:1 743:1 744:1 1602:1 2453:1 2981:1 2982:1 2983:1 2984:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP investigate) (NP (NP (NP (NP (JJ molecular) (NN mechanism) (JJ chemopreventive) (NN effect)) (JJ folic) (NN acid) (NN tributyrin)) (ADVP (RB alone))) (NN combination) (NN rat) (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 624:D27.505.696.706.018 839:D03.438.733.631.400|ES| 19:1 75:1 131:1 161:1 162:1 241:1 459:1 530:1 691:1 849:1 900:1 1275:1 1567:1 1946:1 2985:1 2986:1
-1 	|BT| (S (NP (DT The) (NN cyclooxygenase-2) (-LRB- -LRB-) (NN COX-2) (-RRB- -RRB-) (NN inhibitor) (NN celecoxib)) (VP (VBN approved) (NP (NP (NN drug) (NN clinic) (NN colon) (NN cancer) (NN chemoprevention)) (VP (VBN tested) (NP (NP (JJ chemopreventive) (JJ therapeutic) (NN efficacy)) (JJ various) (JJ clinical) (NN trial)))))) |ET| |BS|12:Z01.542.049 52:E02 67:D26 253:E02.319.162 349:D27.505.519.389.310.500 683:D27.505.519.389.310 684:D02.065.884.247 840:E01.789.800 841:E05.318.760.250.500 842:N02.278.035|ES| 10:1 14:1 18:1 19:1 61:1 76:1 84:1 113:1 191:1 380:1 541:1 691:1 870:1 1096:1 1946:1 2304:1 2343:1 2807:1 2987:1 2988:1 2989:1
-1 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP provide) (NP (JJ additional) (NN evidence) (JJ potential) (NN use) (NN roxithromycin) (NN treatment) (JJ hepatocellular) (NN carcinoma) (NN prevention)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 843:D02.540.576.500.992.630|ES| 19:1 38:1 303:1 304:1 546:1 691:1 711:1 793:1 827:1 980:1 1474:1 1659:1 2990:1
-1 	|BT| (NP (NP (NP (DT The) (JJ Dual) (NN Inhibition) (NN RNA) (NN Pol)) (SBAR (S (NP (PRP I)) (NP (NN Transcription) (NNP PIM) (NN Kinase) (NNP New) (JJ Therapeutic) (NNP Approach) (NNP Treat) (NNP Advanced) (NNP Prostate) (NNP Cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 52:E02 209:G02.111.087.847 844:D08.811.913.696.445.735.270.750|ES| 19:1 469:1 515:1 691:1 1197:1 1412:1 1919:1 2280:1 2350:1 2703:1 2991:1 2992:1 2993:1 2994:1 2995:1 2996:1 2997:1
-1 	|BT| (S (NP (DT The) (JJ oncogenic) (NN kinase) (NN inhibitor) (NN sorafenib)) (ADVP (RB significantly)) (VP (VB prolong) (SBAR (S (NP (JJ median) (NN survival) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (, ,) (SBAR (IN although) (S (NP (NN response) (JJ disease-stabilizing) (JJ cytostatic)) (NP (QP (RB rather) (CD one)) (NN tumor) (NN regression))))))))) |ET| |BS|8:C04 50:M01.643 96:I03.784 104:C04.557.470.200.025.255 279:D27.888.569.100 288:C23.550.288 469:D08.811.913.696 845:D27.888.569.199 846:F01.393.784|ES| 2:1 7:1 10:1 14:1 19:1 120:1 124:1 274:1 303:1 304:1 380:1 441:1 470:1 494:1 691:1 953:1 997:1 1010:1 1170:1 1592:1 2063:1 2998:1 2999:1 3000:1 3001:1 3002:1
-1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ allows) (SBAR (S (NP (NN u)) (VP (VBP conclude) (SBAR (S (NP (JJ diosmin) (JJ dietary) (NN supplement)) (, ,) (VP (MD could) (VP (VBN used) (S (NP (JJ chemopreventive) (NN agent)) (VP (VBP prevent) (NP (NN hepatocarcinogenesis))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 557:D02.241.081.069.600.150 715:D03.383.663.283.266.450.260.222 847:G07.203.300.456|ES| 2:1 19:1 131:1 476:1 691:1 728:1 733:1 900:1 908:1 1307:1 1946:1 1968:1 2243:1 2594:1 2695:1 3003:1 3004:1
-1 	|BT| (NP (NP (NP (DT The) (JJ present) (NN study) (NN offer) (NN strategy) (JJ novel) (NN CUR) (NN analogue)) (, ,) (PRN (-LRB- -LRB-) (NP (NN 1E) (CD ,4) (NN E)) (-RRB- -RRB-)) (NP (NP (NP (NN -1,5-bis) (-LRB- -LRB-) (NN 2-bromophenyl) (-RRB- -RRB-) (NN penta-1,4-dien-3-one)) (PRN (-LRB- -LRB-) (NP (NN GL63)) (-RRB- -RRB-))) (, ,) (NP (VBN used) (JJ potential) (NP (NP (JJ therapeutic) (NN agent) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (ADVP (FW vitro) (FW vivo))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 131:1 216:1 303:1 304:1 378:1 441:1 476:1 541:1 691:1 728:1 827:1 891:1 1042:1 1114:1 1307:1 1380:1 3005:1 3006:1 3007:1 3008:1 3009:1 3010:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VBP investigate) (FRAG (NP (NP (JJ chemopreventive) (NN action) (JJ possible) (NN mechanism) (NN saffron) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN liver) (NN cancer) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 701:B01.650.940.800.575.100.549.500|ES| 10:1 14:1 18:1 19:1 162:1 409:1 459:1 691:1 836:1 849:1 1359:1 1497:1 1875:1 1946:1 1952:1 2013:1 2523:1 3011:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN study)) (VP (VBP evaluate) (NP (NP (NP (JJ anticancer) (NN potency) (NN mechanism) (JJ novel) (NN difluorodiarylidenyl) (NN piperidone)) (PRN (-LRB- -LRB-) (NP (NN H-4073)) (-RRB- -RRB-))) (S (NP (NP (NN N-hydroxypyrroline) (NN modification)) (PRN (-LRB- -LRB-) (NP (NN HO-3867)) (-RRB- -RRB-))) (NP (JJ human) (JJ ovarian) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 179:D01.248.497.300.459.700 225:E05.337 259:D12.776.395.240.150.500 848:D03.383.621.808|ES| 10:1 14:1 18:1 19:1 36:1 131:1 162:1 691:1 890:1 891:1 1763:1 1880:1 2374:1 2796:1 3011:1 3012:1 3013:1 3014:1 3015:1 3016:1
-1 	|BT| (NP (NP (NP (DT The) (NN rate) (NN proliferation) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN reduced) (JJ treated) (NN gamma-secretase) (NN inhibitor) (NN dibenzazepine)) (VP (VBP inhibit) (NP (NP (NN Notch) (NN signaling) (JJ small) (VBG interfering) (NN RNA)) (VP (VBD directed) (NP (NN Notch))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 117:D13.150.650.700 122:C14.280.383 125:D08.811.277.656.300.032 212:E01.370.225.500.385.500 792:A11.251.210.190.475|ES| 18:1 19:1 36:1 41:1 94:1 113:1 195:1 256:1 299:1 380:1 452:1 515:1 691:1 750:1 1099:1 1370:1 1866:1 3017:1 3018:1 3019:1 3020:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBD indicated) (SBAR (S (NP (NN 6-MSITC)) (VP (VBD exerted) (NP (NP (NP (JJ chemopreventive) (NN effect)) (JJ present) (JJ short-term) (NN colon) (NN carcinogenesis) (NN bioassay)) (, ,) (NP (NP (NN alteration) (NN cell) (NN proliferation) (NN activity) (NN drug)) (VP (VBG metabolizing) (NP (NN enzyme) (NN level)))))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 67:D26 106:E05.091 212:E01.370.225.500.385.500 624:D27.505.696.706.018 649:E01.370.225.124.200 849:G08.686.785.760.769.490.500|ES| 2:1 19:1 75:1 94:1 101:1 113:1 191:1 207:1 249:1 299:1 399:1 691:1 951:1 1307:1 1541:1 1946:1 2102:1 2388:1 2931:1 3021:1 3022:1 3023:1
-1 	|BT| (S (NP (DT The) (JJ selective) (NN EGFR) (NN inhibitor) (NN Gefitinib)) (VP (VBD found) (S (VP (VBP prevent) (NP (NN hepatocarcinogenesis) (NN rat) (JJ cirrhotic) (NN liver)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 37:1 187:1 380:1 691:1 733:1 836:1 849:1 900:1 1749:1 2968:1 3024:1
-1 	|BT| (S (NP (DT The) (NN study)) (VP (VBD suggested) (SBAR (S (NP (NN HO-3867)) (VP (MD may) (NP (NP (JJ useful) (JJ safe) (JJ effective) (JJ anticancer) (NN agent)) (JJ ovarian) (NN cancer) (NN therapy))))))) |ET| |BS|52:E02|ES| 18:1 19:1 130:1 131:1 491:1 691:1 728:1 925:1 1036:1 1639:1 1763:1 1880:1 2737:1 3016:1
-1 	|BT| (S (NP (DT The) (JJ sulfated) (NN polysaccharide) (NNP U.) (NN lactuca)) (VP (MD may) (SBAR (S (NP (JJ unique) (NN property) (VBG providing) (NN protection) (JJ DENA-induced) (JJ oxidative) (NN stress)) (VP (MD could) (VP (VB contribute) (NP (NN chemoprevention) (JJ experimental) (NN hepatocarcinogenesis)))))))) |ET| |BS|253:E02.319.162 554:D02.654.442.200 716:G03.495.710 803:D01.248.497.158.845 804:D09.698|ES| 19:1 263:1 450:1 491:1 691:1 841:1 870:1 900:1 908:1 1469:1 2522:1 2583:1 2734:1 2839:1 2840:1 2841:1 2842:1 3025:1 3026:1
-1 	|BT| (S (NP (DT The) (NN theme) (NN study)) (VP (VBP evaluate) (SBAR (S (NP (JJ therapeutic) (NN efficacy)) (VP (VBD nanoencapsulated) (FRAG (NP (JJ flavonoidal) (NN quercetin)) (-LRB- -LRB-) (NP (NP (NP (CD 3,5,7,3) ('' ') (NN ,4)) ('' ') (PRN (: -) (NP (NP (NN pentahydroxy) (NN flavone)) (, ,) (NP (NN QC))) (-RRB- -RRB-))) (S (VP (VBG combating) (NP (JJ DEN-induced) (NN hepatocarcinogenesis) (NN rat))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 533:D03.383.663.283.266.450.284.777 850:D03.383.663.283.266.450.260 851:J01.897.608|ES| 2:1 10:1 14:1 19:1 131:1 541:1 691:1 849:1 890:1 900:1 1884:1 2304:1 2735:1 3027:1 3028:1 3029:1 3030:1 3031:1 3032:1 3033:1
-1 	|BT| (NP (NP (JJ Therapeutic) (NN effect) (JJ multi-targeted) (NN imidazolium) (NN compound) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255|ES| 19:1 75:1 303:1 304:1 2433:1 2993:1 3034:1 3035:1
-1 	|BT| (S (NP (NP (NN Therapy)) (VP (VBG targeting) (NP (NN Vav3) (NN combination) (NN docetaxel)))) (VP (MD may) (NP (JJ practical) (NN implication) (NN managing) (JJ castration-resistant) (NN prostate) (NN cancer)))) |ET| |BS|618:E02.186 852:C04.588.945.440.770.500|ES| 18:1 19:1 77:1 85:1 491:1 530:1 616:1 3036:1 3037:1 3038:1 3039:1 3040:1 3041:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (JJ genetic) (NN amplification) (NN TYMS) (JJ major) (NN mechanism) (NN 5-FU) (NN resistance)) (PP (FW vivo) (NP (NP (JJ important) (NN implication) (NN management) (JJ colorectal) (NN cancer) (NN patient)) (JJ recurrent) (NN disease)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 288:C23.550.288 392:G05.355.315.250 496:C23.550.291.937 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 853:N04.590.607|ES| 17:1 18:1 19:1 85:1 120:1 162:1 378:1 462:1 792:1 793:1 796:1 864:1 902:1 921:1 998:1 1094:1 1753:1 2308:1 3042:1 3043:1
-1 	|BT| (NP (DT These) (VBG finding) (S (VP (VBP confirm) (NP (NN hypothesis) (NN ODC) (NN polymorphism) (JJ genetic) (NN marker) (NN colon) (NN cancer) (NN risk))) (, ,) (NP (NP (NP (NN support) (NN use) (NN ODC) (NN inhibitor) (NN aspirin)) (, ,) (NP (NP (JJ nonsteroidal) (JJ antiinflammatory) (NN drug)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))) (, ,)) (NN combination) (NN strategy) (NN colon) (NN cancer) (NN prevention)))) |ET| |BS|61:E05.318.740.600.800 149:G05.360.340.024.340.364.875.890 158:D23.101 307:G05.365.795 670:D02.455.426.559.389.657.410.595.176 796:D27.505.696.663.850.014.040.500|ES| 2:1 10:1 14:1 18:1 19:1 113:1 171:1 191:1 380:1 530:1 534:1 792:1 864:1 927:1 1060:1 1114:1 1364:1 1474:1 1659:1 2477:1 2487:1 2697:1 2966:1 3044:1 3045:1 3046:1
-1 	|BT| (PP (DT These) (S (VP (VBG finding) (S (VP (VBP suggest) (SBAR (S (NP (NN sulindac)) (VP (MD may) (NP (NP (JJ effective) (NN agent) (NN colon) (NN cancer) (NN prevention)) (NP (JJ human) (JJ low) (NN 15-PGDH)))))))) (, ,) (S (NP (NN use)) (MD may) (ADVP (RB also)) (VP (VBN associated) (NP (JJ inflammatory) (NN lesion) (NN colon))))))) |ET| |BS|46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 251:D02.455.426.559.847.486.875|ES| 2:1 5:1 18:1 19:1 36:1 113:1 133:1 169:1 491:1 531:1 728:1 792:1 796:1 869:1 927:1 1131:1 1474:1 1639:1 1659:1 2430:1
-1 	|BT| (NP (NP (DT These) (NN observation) (NN show)) (, ,) (NP (JJ first) (NN time)) (, ,) (S (NP (NP (NN CP-31398) (NN posse) (JJ significant) (JJ dose-dependent) (JJ chemopreventive) (NN activity)) (JJ well-established) (NN colon) (NN cancer) (NN model) (NN combination) (JJ low-dose) (NN CP-31398) (NN celecoxib)) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NN colon) (NN cancer) (JJ chemopreventive) (NN efficacy))))) |ET| |BS|322:G01.910 429:N04.761.559.590.900 430:E05.581.249 684:D02.065.884.247|ES| 2:1 18:1 19:1 72:1 113:1 124:1 135:1 385:1 399:1 429:1 530:1 792:1 816:1 1081:1 1477:1 1770:1 1946:1 2304:1 2807:1 2824:1 3047:1 3048:1 3049:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (ADVP (RB also)) (VP (VBP support) (NP (NN role) (NNP BMX) (JJ potential) (NN drug) (NN candidate) (NN use) (NN combination) (NN cisplatin) (NN treatment) (JJ human) (NN lung) (NN cancer))))) |ET| |BS|15:F01.829.316.616 52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 375:Z01.639.100 498:D01.210.375|ES| 5:1 18:1 19:1 31:1 36:1 101:1 191:1 328:1 530:1 546:1 792:1 827:1 1243:1 1364:1 1659:1 1761:1 3050:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VP (VBP indicate) (SBAR (S (NP (NP (NN chitin)) (, ,) (NP (NN chitosan) (JJ related) (NN compound))) (VP (VBP exert) (NP (NP (JJ unequivocal) (JJ chemopreventive) (NN effect)) (NP (JJ heterocyclic) (JJ amine-induced) (NN hepatocarcinogenesis))))))) (, ,) (SBAR (S (NP (NN effect) (NN organ)) (VP (MD may) (SBAR (S (NP (NN tissue) (JJ specific) (JJ possible) (JJ inhibitory) (NN action) (JJ mammary) (NN gland)) (VP (VBD offset) (NP (NN promotion) (NN colon) (NN lesion) (NN development))))))))))) |ET| |BS|46:A03.556.124.526.356 98:A10 609:A01.236.249 624:D27.505.696.706.018 854:D05.750.078.139.500 855:D05.750.078.139 856:D02.092|ES| 2:1 19:1 35:1 75:1 101:1 113:1 272:1 419:1 491:1 540:1 592:1 792:1 900:1 1131:1 1359:1 1382:1 1479:1 1946:1 2013:1 2248:1 2337:1 2429:1 2433:1 2843:1 3051:1 3052:1 3053:1 3054:1 3055:1 3056:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NNP Valerian) (VP (VBP exhibit) (S (NP (JJ inhibitory) (NN effect) (NN rat) (NN hepatocarcinogenesis)) (VP (VBG inhibiting) (NP (JJ oxidative) (NN DNA) (NN damage)))) (, ,) (S (VP (VBG suppressing) (NP (NP (NN cell) (NN proliferation)) (VP (VBG inducing) (NP (NP (NP (NN apoptosis) (NN GST-P)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN focus) (VBG activating) (NN GABA) (-LRB- -LRB-) (NN A) (-RRB- -RRB-) (JJ R-mediated) (NN signaling)))))))))))) |ET| |BS|39:G04.299.139.160 69:G02.111.087.800 122:C14.280.383 175:J01.897.280.500.269 183:G04.299.233.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 599:M01.526.799.500 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 859:D02.241.081.114.500.350|ES| 2:1 10:1 14:1 19:1 69:1 75:1 89:1 94:1 101:1 195:1 299:1 587:1 666:1 792:1 849:1 880:1 900:1 1431:1 1479:1 1848:1 1864:1 1958:1 2250:1 2429:1 2583:1 3057:1 3058:1 3059:1 3060:1 3061:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP provide) (SBAR (S (NP (JJ preclinical) (NN evidence)) (VP (VBP continue) (NP (NP (NN development) (NN alantolactone) (NN STAT3) (NN inhibitor)) (JJ potential) (JJ therapeutic) (NN agent) (NN breast) (NN cancer)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 82:D12.644.360.024.342.300|ES| 18:1 19:1 23:1 35:1 38:1 101:1 251:1 380:1 541:1 711:1 728:1 792:1 827:1 1494:1 2686:1 3062:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NN show) (NN Cx32) (NN luteolin) (JJ suppressive) (NN role)) (NN inflammation) (, ,) (NN fibrosis) (NN hepatocarcinogenesis) (NN NASH) (NN progression)) (, ,) (S (VP (VBG suggesting) (NP (JJ potential) (JJ therapeutic) (NN application) (NNP NASH)))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 52:E02 525:C23.550.470 691:C23.550.355 704:D03.383.663.283.266.450.260.555|ES| 2:1 19:1 31:1 48:1 101:1 165:1 429:1 541:1 792:1 827:1 900:1 949:1 1009:1 1974:1 2547:1 3063:1 3064:1 3065:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN simvastatin)) (VP (MD could) (NP (NP (JJ potential) (JJ chemopreventive) (JJ therapeutic) (NN agent)) (NP (NP (NNP CAC)) (NP (ADVP (RB well)) (NP (ADJP (FW de) (FW novo)) (NN colon) (NN cancer))))))))))) |ET| |BS|52:E02 754:D02.455.426.559.847.638.400.900 860:Z01.107.567.875.500.200 861:Z01.542.315|ES| 18:1 19:1 101:1 113:1 541:1 728:1 787:1 792:1 796:1 827:1 908:1 1946:1 2679:1 3066:1 3067:1 3068:1
-1 	|BT| (S (NP (NNS Thiazolidinediones)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (NN hepatitis) (NN B) (JJ virus-transgenic) (NN mouse) (NN peroxisome) (JJ proliferator-activated) (NN receptor) (JJ gamma-independent) (NN regulation) (NN nucleophosmin)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425|ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1
-1 	|BT| (S (NP (NN Thioredoxin) (NN reductase) (CD 1)) (VP (VBZ protects) (VP (ADVP (RB chemically)) (VBN induced) (NN hepatocarcinogenesis) (PP (IN via) (NP (NN control) (JJ cellular) (NN redox) (NN homeostasis)))))) |ET| |BS|41:A11 152:G07.700.345 864:D08.811.682.667.750.500 865:G02.149.767.650|ES| 19:1 96:1 98:1 289:1 412:1 500:1 596:1 900:1 1863:1 2581:1 3073:1 3074:1 3075:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (VP (VBP result) (NP (NN support) (JJ future) (NN utilization) (NN decorin) (NN antitumor) (NN agent) (NN liver) (NN cancer)))) |ET| |BS|354:I01.320 375:Z01.639.100 660:D27.505.954.248 708:D12.776.395.650.750.625|ES| 2:1 18:1 19:1 101:1 728:1 836:1 1190:1 1364:1 1691:1 2244:1 2901:1 3076:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PKCbetaII) (JJ important) (NN target) (NN colon) (NN cancer) (NN chemoprevention) (JJ PKCbeta-selective) (NN inhibitor) (NN enzastaurin)) (VP (MD may) (VP (VB represent) (NP (NP (JJ effective) (JJ chemopreventive) (NN agent) (NN patient)) (JJ high) (NN risk) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 253:E02.319.162 866:D08.811.913.696.620.682.700.725.049 867:D08.811.913.696.620.682.700.725.049 868:M01.380.600|ES| 2:1 18:1 19:1 113:1 120:1 160:1 171:1 178:1 380:1 491:1 728:1 799:1 870:1 902:1 1639:1 1691:1 1946:1 2855:1 3077:1 3078:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NP (NN combination) (NN As2O3) (NN Ad-PML) (JJ synergistic) (JJ inhibitory) (NN effect)) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (, ,) (S (VP (ADVP (RB possibly)) (VBG resulting) (NP (NN regulation) (JJ apoptotic) (NN gene) (NN expression)))) (VP (VBD enhanced) (NP (NNP HCC) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255 140:G05.355.315|ES| 2:1 9:1 10:1 14:1 19:1 75:1 89:1 115:1 303:1 304:1 384:1 385:1 438:1 441:1 530:1 1548:1 1691:1 2012:1 2223:1 2429:1 3079:1 3080:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN study)) (VP (VBP show) (NP (JJ myrtenal) (NN ability) (VBP suppress) (JJ hepatocellular) (NN carcinoma) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 385:F02.784.629.131|ES| 2:1 19:1 131:1 303:1 304:1 429:1 849:1 1300:1 1691:1 2441:1 2682:1
-1 	|BT| (NP (NP (NNP Thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN expression)) (, ,) (NP (JJ histological) (NN tumour) (NN regression) (JJ 5-FU-based) (JJ neo-adjuvant) (JJ chemoradiotherapy) (JJ rectal) (NN cancer))) |ET| |BS|8:C04 333:D01.045 560:D03.383.742.698.875.404 561:E02.186.079.500 713:D08.811.913.555.500.862 846:F01.393.784 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350|ES| 2:1 18:1 19:1 66:1 115:1 1011:1 1986:1 1987:1 1988:1 1989:1 3002:1 3081:1 3082:1 3083:1 3084:1 3085:1 3086:1
-1 	|BT| (S (NP (NNP Thymoquinone)) (VP (VBZ reduces) (SBAR (S (NP (NN mouse) (NN colon) (NN tumor) (NN cell) (NN invasion)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ murine) (NN colon) (NN cancer) (NN model))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 51:C04.588.274.476.411.307.180 122:C14.280.383|ES| 7:1 18:1 19:1 52:1 72:1 94:1 102:1 113:1 142:1 615:1 620:1 627:1 3087:1
-1 	|BT| (NP (NP (S (VP (TO To) (ADVP (RBR better)) (VP (VB understand) (NP (NP (JJ anticancer) (NN activity) (NNP Levamisole)) (PRN (-LRB- -LRB-) (NP (NNP LMS)) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN serf) (JJ adjuvant) (NN colon) (NN cancer) (NN therapy) (NN combination) (NN 5-Fluorouracil)) (, ,) (NP (NP (NN study) (NN analysis) (NNP LMS) (POS ')) (NN ability)) (S (VP (VBP induce) (NP (NP (NN apoptosis) (NN growth) (NN arrest)) (NP (VBN cultured) (JJ human) (JJ micro) (: -) (NP (JJ macrovascular) (JJ endothelial) (NN cell) (PRN (-LRB- -LRB-) (NP (NNS ECs)) (-RRB- -RRB-)) (NN fibroblast))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 385:F02.784.629.131 560:D03.383.742.698.875.404 618:E02.186 685:D27.505.696.477.067 687:D26.650.064 871:D02.886.675.346 872:A11.329.228 873:A11.436.275|ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 102:1 113:1 130:1 131:1 243:1 399:1 530:1 602:1 661:1 828:1 829:1 882:1 904:1 1232:1 1300:1 1489:1 1880:1 2213:1 2404:1 2479:1 3088:1 3089:1 3090:1 3091:1 3092:1 3093:1
-1 	|BT| (S (S (VP (TO To) (VP (VB improve) (NP (JJ clinical) (NN outcome))))) (, ,) (NP (NN investigation) (JJ potential) (NN bortezomib) (NN therapy) (NN thyroid) (NN cancer)) (ADVP (RB clearly)) (VP (VBD warranted))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 225:E05.337 675:D01.029.260.110.500|ES| 2:1 18:1 19:1 84:1 130:1 547:1 827:1 828:1 969:1 1497:1 2466:1 2816:1 2838:1 3094:1
-1 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1
-1 	|BT| (S (NP (NN Tongue) (NN cancer) (NN prevention) (NN study)) (VP (VBD conducted) (NP (NP (JJ zinc-deficient) (NN rat)) (NP (ADJP (RB previously) (VBN exposed)) (NN tongue) (NN carcinogen) (NN celecoxib) (NN treatment))) (VP (PP (IN without) (NP (NN zinc) (NN replenishment))) (, ,) (NP (NP (NN zinc) (NN replenishment)) (ADVP (RB alone)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 684:D02.065.884.247 874:D01.268.556.940 875:A03.556.500.885 876:F01.145|ES| 2:1 18:1 19:1 131:1 241:1 546:1 849:1 1195:1 1474:1 1527:1 2125:1 2807:1 3099:1 3100:1 3101:1 3102:1 3103:1 3104:1 3105:1
-1 	|BT| (S (NP (NP (NP (NN Treatment) (NN mouse) (NN EGFR-inhibitor)) (PRN (-LRB- -LRB-) (NP (NN EGFRi)) (-RRB- -RRB-))) (, ,) (NP (NN Canertinib)) (, ,)) (VP (VBP 1h) (ADJP (JJ post-APAP)) (VP (VBD resulted) (NP (NP (JJ robust) (NN inhibition) (NN EGFR-activation) (JJ striking) (NN reduction)) (JJ APAP-induced) (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 52:E02 242:A03.620 661:D02.065.199.092.040 877:N03.540.571.608|ES| 2:1 10:1 14:1 19:1 52:1 103:1 370:1 594:1 836:1 2416:1 3106:1 3107:1 3108:1 3109:1 3110:1 3111:1 3112:1 3113:1 3114:1 3115:1
-1 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ inhibits) (NP (NN tumor) (NN growth) (JJ hepatocellular) (NN carcinoma)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|8:C04 45:G07.700.320.249 104:C04.557.470.200.025.255 122:C14.280.383|ES| 7:1 19:1 102:1 216:1 303:1 304:1 378:1 615:1 3116:1
-1 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (JJ Antidiabetic) (NNS thiazolidinediones)) (PRN (-LRB- -LRB-) (NP (NN TZD)) (-RRB- -RRB-))) (PP (FW vitro) (NP (NP (JJ antiproliferative) (NN effect) (JJ epithelial) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422|ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1
-1 	|BT| (NP (NP (NP (NP (JJ Ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (NP (NP (JJ known) (NN suppressor) (JJ cholestatic) (NN liver) (NN disease)) (JJ colorectal) (NN cancer) (NN development)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 650:C06.552 737:D04.808.105.225.272.962 879:C06.130.120.135|ES| 10:1 14:1 17:1 18:1 19:1 35:1 556:1 700:1 836:1 998:1 1275:1 2631:1 3121:1 3122:1
-1 	|BT| (S (NP (NN Valerian)) (VP (VBZ inhibits) (NP (NP (NP (NN rat) (NN hepatocarcinogenesis) (VBG activating) (NN GABA)) (PRN (-LRB- -LRB-) (NP (NN A)) (-RRB- -RRB-))) (NP (JJ receptor-mediated) (NN signaling))))) |ET| |BS|69:G02.111.087.800 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 880:D12.776.157.530.400.175.562|ES| 10:1 14:1 19:1 69:1 195:1 615:1 849:1 900:1 1958:1 3057:1 3060:1 3123:1
-1 	|BT| (NP (NP (NN Vanadium) (JJ chemopreventive) (JJ early) (NN stage) (JJ 2-AAF-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 837:D01.268.556.920 881:D02.065.064.150|ES| 19:1 849:1 900:1 1128:1 1129:1 1946:1 3124:1 3125:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (JJ possible) (NP (NP (JJ beneficial) (NN use) (NN pamidronate) (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255|ES| 10:1 14:1 19:1 303:1 304:1 441:1 546:1 843:1 984:1 1175:1 1359:1 1659:1 3126:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP find) (SBAR (S (JJ enzastaurin) (ADVP (RB potently)) (VP (VBZ reduces) (NP (NP (JJ azoxymethane-induced) (NN colon) (NN tumor) (NN initiation) (NN progression)) (VP (VBG inhibiting) (NP (JJ PKCbetaII-mediated) (NN tumor) (NN cell) (NN proliferation) (NN beta-catenin) (NN accumulation))))))))) |ET| |BS|8:C04 16:C23.550.291.656 23:D12.776.091.249 51:C04.588.274.476.411.307.180 122:C14.280.383 132:D02.172.080 183:G04.299.233.750 866:D08.811.913.696.620.682.700.725.049|ES| 7:1 19:1 48:1 60:1 94:1 113:1 142:1 299:1 637:1 843:1 880:1 2120:1 2533:1 2855:1 3127:1 3128:1 3129:1
-1 	|BT| (S (S (S (NP (PRP We)) (VP (VBD found) (S (VP (VBG impairing) (NP (JJ autophagy) (NNS hepatocytes)))))) (VP (MD would) (VP (VB induce) (NP (JJ oxidative) (NN stress) (NN DNA) (NN damage))))) (, ,) (NP (VBD followed) (NN initiation) (NN hepatocarcinogenesis)) (, ,) (VP (MD could) (VP (VBD suppressed) (NP (NN antioxidant) (NN N-acetylcysteine))))) |ET| |BS|262:A11.436.348 390:G04.299.139.399 526:G05.355.180 700:D27.505.519.217 716:G03.495.710 791:D02.886.030.230.259|ES| 2:1 19:1 37:1 243:1 307:1 637:1 666:1 775:1 843:1 866:1 894:1 900:1 908:1 1317:1 1848:1 2521:1 2522:1 2583:1 3130:1 3131:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD demonstrated) (NP (NP (NP (JJ total) (NNP Astragalus) (NN saponin)) (PRN (-LRB- -LRB-) (NP (NNP AST)) (-RRB- -RRB-))) (NN posse) (JJ anticarcinogenic) (JJ proapoptotic) (NN property) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft)))) |ET| |BS|8:C04 41:A11 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 882:D09.408.782|ES| 7:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 265:1 333:1 772:1 841:1 843:1 1175:1 1885:1 2493:1 3048:1 3132:1 3133:1 3134:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBN shown) (SBAR (S (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (VP (VBD prevented) (SBAR (S (NP (JJ AOM-induced) (NN colon) (NN cancer)) (VP (VBD suppressed) (NP (NN Cox-2) (NN induction)))))))))) |ET| |BS|132:D02.172.080 737:D04.808.105.225.272.962|ES| 5:1 10:1 14:1 18:1 19:1 62:1 113:1 237:1 307:1 736:1 843:1 1275:1 1944:1 2630:1 2631:1 3135:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD shown) (SBAR (S (NP (NP (JJ dietary) (NN fish) (NN oil) (NN pectin)) (PRN (-LRB- -LRB-) (NP (NN FP)) (-RRB- -RRB-))) (VP (VBZ protects) (NP (NP (JJ radiation-enhanced) (NN colon) (NN cancer)) (VP (VBG upregulating) (NP (NN apoptosis) (JJ colonic) (NN mucosa))))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 46:A03.556.124.526.356 281:E02.815 302:A10.615.550 489:B01.050.150.900.493 595:G07.203.650.240 883:D10.212.302.380 884:Z01.639.760.815 885:G01.358.500.505 886:D10.627.430 887:G01.750|ES| 10:1 14:1 18:1 19:1 89:1 113:1 237:1 579:1 677:1 843:1 1863:1 2594:1 2614:1 3136:1 3137:1 3138:1 3139:1 3140:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (S (NP (NP (NN NF-kappaB) (NN suppression) (JJ novel) (NN inhibitor) (NN dimethylaminoparthenolide)) (PRN (-LRB- -LRB-) (NP (NN DMAPT)) (-RRB- -RRB-))) (VP (MD may) (VP (VB enhance) (NP (NN effect) (NN gemcitabine) (JJ pancreatic) (NN cancer)))))))) |ET| |BS|210:D12.776.260.600 259:D12.776.395.240.150.500|ES| 10:1 14:1 18:1 19:1 75:1 380:1 467:1 491:1 714:1 843:1 891:1 1690:1 2453:1 2504:1 2505:1 3141:1 3142:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (JJ significant) (NN reduction) (NN number) (NN size) (JJ small) (JJ intestinal) (NN polyp) (NN APC)) (PRN (-LRB- -LRB-) (NP (NP (NN min)) (CC +) (: /) (: -)) (-RRB- -RRB-))) (NN mouse) (VBN treated) (CC either) (NP (NP (NP (NP (NN celecoxib)) (PRN (-LRB- -LRB-) (NP (JJ selective) (NN COX-2) (NN inhibitor)) (-RRB- -RRB-))) (NN erlotinib)) (PRN (-LRB- -LRB-) (NP (NP (NN Tarceva)) (, ,) (NP (NN EGFR) (NN inhibitor))) (-RRB- -RRB-)))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 52:E02 193:C23.300.825.411 349:D27.505.519.389.310.500 684:D02.065.884.247 888:D03.438.786.375|ES| 2:1 10:1 11:1 14:1 19:1 39:1 52:1 76:1 109:1 135:1 187:1 261:1 370:1 380:1 646:1 647:1 750:1 843:1 1099:1 1749:1 2142:1 2342:1 2807:1 3143:1 3144:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NN embelin)) (VP (VBZ inhibits) (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN vitro))))) (, ,) (VP (ADVP (RB effectively)) (VBZ suppresses) (NP (JJ 1,2-dimethylhydrazine) (JJ dihydrochloride-induced) (NN colon) (NN carcinogenesis) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383|ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1
-1 	|BT| (S (NP (PRP We)) (VP (VP (VBP propose) (SBAR (S (NP (JJ estrogen-mediated) (NN inhibition) (NN IL-6) (NN production) (NNS KCs)) (VP (VBZ reduces) (NP (NP (NN liver) (NN cancer) (NN risk) (NN female)) (, ,) (NP (NP (NN finding)) (VP (MD may) (VP (VBN used))))))))) (VP (VBP prevent) (NP (NN HCC) (NN male))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 61:E05.318.740.600.800 104:C04.557.470.200.025.255 201:D12.644.276.374.465.224 889:D27.505.696.399.472.277|ES| 2:1 18:1 19:1 103:1 142:1 171:1 441:1 476:1 491:1 733:1 836:1 843:1 927:1 1402:1 1404:1 2677:1 3146:1 3147:1 3148:1 3149:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD studied) (NP (NP (NN mechanism) (VBG underlying) (NN inhibition) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NN lycopene) (NN rat)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200|ES| 10:1 14:1 19:1 103:1 162:1 401:1 409:1 435:1 843:1 849:1 900:1 1875:1 1952:1 2566:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP suggest) (SBAR (S (NP (NN fisetin)) (VP (MD could) (NP (JJ useful) (NN agent) (NN prevention) (NN treatment) (NN colon) (NN cancer))))))) |ET| |BS|52:E02|ES| 18:1 19:1 113:1 546:1 728:1 796:1 843:1 908:1 1036:1 1474:1 2978:1
-1 	|BT| (S (NP (NP (NNP Zerumbone)) (, ,) (NP (JJ tropical) (NN ginger) (NN sesquiterpene)) (, ,)) (VP (VBZ inhibits) (NP (NN colon) (NN lung) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 182:A04.411 762:D02.455.849.765 890:B01.650.940.800.575.100.975.900.444|ES| 2:1 19:1 52:1 113:1 207:1 328:1 615:1 2687:1 3150:1 3151:1 3152:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN Androgen) (NN effect) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBP remain) (SBAR (S (NP (JJ controversial) (NN androgen) (NN ablation) (NN therapy) (NN treat) (NNP HCC)) (ADVP (RB also)) (VP (VBP lead) (NP (JJ inconsistent) (NN result)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 86:D01.268.556.435 104:C04.557.470.200.025.255 891:D27.505.696.399.472.161 892:D27.505.696.399.472.161|ES| 5:1 10:1 14:1 19:1 75:1 91:1 101:1 104:1 130:1 254:1 303:1 304:1 441:1 1046:1 1090:1 1777:1 1778:1 1852:1 2181:1 3153:1 3154:1 3155:1
-1 	|BT| (NP (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (NP (NP (NP (NN Chromodomain) (NN helicase/adenosine) (NN triphosphatase) (NN DNA) (NN binding) (NN protein)) (NP (ADJP (JJ 1-like) (-LRB- -LRB-) (NN CHD1L) (-RRB- -RRB-) (JJ SNF2-like)) (NN transcription) (NN factor))) (VP (VBN involved) (S (VP (NN development) (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|14:F01.525 104:C04.557.470.200.025.255 166:D12.776.930 893:D08.811.277.040.025 894:D08.811.277.040.025|ES| 4:1 10:1 14:1 19:1 35:1 36:1 104:1 185:1 303:1 304:1 441:1 487:1 666:1 774:1 1046:1 1487:1 1777:1 1778:1 3156:1 3157:1 3158:1 3159:1 3160:1 3161:1
-1 	|BT| (NP (NP (NN BACKGROUND)) (: :) (S (NP (PRP It)) (VP (VBD suggested) (NP (NP (JJ altered) (NN iron) (NN metabolism) (NN liver) (NN tumor)) (, ,) (NP (VBN characterized) (JJ iron-deficient) (NN phenotype)) (, ,) (NP (NN importance) (NN tumor) (NN growth)))))) |ET| |BS|8:C04 45:G07.700.320.249 80:G05.695 515:C04.588.274.623 895:D01.490.600 896:D01.268.556.412 897:Z01.252.245.500.375 898:G03.495|ES| 2:1 7:1 19:1 102:1 104:1 236:1 693:1 836:1 925:1 985:1 1046:1 1327:1 1660:1 3162:1 3163:1 3164:1
-1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (DT The) (NP (NN ErbB2/Her2/Neu) (NN receptor) (NN tyrosine) (NN kinase))) (VP (VBD amplified) (NP (ADJP (QP (RB approximately) (CD 30)) (NN %)) (JJ human) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400|ES| 18:1 19:1 23:1 36:1 104:1 186:1 369:1 470:1 691:1 1046:1 1520:1 1843:1 2208:1 2341:1 3165:1
-1 	|BT| (NP (NP (NP (NP (NN Dehydroepiandrosterone)) (PRN (-LRB- -LRB-) (NP (NN DHEA)) (-RRB- -RRB-))) (, ,) (NP (JJ major) (NN precursor) (NN androgen) (NN estrogen)) (, ,)) (NP (NP (JJ several) (JJ beneficial) (NN effect) (JJ immune) (NN system)) (, ,) (NP (NN memory) (NN function)) (, ,) (S (VP (VBG modulating) (NP (NP (NN effect) (NN diabetes)) (, ,) (NP (NN obesity)) (, ,) (NP (NN chemical) (NN carcinogenesis))))))) |ET| |BS|33:C04.697.098 564:C18.654.726.500 726:C18.452.394.750 740:D04.808.054.079.429.625 889:D27.505.696.399.472.277 892:D27.505.696.399.472.161 899:F02.463.425.540 900:A15.382|ES| 2:1 10:1 14:1 19:1 33:1 75:1 207:1 262:1 462:1 593:1 984:1 2009:1 2010:1 2124:1 2435:1 2633:1 3154:1 3166:1 3167:1 3168:1 3169:1 3170:1
-1 	|BT| (NP (NP (NP (NP (JJ Dimethylarsinic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN DMA)) (-RRB- -RRB-))) (JJ major) (NN metabolite) (JJ inorganic) (JJ arsenical)) (, ,) (NP (ADJP (RB epidemiologically) (JJ significant)) (NN chemical) (NN relation) (NN liver) (NN cancer) (NN mammal))) |ET| |BS|901:B01.050.150.900.649 902:D02.691.088.100 903:D01.075|ES| 2:1 10:1 14:1 18:1 19:1 135:1 462:1 836:1 1275:1 1678:1 2124:1 3171:1 3172:1 3173:1 3174:1 3175:1 3176:1 3177:1
-1 	|BT| (NP (NP (NP (NN Ethanol) (NN consumption) (NN cause) (JJ serious) (NN liver) (NN injury)) (PP (VBG including) (NP (NN cirrhosis) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 242:A03.620 357:C06.552.630 662:C23.550.355 904:F01.145.317.269|ES| 19:1 303:1 304:1 561:1 836:1 1199:1 1779:1 2387:1 2416:1 3178:1 3179:1
-1 	|BT| (S (NP (NP (NP (NN Expression) (NN cyclooxygenase)) (PRN (-LRB- -LRB-) (NP (NN COX)) (-RRB- -RRB-))) (CD -2) (NN protein) (NN rat) (NN hepatocarcinogenesis)) (VP (VBN associated) (NP (NP (JJ fatty) (NN change)) (, ,) (NP (NN fibrosis)) (, ,)) (NP (NP (NN cirrhosis) (JJ oxidative) (NN DNA) (NN damage)) (, ,) (VP (VBD caused) (SBAR (S (NP (ADJP (ADJP (JJ choline-deficient)) (, ,) (ADJP (ADJP (NN L-amino) (JJ acid-defined)) (PRN (-LRB- -LRB-) (ADJP (JJ CDAA)) (-RRB- -RRB-)))) (NN diet)) (VP (VBD investigated) (NP (NP (NN F344) (JJ male) (NN rat)) (, ,) (PP (IN along) (NP (NP (JJ chemopreventive) (NN efficacy) (JJ specific) (NN COX-2) (NN inhibitor)) (, ,) (NP (NP (NN nimesulide)) (PRN (-LRB- -LRB-) (NP (NN NIM)) (-RRB- -RRB-))))))))))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 349:D27.505.519.389.310.500 357:C06.552.630 526:G05.355.180 590:B01.050.050.199.520.760.200 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125 662:C23.550.355 691:C23.550.355|ES| 2:1 4:1 10:1 14:1 19:1 76:1 169:1 200:1 316:1 380:1 403:1 540:1 666:1 849:1 900:1 949:1 1199:1 1402:1 1848:1 1946:1 2070:1 2188:1 2190:1 2191:1 2304:1 2506:1 2583:1 2666:1 3180:1 3181:1 3182:1 3183:1 3184:1 3185:1 3186:1 3187:1
-1 	|BT| (NP (NP (NNP Hepatitis) (NN B) (NN virus) (-LRB- -LRB-) (NN HBV) (-RRB- -RRB-) (: -)) (NP (VBN induced) (NN hepatitis) (NP (NP (JJ carcinogen-induced) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (JJ associated) (NN serum) (NN androgen) (NN concentration)))) |ET| |BS|104:C04.557.470.200.025.255 279:D27.888.569.100 782:A12.207.152.846 863:B04.280.375.650.425 892:D27.505.696.399.472.161 905:F02.830.104.214|ES| 10:1 14:1 19:1 169:1 303:1 304:1 409:1 441:1 763:1 1422:1 1954:1 2048:1 2421:1 2741:1 3154:1 3188:1 3189:1
-1 	|BT| (S (PP (IN In) (NP (NN line) (NN observation))) (, ,) (NP (JJR lower) (NN serum) (NN level) (JJ active) (NN Caspase-3)) (VP (VBD found) (SBAR (S (NP (NN patient) (JJ metastasised) (NN CRC)) (VP (VBD revealed) (NP (NP (JJ stable) (NN disease) (NN tumour) (NN regression)) (VBN compared) (NN disease) (NN progression))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 50:M01.643 288:C23.550.288 429:N04.761.559.590.900 430:E05.581.249 782:A12.207.152.846 846:F01.393.784 906:D08.811.277.656.262.500.126.350.300|ES| 2:1 19:1 37:1 48:1 50:1 117:1 120:1 197:1 244:1 245:1 249:1 264:1 275:1 360:1 998:1 1011:1 1477:1 2741:1 3002:1 3190:1 3191:1
-1 	|BT| (S (PP (IN In) (NP (NN order))) (VB clarify) (SBAR (IN whether) (S (NP (NP (JJ peroxisomal) (NN hydrogen) (NN peroxide)) (PRN (-LRB- -LRB-) (NP (NN H2O2)) (-RRB- -RRB-))) (VP (VBP play) (NP (JJ important) (NN role) (NN peroxisome) (JJ proliferator-induced) (NN hepatocarcinogenesis))))) (, ,) (NP (VBN examined) (NN change) (NN metabolism) (JJ peroxisomal) (NN H2O2)) (ADVP (FW vivo) (FW vitro)) (VP (VBG using) (NP (NP (JJ male) (NN Fischer-344) (NN rat) (NN fed) (NN clofibrate)) (, ,) (NP (NP (JJ bezafibrate) (FW di)) (PRN (-LRB- -LRB-) (NP (NN 2-ethylhexyl)) (-RRB- -RRB-))) (NP (NP (NN phthalate)) (PRN (-LRB- -LRB-) (NP (NN DEHP)) (-RRB- -RRB-)))) (NP (CD 78) (NN week)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 479:G08.686.157.500 590:B01.050.050.199.520.760.200 663:C16.320.565.398.500.330.500 898:G03.495 907:D01.248.497.158.685.750.424 908:A11.284.430.214.190.500.585.600 909:D02.065.277.067 910:D02.241.081.114.968.500.500.195 911:D02.241.223.805.250 912:D27.888.569.100.675|ES| 2:1 10:1 14:1 19:1 31:1 200:1 216:1 221:1 238:1 244:1 324:1 350:1 378:1 783:1 849:1 900:1 902:1 1402:1 1887:1 2426:1 3163:1 3192:1 3193:1 3194:1 3195:1 3196:1 3197:1 3198:1 3199:1 3200:1 3201:1 3202:1 3203:1 3204:1 3205:1 3206:1
-1 	|BT| (S (S (VP (VBG Mounting) (NP (NN evidence)))) (VP (VBP underline) (NP (NP (NP (NP (NP (NP (NN role) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-))) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))) (NN development)) (, ,) (NP (JJ functional) (NN interaction) (NN pathway))) (VP (VBN involved) (NP (NNP HCC) (NN progression)))) (VP (VBP remain) (ADJP (JJ uninvestigated))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 22:D08.811.682.664.500.772.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 31:1 35:1 38:1 48:1 63:1 64:1 65:1 66:1 67:1 303:1 304:1 383:1 415:1 441:1 618:1 774:1 2181:1 3207:1 3208:1 3209:1
-1 	|BT| (S (NP (NNP Sorafenib) (NN increase) (NN survival) (NN rate) (NN patient)) (VP (VBD advanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 779:E05.318.308.985.550.900|ES| 10:1 14:1 19:1 40:1 41:1 120:1 274:1 303:1 304:1 441:1 997:1 3210:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN ADAM9)) (VP (VBZ contributes) (NP (NN pathogenesis) (NN prostate) (NN cancer)) (ADVP (RB potentially)) (ADVP (RB also)) (NP (NN carcinoma)) (, ,) (S (VP (VBG raising) (SBAR (S (NP (NN possibility) (NN ADAM9)) (VP (MD might) (NP (JJ good) (NN target) (NN antitumor) (NN drug))))))))))))) |ET| |BS|265:C04.557.470.200 369:E02.319.300|ES| 2:1 5:1 18:1 19:1 77:1 101:1 160:1 191:1 304:1 343:1 501:1 773:1 796:1 798:1 845:1 1318:1 1537:1 1538:1 2244:1 3211:1 3212:1
-1 	|BT| (S (NP (DT The) (NN purpose) (NN investigation)) (VP (VB evaluate) (NP (NP (JJ possible) (NN influence) (NN mixture) (NN pesticide) (JJ medium-term) (NN carcinogenesis)) (VP (VBG using) (NP (VBN improved) (NN hepatocarcinogenesis) (NN protocol)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 225:E05.337 826:F01.752.609 849:G08.686.785.760.769.490.500 913:D27.720.031.700 914:L01.178|ES| 19:1 207:1 350:1 691:1 867:1 890:1 900:1 1359:1 1497:1 2410:1 3011:1 3213:1 3214:1 3215:1 3216:1
-1 	|BT| (S (NP (EX There)) (VP (VBG increasing) (NP (NN interest) (NP (NP (NNS phytoestrogens) (JJ potential) (JJ alternative) (JJ synthetic) (JJ selective) (NN estrogen) (NN receptor) (NNS modulators)) (PRN (-LRB- -LRB-) (NP (NNS SERMs)) (-RRB- -RRB-))) (NN prevention) (NN therapy) (NN breast) (NN cancer)))) |ET| |BS|52:E02 375:Z01.639.100 831:D27.505.696.399.472.277.540.500 915:D06.347.360.827|ES| 10:1 14:1 18:1 19:1 23:1 130:1 186:1 715:1 827:1 1474:1 1749:1 2311:1 2671:1 2955:1 3168:1 3217:1 3218:1 3219:1 3220:1
-1 	|BT| (NP (NP (S (VP (TO To) (VP (VB clarify) (S (VP (VBG modifying) (NP (NP (NN effect) (NN N-Acetyl-L-Cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ antioxidative) (NN ability)) (, ,) (NP (NN hepatocarcinogenesis)) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (NP (NN FF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PPAR)) (-RRB- -RRB-))) (NN alpha)) (NP (NN agonist))) (, ,) (NP (NP (JJ male) (NN F344/N) (NN rat)) (VP (VBN administered) (NP (NP (NP (ADJP (JJ single) (JJ intraperitoneal)) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN initiator))))) (VP (VBD followed) (NP (NN administration) (NN diet) (VBG containing) (CD 3,000) (NN ppm) (NN FF) (CD 16) (NN week))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1
-1 	|BT| (NP (NP (NP (NNP UNLABELLED) (: :) (NN Activation) (NN beta-catenin)) (, ,) (NP (NP (JJ central) (NN effector) (JJ canonical) (NN Wnt) (NN pathway)) (VP (VBD recognized) (NP (NP (NN oncogene)) (, ,) (NP (VBN implicated) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|9:G05.360.340.024.340.375.500 23:D12.776.091.249 104:C04.557.470.200.025.255 105:G02.149.115.800.925|ES| 2:1 19:1 24:1 60:1 87:1 104:1 303:1 304:1 383:1 570:1 877:1 977:1 2266:1 3235:1 3236:1 3237:1
-1 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (JJ Antidiabetic) (NNS thiazolidinediones)) (PRN (-LRB- -LRB-) (NP (NN TZD)) (-RRB- -RRB-))) (PP (FW vitro) (NP (NP (JJ antiproliferative) (NN effect) (JJ epithelial) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|104:C04.557.470.200.025.255 862:D02.886.675.933 878:D27.505.696.422|ES| 2:1 10:1 14:1 18:1 19:1 75:1 104:1 127:1 216:1 303:1 304:1 441:1 561:1 2266:1 3117:1 3118:1 3119:1 3120:1
-1 	|BT| (NP (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (DT The) (NN Wnt/beta-catenin) (NN pathway)) (VP (VBN implicated) (NP (NP (NN pathogenesis) (JJ hepatocellular) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|23:D12.776.091.249 147:G02.149.115.800.925|ES| 10:1 14:1 18:1 19:1 104:1 302:1 303:1 383:1 441:1 501:1 691:1 977:1 2266:1
-1 	|BT| (S (NP (NN 17-Allylamino-17-demethoxygeldanamycin)) (VP (VBZ overcomes) (NP (NN TRAIL) (NN resistance) (NN colon) (NN cancer) (NN cell) (NN line)))) |ET| |BS|94:A11.251.210|ES| 18:1 19:1 94:1 113:1 264:1 1094:1 1695:1 3238:1 3239:1
-1 	|BT| (S (NP (NN 5-Lipoxygenase)) (VP (VBZ contributes) (NP (NN progression) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 918:D08.811.682.690.416.583.500.055|ES| 19:1 48:1 303:1 304:1 845:1 3240:1
-1 	|BT| (S (NP (DT A) (JJ novel) (JJ CYR61-triggered) (`` `) (NN CYR61-alphavbeta3) (NN integrin) (NN loop)) ('' ') (VP (VBZ regulates) (NP (NN breast) (NN cancer) (NN cell) (NN survival) (NN chemosensitivity) (NN activation) (NN ERK1/ERK2) (NN MAPK) (NN signaling) (NN pathway)))) |ET| |BS|69:G02.111.087.800 108:G04.299.316 116:D08.811.913.696.620.682.700.567.249.750 126:G02.111.087.800 259:D12.776.395.240.150.500 573:N05.715.350.200.650 919:D08.811.913.696.620.682.700.567.249.500 920:D12.776.543.750.705.408|ES| 18:1 19:1 23:1 69:1 94:1 195:1 225:1 248:1 274:1 383:1 386:1 603:1 809:1 891:1 1489:1 3241:1 3242:1 3243:1 3244:1
-1 	|BT| (NP (NP (NP (DT A) (JJ novel) (NN inhibitor) (JJ fatty) (NN acid) (NN synthase) (NN show) (NN activity) (NN HER2)) (CC +) (NP (NN breast) (NN cancer) (NN xenograft) (JJ active) (JJ anti-HER2) (JJ drug-resistant) (NN cell) (NN line)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 92:E04.936.764 93:A01.941.875 94:A11.251.210 259:D12.776.395.240.150.500 921:D08.811.682.664.500.772 922:D10.251|ES| 18:1 19:1 23:1 66:1 69:1 94:1 197:1 264:1 265:1 380:1 399:1 429:1 891:1 1275:1 2070:1 3245:1 3246:1 3247:1
-1 	|BT| (S (NP (DT A) (NP (JJ pivotal) (NN signaling) (NN network) (JJ colorectal) (NN cancer) (NN cell))) (VP (VBZ involves) (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3beta)) (PRN (-LRB- -LRB-) (NP (NN GSK3beta)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ multifunctional) (NN kinase)) (SBAR (WHNP (WP$ whose) (NN role) (NN tumor) (NN cell) (NN survival)) (S (VP (VBN defined)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 69:G02.111.087.800 108:G04.299.316 469:D08.811.913.696 588:I01.880.853.500.600|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 66:1 69:1 92:1 93:1 94:1 195:1 274:1 470:1 680:1 919:1 1673:1 1878:1 1894:1 2154:1 3248:1
-1 	|BT| (S (S (NP (DT A) (JJ potential) (VBG underlying) (NN mechanism) (NN role) (NN ADAM9) (NN prostate) (NN cancer)) (VP (VBD emerged) (NP (JJ cell-based) (NN assay)))) (: :) (S (NP (NN ADAM9)) (VP (VBP cleave) (NP (NP (NN release) (JJ epidermal) (NN growth) (NN factor) (NN FGFR2iiib) (NN cell)) (, ,) (NP (JJ pivotal) (NN function) (NN pathogenesis) (NN disease)))))) |ET| |BS|15:F01.829.316.616 41:A11 106:E05.091 288:C23.550.288 333:D01.045 589:E02.204.125 923:D06.472.317.350|ES| 2:1 18:1 19:1 31:1 33:1 69:1 77:1 94:1 102:1 104:1 162:1 184:1 185:1 310:1 435:1 501:1 827:1 998:1 1113:1 2165:1 3211:1 3248:1 3249:1 3250:1 3251:1
-1 	|BT| (S (NP (JJ Aberrant) (NN beta-catenin) (JJ intracellular) (NN distribution)) (VP (VBD found) (NP (NP (JJ gastric) (NP (NN cancer)) (, ,) (NP (NN pattern) (NN Wnt) (NN expression) (JJ stepwise) (NN gastrocarcinogenesis) (JJ potential) (NN influence) (NN beta-catenin) (NN distribution)) (ADJP (RB still) (JJR lesser))) (VP (VBN known))))) |ET| |BS|23:D12.776.091.249 826:F01.752.609 924:A11.284.430.214|ES| 2:1 18:1 19:1 37:1 60:1 80:1 86:1 115:1 260:1 556:1 776:1 827:1 867:1 877:1 2805:1 3252:1 3253:1 3254:1 3255:1
-1 	|BT| (NP (NP (JJ Aberrant) (NN methylation) (NN histone) (NN deacetylation) (NN cyclooxygenase) (CD 2) (JJ gastric) (NN cancer))) |ET| |BS|24:D08.811.600.720.750 36:G02.111.087.029.538 399:D12.776.660.470|ES| 18:1 19:1 80:1 81:1 86:1 148:1 503:1 3180:1 3256:1
-1 	|BT| (S (NP (ADJP (QP (IN About) (CD 80)) (NN %)) (JJ gastric) (NN cancer)) (VP (VBD showed) (NP (JJ high) (NN level) (NN expression) (NN cyclooxygenase) (CD 2)) (, ,) (S (NP (NN subset) (NN case)) (VP (VBP express) (PP (IN without) (NP (JJ unknown) (NN reason))))))) |ET| |BS|24:D08.811.600.720.750|ES| 2:1 18:1 19:1 86:1 115:1 132:1 148:1 178:1 208:1 249:1 369:1 573:1 934:1 1195:1 1285:1 2182:1 3180:1 3257:1 3258:1
-1 	|BT| (S (NP (VBN Accelerated) (NN liver) (NN regeneration) (NN hepatocarcinogenesis) (NN mouse)) (VP (VBG overexpressing) (NP (NN serine-45) (JJ mutant) (NN beta-catenin)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 925:G10.261.326.520 926:D12.125.154.800|ES| 19:1 52:1 60:1 811:1 836:1 900:1 3259:1 3260:1 3261:1 3262:1
-1 	|BT| (S (NP (NN Acylglycerol) (NN kinase)) (VP (VBZ promotes) (NP (NN cell) (NN proliferation) (NN tumorigenicity) (NN breast) (NN cancer)) (PP (IN via) (NP (NN suppression) (NN FOXO1) (NN transcription) (NN factor))))) |ET| |BS|183:G04.299.233.750 209:G02.111.087.847|ES| 18:1 19:1 23:1 94:1 185:1 298:1 299:1 300:1 470:1 487:1 596:1 2453:1 3263:1 3264:1
-1 	|BT| (S (PP (IN After) (NP (JJ 2-week) (NN treatment))) (, ,) (NP (NN animal)) (VP (VBN subjected) (SBAR (`` ``) (S (NP (NP (JJ resistant) (NN hepatocyte) ('' '') (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (NP (NN initiation) (NN diethylnitrosamine)) (, ,) (NP (NN selection/promotion) (JJ 2-acetylaminofluorene) (JJ partial) (NN hepatectomy))) (-RRB- -RRB-))) (VP (VBD euthanized) (NP (ADJP (CD 8) (NN week)) (NN treatment))))))) |ET| |BS|19:B01.050 52:E02 262:A11.436.348 554:D02.654.442.200 812:G05.355.800 881:D02.065.064.150 927:E02.760.905.850 928:E04.210.556|ES| 2:1 10:1 14:1 19:1 46:1 72:1 427:1 546:1 637:1 781:1 783:1 900:1 1909:1 1952:1 3265:1 3266:1 3267:1 3268:1 3269:1 3270:1 3271:1 3272:1 3273:1 3274:1
-1 	|BT| (S (NP (NP (NP (JJ Aldo-keto) (NN reductase) (NN family) (CD 1) (NN B10)) (PRN (-LRB- -LRB-) (NP (NN AKR1B10)) (-RRB- -RRB-))) (, ,) (NP (NN member) (JJ aldo-keto) (NN reductase) (NN superfamily)) (, ,)) (VP (VP (VBN overexpressed) (NP (JJ human) (JJ hepatocellular) (NN carcinoma))) (, ,) (NP (NN lung) (JJ squamous) (NN cell) (NN carcinoma) (NN lung) (NN adenocarcinoma)))) |ET| |BS|44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 182:A04.411 929:C04.557.470.200.400|ES| 2:1 10:1 14:1 19:1 25:1 36:1 94:1 95:1 96:1 97:1 98:1 99:1 255:1 303:1 304:1 328:1 769:1 1067:1 3275:1 3276:1 3277:1
-1 	|BT| (S (NP (DT All) (NN result)) (VP (VBP suggest) (SBAR (S (NP (JJ low) (NN concentration) (NN acrylamide)) (VP (MD may) (VP (VB contribute) (NP (NP (NN progression) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 905:F02.830.104.214 930:D02.065.122.015|ES| 10:1 14:1 19:1 48:1 101:1 303:1 304:1 441:1 450:1 491:1 531:1 796:1 965:1 3189:1 3278:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (NN liver) (NN tumor)) (, ,) (NP (NN IL-22TG) (NN mouse) (JJ susceptible) (JJ diethylnitrosamine-induced) (NN liver) (NN cancer))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 554:D02.654.442.200 897:Z01.252.245.500.375 931:Z01.107.567.875.350.350 932:D12.644.276.374.465|ES| 2:1 7:1 18:1 19:1 52:1 107:1 648:1 836:1 899:1 1506:1 2732:1 3279:1
-1 	|BT| (S (IN Although) (, ,) (NP (NP (NN NLK) (VBN known) (NN tumor) (NN suppressor) (NN Wnt/beta-catenin) (NN signaling) (NN pathway) (NN colon) (NN cancer)) (, ,) (NP (NN event) (VBG occurring) (NP (JJ downstream) (NN NLK) (NN pathway) (NN type) (NN cancer)))) (VP (VBP remain) (ADJP (JJ unclear)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 18:1 19:1 107:1 113:1 195:1 205:1 302:1 383:1 443:1 543:1 556:1 560:1 700:1 1737:1 2181:1 3280:1
-1 	|BT| (NP (NP (PP (IN Among) (NP (NNS others))) (, ,) (NP (NN bladder) (, ,) (NN lung) (, ,) (NN colon) (, ,) (NN breast) (NN cancer) (VBN associated) (NN 4-ABP)))) |ET| |BS|46:A03.556.124.526.356 182:A04.411 933:A05.810.890|ES| 2:1 18:1 19:1 23:1 113:1 169:1 328:1 564:1 1000:1 3281:1 3282:1
-1 	|BT| (NP (NP (NP (JJ Antagonistic) (NN effect) (NN selenium) (NN lipid) (NN peroxide)) (NN growth) (NN control) (JJ early) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 934:D01.248.497.158.685.750.637 935:D01.268.185.850|ES| 19:1 75:1 102:1 289:1 303:1 304:1 1128:1 2401:1 3196:1 3283:1 3284:1
-1 	|BT| (NP (NP (NP (JJ Anticancer) (NN effect) (NN wogonin) (NN estrogen) (JJ receptor-positive)) (: -) (NP (JJ negative) (JJ human) (NN breast) (NN cancer) (NN cell) (NN line) (NN vitro) (JJ nude) (NN mouse) (NN xenograft)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 936:D12.776.826.750.350|ES| 18:1 19:1 23:1 36:1 52:1 75:1 94:1 216:1 264:1 265:1 266:1 2444:1 2446:1 3168:1 3285:1 3286:1
-1 	|BT| (S (NP (JJ Antisense) (NP (JJ E1AF-transfected) (NN MKN45) (JJ gastric) (NN cancer) (NN cell))) (VP (VBD expressed) (NP (VBN reduced) (NN level) (NN matrilysin)) (NP (DT le) (NP (JJ invasive) (NN vitro) (JJ mock-transfected) (NN MKN45) (NN cell))))) |ET| |BS|41:A11 937:D08.811.277.656.300.480.525.700.250|ES| 6:1 18:1 19:1 86:1 94:1 144:1 216:1 249:1 452:1 489:1 2850:1 3287:1 3288:1 3289:1 3290:1
-1 	|BT| (S (NP (NN Apoptosis) (JJ signal-regulating) (NN kinase) (CD 1)) (VP (VBZ inhibits) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG controlling) (NP (JJ tumor-suppressing) (NN function) (JJ stress-activated) (JJ mitogen-activated) (NN protein) (NN kinase)))))) |ET| |BS|8:C04 122:C14.280.383 478:D08.811.913.696.620.682.700.567 938:D08.811.913.696.620.682.700.559.500|ES| 4:1 19:1 33:1 98:1 470:1 615:1 900:1 2220:1 3291:1 3292:1 3293:1 3294:1 3295:1
-1 	|BT| (NP (NP (NN Aspirin) (NN use) (NN survival) (NN diagnosis) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 96:I03.784 263:E01 670:D02.455.426.559.389.657.410.595.176|ES| 17:1 18:1 19:1 274:1 1037:1 1659:1 2449:1
-1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (NP (NNP Drug) (NN combination) (NN therapy)) (VP (VBG using) (NP (NP (NN cisplatin) (JJ natural) (NN product)) (JJ common) (NN practice) (NN treatment) (JJ human) (NN lung) (NN cancer))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 498:D01.210.375 793:D20.215 939:E02.319.310|ES| 18:1 19:1 36:1 104:1 130:1 328:1 350:1 530:1 546:1 655:1 675:1 1046:1 1761:1 2333:1 2345:1 3296:1
-1 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NP (JJ Epidermal) (NN growth) (NN factor) (JJ receptor-tyrosine) (NN kinase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN EGFR-TKIs)) (-RRB- -RRB-))) (VP (VBD approved) (NP (NP (NN patient)) (JJ recurrent) (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|50:M01.643 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 496:C23.550.291.937 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 94:1 102:1 104:1 120:1 185:1 328:1 329:1 380:1 470:1 694:1 1046:1 1753:1 2340:1 2343:1 3297:1 3298:1
-1 	|BT| (S (NP (NP (NP (NN Balb/c) (NN mouse) (VBN treated) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN dextran) (NN sulfate) (NN sodium)) (VP (VBP induce) (NP (NN colon) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 131:D09.698.365.272.300 132:D02.172.080 940:B01.050.050.199.520.520.338|ES| 10:1 14:1 18:1 19:1 52:1 113:1 243:1 406:1 407:1 1099:1 1993:1 1994:1 3299:1 3300:1
-1 	|BT| (S (NP (NP (NP (NN Beta-catenin/T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Tcf)) (-RRB- -RRB-))) (NN signaling)) (NP (RB constitutively) (JJ active) (NN majority) (JJ human) (JJ colorectal) (NN cancer)) (, ,) (VP (VBG accompanying) (NP (NN change) (NN Bcl-2) (NN expression)))) |ET| |BS|4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800|ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1
-1 	|BT| (S (NP (NN Beta-ionone)) (VP (VP (VBZ inhibits) (NP (JJ colonic) (JJ aberrant) (NN crypt) (NN focus) (NN formation) (NN rat))) (, ,) (VP (VBZ suppresses) (NP (NN cell) (NN growth))) (, ,) (VP (VBZ induces) (NP (NN retinoid) (NN X) (NN receptor-alpha) (JJ human) (NN colon) (NN cancer) (NN cell))))) |ET| |BS|20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 824:C04.834.020 941:D12.776.826.701.500.500|ES| 2:1 18:1 19:1 36:1 43:1 94:1 102:1 113:1 214:1 615:1 677:1 686:1 849:1 929:1 1431:1 1725:1 1889:1 2454:1 2573:1 2913:1
-1 	|BT| (FRAG (NP (NNP Boswellia) (NNP serrata) (NN resin) (NN extract)) (VBZ alleviates) (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (: /) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN tumorigenesis))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 942:D05.750.078.840.490|ES| 10:1 14:1 19:1 78:1 113:1 406:1 407:1 409:1 1993:1 1994:1 2496:1 3301:1 3302:1 3303:1 3304:1 3305:1 3306:1
-1 	|BT| (S (NP (JJ Branched-chain) (NN amino) (NN acid) (-LRB- -LRB-) (NN BCAA) (-RRB- -RRB-)) (, ,) (VP (VB improve) (NP (NP (NN protein) (NN malnutrition) (NN patient) (NN liver) (NN cirrhosis)) (, ,) (S (VP (VB reduce) (NP (NN risk) (JJ hepatocellular) (NN carcinoma) (NN patient) (NN obesity))))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 564:C18.654.726.500 639:D12.125.070 943:C18.654.521.719.500|ES| 2:1 4:1 10:1 14:1 19:1 120:1 171:1 303:1 304:1 836:1 1199:1 1275:1 2010:1 2189:1 2360:1 2361:1 2465:1 2466:1 3307:1
-1 	|BT| (S (NP (NP (NN Breast) (NN cancer)) (VP (VBG expressing) (NP (VBN activated) (NN HER2/neu) (JJ sensitive) (FW gefitinib) (FW vitro) (FW vivo)))) (VP (VBZ acquires) (NP (NN resistance) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 259:D12.776.395.240.150.500 438:G05.365.590.675|ES| 18:1 19:1 34:1 163:1 216:1 378:1 810:1 891:1 901:1 1094:1 2121:1 3308:1 3309:1 3310:1 3311:1
-1 	|BT| (NP (NP (NP (NN BTG3) (NN tumor) (NN suppressor) (NN gene) (NN promoter) (NN demethylation)) (, ,) (NP (NN histone) (NN modification) (NN cell) (NN cycle) (NN arrest)) (NP (NN genistein) (JJ renal) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375|ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1
-1 	|BT| (S (NP (NN Caveolin-1)) (VP (VBZ enhances) (NP (JJ resveratrol-mediated) (NN cytotoxicity) (NN transport) (JJ hepatocellular) (NN carcinoma) (NN model)))) |ET| |BS|104:C04.557.470.200.025.255 945:D12.644.360.024.264 946:D27.888.569.213 947:G03.495.166|ES| 19:1 72:1 303:1 304:1 1356:1 3315:1 3316:1 3317:1 3318:1
-1 	|BT| (S (NP (JJ Cellular) (JJ FLICE-inhibitory) (NN protein) (NN down-regulation)) (VP (VBZ contributes) (NP (JJ celecoxib-induced) (NN apoptosis) (JJ human) (NN lung) (NN cancer) (NN cell)))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 684:D02.065.884.247 948:D12.644.360.024.296.024|ES| 4:1 18:1 19:1 36:1 89:1 94:1 257:1 328:1 845:1 3319:1 3320:1 3321:1
-1 	|BT| (NP (NP (NN Characterization) (JJ nuclear) (JJ receptor-mediated) (JJ murine) (NN hepatocarcinogenesis) (NN herbicide) (NN pronamide) (JJ human) (NN relevance))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 949:D27.720.031.700.366 950:D12.776.826|ES| 19:1 36:1 627:1 900:1 1064:1 1256:1 3123:1 3322:1 3323:1 3324:1
-1 	|BT| (S (NP (NNP Chitinase) (JJ 3-like) (CD 1)) (VP (VBZ promotes) (NP (NN macrophage) (NN recruitment) (NN angiogenesis) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 658:A11.329.372 951:D08.811.277.450.207|ES| 17:1 18:1 19:1 98:1 298:1 2402:1 2502:1 3325:1 3326:1 3327:1
-1 	|BT| (S (NP (NNP Chlorophyllin)) (VP (VP (VBN shown) (ADVP (RB significantly)) (VP (VB reduce) (S (NP (JJ genotoxic) (NN AFB) (NNS biomarkers)) (ADJP (JJ human))))) (, ,) (ADVP (RB therefore)) (VP (VBP hold) (NP (NP (NN promise) (JJ practical) (NN mean)) (VP (VBG reducing) (NP (NN incidence) (JJ AFB-induced) (NN liver) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 158:D23.101 434:E05.318.308.985.525.375|ES| 2:1 18:1 19:1 36:1 124:1 218:1 237:1 836:1 1269:1 1511:1 2215:1 2361:1 2825:1 2827:1 3039:1 3328:1 3329:1 3330:1 3331:1 3332:1
-1 	|BT| (S (NP (NN Claudin-1) (NN overexpression) (JJ intestinal) (JJ epithelial) (NN cell)) (VP (VBZ enhances) (NP (NN susceptibility) (JJ adenamatous) (NN polyposis) (JJ coli-mediated) (NN colon) (NN tumorigenesis)))) |ET| |BS|3:C04.557.470.035.215.100 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 75:A11.436 401:C23.550.291.687 952:D12.776.543.984.200.100|ES| 19:1 58:1 78:1 94:1 109:1 113:1 127:1 152:1 1353:1 1356:1 3333:1 3334:1 3335:1
-1 	|BT| (S (NP (NNP Coffee)) (VP (VBZ reduces) (NP (NP (NN liver) (NN damage) (NN rat) (NN model) (NN steatohepatitis)) (: :) (NP (VBG underlying) (NN mechanism) (NN role) (NNS polyphenols) (NNS melanoidins))))) |ET| |BS|15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249|ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1
-1 	|BT| (FRAG (ADVP (RB Collectively)) (, ,) (NP (NP (NNS data)) (SBAR (IN along) (S (NP (JJ negative) (NN genotoxicity)) (VP (VBP demonstrate) (SBAR (S (NP (NP (NN oxyfluorfen)) (PRN (-LRB- -LRB-) (NP (ADJP (QP (JJR >) (CD 98)) (NN %)) (NN purity)) (-RRB- -RRB-))) (ADJP (JJ potential)) (VP (VBP induce) (S (NP (NN mouse) (NN liver) (NN tumor)) (ADJP (JJ nongenotoxic)))))) (, ,) (NP (NP (JJ mitogenic) (NNP MOA) (JJ clear) (NN threshold)) (VP (VBD predicted) (NP (JJ carcinogenic) (JJ human) (JJ relevant) (NN exposure) (NN level))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 515:C04.588.274.623 575:V02.050 953:D27.505.519.593.624|ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 243:1 249:1 369:1 449:1 502:1 793:1 827:1 836:1 865:1 1466:1 1872:1 1953:1 2666:1 3336:1 3337:1 3338:1 3339:1 3340:1 3341:1 3342:1 3343:1 3344:1 3345:1 3346:1
-1 	|BT| (S (NP (VBN Combined) (NN lapatinib) (NN panobinostat) (NN treatment)) (VP (VBD interacted) (ADVP (RB synergistically)) (VP (VB inhibit) (NP (NP (NN proliferation) (NN colony) (NN formation) (NN CRC) (NN cell) (NN line)) (VP (VBN tested)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 94:A11.251.210 109:I01.696.116 122:C14.280.383|ES| 19:1 43:1 94:1 245:1 264:1 299:1 314:1 546:1 741:1 1370:1 2488:1 2988:1 3347:1 3348:1 3349:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (PRP$ Our) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (JJ sustained) (NN LPS) (NN accumulation)) (VP (VBZ represents) (NP (JJ pathological) (NN mediator) (NP (NP (JJ inflammation-associated) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN manipulation) (NN gut) (NN flora))))))) (VP (VBP prevent) (SBAR (S (NP (JJ pathogenic) (JJ bacterial) (NN translocation) (NN endotoxin) (NN absorption)) (VP (MD may) (ADVP (RB favorably)) (VP (VB influence) (NP (NP (NN liver) (NN function) (NN patient) (NN cirrhosis) (NN risk)) (VP (VBG developing) (NP (NNP HCC))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 327:G06.930 357:C06.552.630 417:H02.403.650 662:C23.550.355 954:G06.755.375 955:G06.755.375 956:D09.400.500 957:G06.099.112.105 958:G01.595.014 959:D23.946.123.329 960:D23.469|ES| 10:1 14:1 19:1 33:1 104:1 120:1 171:1 303:1 304:1 441:1 491:1 590:1 658:1 733:1 793:1 836:1 867:1 1199:1 1426:1 1479:1 1618:1 1698:1 1847:1 1849:1 1882:1 2120:1 2516:1 3350:1 3351:1 3352:1 3353:1 3354:1 3355:1 3356:1 3357:1 3358:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NNP Bromelain)) (VP (VBZ exerts) (NP (NP (JJ antiproliferative) (JJ proapoptotic) (NN effect)) (JJ colorectal) (NN carcinoma) (NN cell) (JJ chemopreventive) (NN action) (NN colon) (NN carcinogenesis)) (FW vivo)))) |ET| |BS|5:C04.588.274.476.411.307 33:C04.697.098 41:A11 46:A03.556.124.526.356 679:D08.811.277.656.262.500.096|ES| 17:1 19:1 75:1 94:1 104:1 113:1 207:1 304:1 378:1 1882:1 1885:1 1946:1 1977:1 2013:1 3120:1 3359:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (JJ Functional) (NN interaction) (NN FOXO3a) (NN ER)) (VP (VBP play) (NP (JJ critical) (NN role)) (S (VP (VBG suppressing) (ADVP (NP (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell) (NN growth) (NN tumorigenesis)) (FW vivo))))))) |ET| |BS|15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 41:A11 45:G07.700.320.249 79:I03.450.642.693 889:D27.505.696.399.472.277|ES| 18:1 19:1 23:1 31:1 78:1 94:1 102:1 104:1 238:1 378:1 618:1 825:1 1882:1 2250:1 3360:1 3361:1 3362:1 3363:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (NP (NP (NNP Metformin)) (, ,) (VP (ADVP (RB generally)) (VBN considered) (S (ADJP (JJ nontoxic) (SBAR (S (ADJP (RB remarkably) (JJ inexpensive)) (, ,) (VP (MD might) (NP (VBN used) (NN combination) (NNS TKIs) (NN patient) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (S (VP (VBG harboring) (S (NP (NN EGFR) (NN mutation)) (VP (VBP overcome) (S (NP (NN TKI) (NN resistance)) (VP (VB prolong) (NP (NN survival)))))))))))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 96:I03.784 110:C04.588.894.797.520.109.220.249 784:D02.078.370.141.450|ES| 2:1 18:1 19:1 34:1 94:1 104:1 120:1 187:1 274:1 328:1 476:1 530:1 694:1 798:1 1061:1 1094:1 1304:1 1882:1 2746:1 2998:1 3364:1 3365:1 3366:1 3367:1 3368:1 3369:1 3370:1
-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN garcinol)) (VP (MD may) (VP (VB merit) (S (NP (JJ clinical) (NN investigation) (NN chemoprophylactic) (NN food) (NN help)) (VP (VB prevent) (NP (JJ colitis-associated) (NN colon) (NN cancer))))))))))) |ET| |BS|53:C06.405.205.265 225:E05.337 680:G07.203.300|ES| 18:1 19:1 84:1 101:1 104:1 113:1 410:1 491:1 658:1 733:1 796:1 1497:1 1882:1 2470:1 3371:1 3372:1 3373:1 3374:1
-1 	|BT| (S (NP (NN CONCLUSION) (: :)) (VP (VP (VBN Taken) (ADVP (RB together))) (, ,) (SBAR (S (NP (NNS data) (VBP show) (NN Akt) (NN inhibitor) (NN AZD5363)) (VP (VBZ synergizes) (SBAR (S (NP (JJ lysosomotropic) (NN inhibitor) (NN autophagy) (NN chloroquine)) (VP (VBP induce) (NP (NN apoptosis) (NN delay) (NN tumor) (NN progression) (NN prostate) (NN cancer) (NN model) (JJ resistant) (NN monotherapy) (NN AZD5363)) (, ,) (S (VP (VBG providing) (NP (NP (JJ new) (JJ therapeutic) (NN approach)) (RRC (ADVP (RB potentially)) (NP (JJ translatable) (NN patient)))))))))))))) |ET| |BS|8:C04 16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 50:M01.643 52:E02 202:C04.588.945.440.770 390:G04.299.139.399 961:D03.438.810.050.180|ES| 2:1 7:1 18:1 19:1 48:1 72:1 77:1 89:1 104:1 120:1 136:1 243:1 380:1 427:1 429:1 541:1 712:1 773:1 793:1 911:1 1289:1 1317:1 1537:1 1538:1 1882:1 3025:1 3375:1 3376:1 3377:1 3378:1 3379:1 3380:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (NN absence) (JJ retinoid-containing) (NN HSC) (NN lipid) (NN droplet)) (VP (VBP promote) (SBAR (S (NP (NN HSC) (NN activation)) (VP (VBZ reduces) (NP (NN hepatocarcinogenesis)))))))) |ET| |BS|711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393|ES| 19:1 104:1 142:1 225:1 239:1 679:1 691:1 900:1 1534:1 2401:1 3381:1 3382:1 3383:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN Raloxifene) (JJ potent) (NN IL-6) (: /) (NN GP130) (NN inhibitor)) (VP (MD may) (VP (VB chemoprevention) (NP (NP (NN agent) (NN liver) (NN cancer)) (VP (VBG targeting) (NP (JJ persistent) (NN STAT3) (NN signaling))))))))))) |ET| |BS|69:G02.111.087.800 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 253:E02.319.162 964:D02.455.426.559.389.150.700.900.775|ES| 18:1 19:1 22:1 101:1 104:1 195:1 239:1 251:1 380:1 491:1 616:1 658:1 728:1 796:1 836:1 870:1 3384:1 3385:1 3386:1
-1 	|BT| (FRAG (NP (NNS CONCLUSIONS) (: :)) (NP (NN Pitavastatin) (JJ effective) (VBG inhibiting) (NP (JJ early) (NN phase) (JJ obesity-related) (NN liver) (NN tumorigenesis))) (, ,) (ADVP (RB therefore)) (, ,) (NP (MD may) (NP (JJ useful) (NN chemoprevention) (NN liver) (NN cancer) (JJ obese) (NN individual)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 242:A03.620 253:E02.319.162 493:M01 564:C18.654.726.500|ES| 2:1 18:1 19:1 78:1 104:1 218:1 239:1 491:1 836:1 870:1 880:1 1036:1 1128:1 1639:1 2467:1 2468:1 2512:1 2529:1 3387:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (VP (VBN Taken) (ADVP (RB together))) (, ,) (S (NP (NNS data)) (VP (VBP provide) (NP (NP (JJ first) (ADJP (FW vitro) (FW vivo)) (NN evidence) (JJ integral) (NN role)) (NP (NN LKB1-AMPK) (NN axis) (JJ honokiol-mediated) (NN inhibition) (NN invasion) (NN migration) (NN breast) (NN cancer) (NN cell)))))) |ET| |BS|15:F01.829.316.616 43:F01.145.544 579:A02.835.232.834.151.383 681:G04.299.283|ES| 2:1 18:1 19:1 23:1 31:1 38:1 94:1 103:1 104:1 216:1 239:1 378:1 514:1 620:1 711:1 793:1 816:1 1537:1 1538:1 2089:1 2269:1 3388:1 3389:1
-1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (DT This) (NN study)) (VP (VBD showed) (SBAR (S (NP (NN 5-LOX)) (VP (VBD up-regulated) (NP (NP (JJ adenomatous) (NN colon) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))))))) |ET| |BS|46:A03.556.124.526.356 142:I01.880.604 150:Z01.542.248.960 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 50:1 57:1 104:1 113:1 118:1 131:1 132:1 239:1 579:1 647:1 677:1 807:1 1301:1 3390:1
-1 	|BT| (S (NP (JJ Conditional) (NN beta-catenin) (NN loss) (NN mouse)) (VP (VBZ promotes) (NP (NP (NN chemical) (NN hepatocarcinogenesis)) (: :) (NP (NN role) (NP (ADJP (JJ oxidative) (NN stress) (JJ platelet-derived)) (NN growth) (NN factor) (NN receptor) (NN alpha/phosphoinositide) (NN 3-kinase)) (NN signaling))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 69:G02.111.087.800 578:D08.811.913.696.620.550 716:G03.495.710 965:D08.811.913.696.620.682.725.400.900|ES| 19:1 31:1 32:1 52:1 60:1 102:1 104:1 185:1 186:1 195:1 298:1 900:1 2124:1 2522:1 2583:1 3391:1 3392:1 3393:1 3394:1
-1 	|BT| (NP (NP (NP (JJ Consistent) (NN finding) (, ,) (JJ ABCB5-expressing) (NN tumor) (NN cell) (NN population)) (RRC (ADVP (RB also)) (NP (NN treatment) (ADJP (JJ refractory) (S (VP (VBD exhibited) (NP (NN resistance) (JJ 5-FU-induced) (NN apoptosis) (JJ colorectal) (NN cancer) (NN xenograft) (NN model) (NN 5-FU) (NN monotherapy))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 52:E02 92:E04.936.764 93:A01.941.875 175:J01.897.280.500.269 275:C23.888 560:D03.383.742.698.875.404 829:M01.686 966:N01.600|ES| 2:1 5:1 7:1 17:1 18:1 19:1 72:1 89:1 94:1 265:1 546:1 609:1 927:1 1094:1 2023:1 2308:1 3379:1 3395:1 3396:1 3397:1 3398:1
-1 	|BT| (NP (NP (NP (JJ Constitutive) (NN activation) (NN phosphoinositide) (NN 3-kinase)) (PRN (-LRB- -LRB-) (NP (NN PI3K)) (-RRB- -RRB-))) (: -) (S (NP (NN Akt) (NN pathway)) (VP (VBZ transmits) (NP (NP (JJ growth-regulatory) (NN signal) (NN play) (JJ central) (NN role)) (S (VP (VBG promoting) (NP (NP (NN survival)) (, ,) (NP (NN proliferation)) (, ,) (NP (NN angiogenesis) (JJ human) (NN prostate) (NN cancer) (NN cell))))))))) |ET| |BS|15:F01.829.316.616 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 96:I03.784 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 2:1 10:1 14:1 18:1 19:1 31:1 36:1 77:1 94:1 225:1 238:1 274:1 299:1 383:1 859:1 881:1 2080:1 2502:1 3235:1 3394:1 3399:1 3400:1 3401:1 3402:1 3403:1
-1 	|BT| (S (NP (JJ Constitutive) (NN activation) (NN Wnt/beta-catenin) (NN pathway)) (VP (VBN implicated) (NP (JJ primary) (NN cause) (NN colon) (NN cancer)))) |ET| |BS|23:D12.776.091.249 147:G02.149.115.800.925|ES| 18:1 19:1 113:1 225:1 302:1 344:1 383:1 977:1 1779:1 3399:1
-1 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NP (JJ partial) (NN loss) (NN A20)) (, ,) (NP (NN A20) (NN heterozygote) (NN mouse)) (, ,)) (ADVP (RB significantly)) (VP (VBZ impairs) (NP (NP (NN liver) (NN regeneration) (NN damage)) (, ,) (NP (VP (VBZ confers) (NP (JJ high) (NN lethality)) (S (VP (ADVP (RB otherwise)) (NP (JJ safe) (NN procedure))))) (NP (FW i.e.) (, ,) (CD 2/3) (JJ partial) (NN hepatectomy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 375:Z01.639.100 925:G10.261.326.520 928:E04.210.556 967:D01.248.497.158.490|ES| 2:1 19:1 32:1 52:1 124:1 178:1 836:1 1508:1 1826:1 1848:1 2729:1 2737:1 3260:1 3272:1 3273:1 3404:1 3405:1 3406:1 3407:1 3408:1 3409:1 3410:1
-1 	|BT| (S (NP (NN Cooperativity) (NN E-cadherin) (NN Smad4) (NN loss)) (VP (VBP promote) (NP (JJ diffuse-type) (JJ gastric) (NN adenocarcinoma) (NN metastasis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 70:A03.556.875.875 84:C04.557.470.200.025 113:C04.697.650 613:D12.776.395.550.200.200 968:F01.145.813.115|ES| 19:1 32:1 86:1 255:1 521:1 679:1 806:1 2267:1 3411:1 3412:1
-1 	|BT| (NP (NP (NN Correlation) (NN Wnt-2) (NN expression) (NN beta-catenin) (JJ intracellular) (NN accumulation) (JJ Chinese) (JJ gastric) (NN cancer)) (: :) (NP (NN relevance) (NN tumour) (NN dissemination))) |ET| |BS|8:C04 23:D12.776.091.249 924:A11.284.430.214|ES| 18:1 19:1 60:1 86:1 104:1 115:1 795:1 1011:1 2120:1 2763:1 3252:1 3324:1 3413:1 3414:1
-1 	|BT| (NP (NP (JJ Critical) (NN function) (NN ADAM9) (NN mouse) (NN prostate) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500|ES| 18:1 19:1 33:1 52:1 77:1 3211:1 3415:1
-1 	|BT| (NP (NP (NN Cross-talk) (NN aryl) (NN hydrocarbon) (NN receptor) (JJ mitogen-activated) (NN protein) (NN kinase) (NN signaling) (NN pathway) (NN liver) (NN cancer) (NN c-raf) (JJ transcriptional) (NN regulation))) |ET| |BS|69:G02.111.087.800 126:G02.111.087.800 142:I01.880.604 148:G12.425.143.281 209:G02.111.087.847 478:D08.811.913.696.620.682.700.567 969:D12.776.260.643.715|ES| 4:1 18:1 19:1 186:1 195:1 383:1 438:1 470:1 559:1 836:1 3295:1 3416:1 3417:1 3418:1 3419:1
-1 	|BT| (S (NP (NN Cryptotanshinone)) (VP (VBZ inhibits) (NP (NP (JJ constitutive) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (NN function)) (VP (VBG blocking) (NP (NN dimerization) (NN DU145) (NN prostate) (NN cancer) (NN cell)))))) |ET| |BS|41:A11 122:C14.280.383 209:G02.111.087.847 250:E07.305.812 970:E06.658.453.560.100 971:G02.149.250|ES| 18:1 19:1 33:1 77:1 94:1 487:1 604:1 615:1 859:1 860:1 861:1 862:1 3420:1 3421:1 3422:1 3423:1
-1 	|BT| (S (NP (NNP Cryptotanshinone)) (ADVP (RB rapidly)) (VP (VBD inhibited) (NP (NN STAT3) (NN Tyr705) (NN phosphorylation) (NN DU145) (NN prostate) (NN cancer) (NN cell) (NN growth) (NN cell)) (NP (CD 96) (NN hour) (NN treatment)))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 82:D12.644.360.024.342.300 122:C14.280.383 972:G02.111.087.677|ES| 18:1 19:1 77:1 94:1 102:1 251:1 365:1 546:1 3420:1 3423:1 3424:1 3425:1 3426:1 3427:1 3428:1
-1 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1
-1 	|BT| (NP (NP (NP (NN Cyclooxygenase) (CD 2) (NN play) (JJ critical) (NN role) (NN development) (JJ gastrointestinal) (NN cancer)) (NP (JJ human) (NN animal) (NN model)))) |ET| |BS|15:F01.829.316.616 24:D08.811.600.720.750 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 285:E05.598|ES| 18:1 19:1 31:1 35:1 36:1 46:1 72:1 148:1 183:1 238:1 825:1 3432:1
-1 	|BT| (S (NP (NP (NN Cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (ADVP (RB constitutively)) (VP (VBD expressed) (NP (NP (NN variety) (NN tumor)) (PP (VBG including) (NP (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 24:D08.811.600.720.750|ES| 6:1 7:1 10:1 14:1 17:1 18:1 19:1 76:1 196:1 561:1 952:1 1158:1
-1 	|BT| (S (NP (NN Decrease) (JJ hepatic) (JJ stellate) (NN cell) (NN rat)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ clofibrate-induced) (NN hepatocarcinogenesis)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 677:A11.561 910:D02.241.081.114.968.500.500.195|ES| 19:1 94:1 385:1 607:1 838:1 849:1 900:1 2461:1 3433:1 3434:1
-1 	|BT| (FRAG (NP (NN Deficiency) (NN folate)) (, ,) (NP (S (VP (VBP play) (NP (NN role) (NN synthesis) (NNP SAM) (NN lead)))) (NP (VBD increased) (NN risk) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 20:G03.495 61:E05.318.740.600.800 79:I03.450.642.693 86:D01.268.556.435 232:D02.886.030.676.180 974:C18.654.521.500.133.699.308|ES| 2:1 18:1 19:1 31:1 47:1 113:1 171:1 238:1 254:1 778:1 3435:1 3436:1 3437:1
-1 	|BT| (NP (NP (JJ Desmoplakin) (NN act) (NN tumor) (NN suppressor) (NN inhibition) (NN Wnt/beta-catenin) (NN signaling) (NN pathway) (JJ human) (NN lung) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249 975:D12.776.220.790.500|ES| 7:1 18:1 19:1 36:1 103:1 195:1 246:1 302:1 328:1 383:1 700:1 3438:1
-1 	|BT| (S (NP (JJ Diet-induced) (NN obesity) (NN ethanol)) (VP (VBP impair) (NP (NN progression) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ mesenteric) (NN vein) (NN injection) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 226:E02.319.267.530 564:C18.654.726.500 595:G07.203.650.240 596:E02.642.249 751:D02.033.375 976:A07.231.908.670.385|ES| 19:1 48:1 52:1 72:1 303:1 304:1 785:1 2010:1 3439:1 3440:1 3441:1 3442:1 3443:1
-1 	|BT| (S (VP (NP (NNP Digital)) (VBG karyotyping) (VP (VBZ identifies) (NP (NN thymidylate) (NN synthase) (NN amplification) (NN mechanism) (NN resistance) (NN 5-fluorouracil) (JJ metastatic) (JJ colorectal) (NN cancer) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430|ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1
-1 	|BT| (NP (NP (NN Disruption) (NN Ptk6) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 78:1 113:1 295:1 2533:1 3444:1 3445:1
-1 	|BT| (S (NP (NN DNA) (NN methylation) (NN alteration)) (VP (VBD detected) (SBAR (S (NP (NN zebrafish) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ environmental) (NN carcinogen) (CD 7)) (, ,) (NP (JJ 12-dimethylbenz) (-LRB- -LRB-) (-RRB- -RRB-) (NN anthracene)))))))) |ET| |BS|366:G02.111.087.029.538.161 515:C04.588.274.623 572:B01.050.150.900.493.200.244.828 977:D27.888.569.100.125|ES| 2:1 7:1 10:1 14:1 19:1 81:1 412:1 666:1 836:1 951:1 988:1 1007:1 2017:1 2125:1 3446:1 3447:1 3448:1
-1 	|BT| (S (NP (NNP Dovitinib)) (ADVP (RB also)) (VP (VP (VBD caused) (NP (NP (NP (NN dephosphorylation) (NN retinoblastoma)) (, ,) (NP (NN upregulation) (NN p-histone) (NN H2A-X) (NN p27)) (, ,)) (NN downregulation) (NN p-cdk-2) (NN cyclin) (NN B1))) (, ,) (VP (VBD resulted) (NP (NN reduction) (JJ cellular) (NN proliferation) (NN induction) (NN tumor) (NN cell) (NN apoptosis))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 85:G02.111.087.225 183:G04.299.233.750 249:G05.355.315.800 339:G02.111.087.880 510:C23.550.444 978:D08.811.913.696.620.682.700.646.500 979:D12.644.360.262.120.100 980:C04.557.465.625.600.725|ES| 2:1 5:1 7:1 19:1 89:1 94:1 299:1 370:1 594:1 595:1 736:1 743:1 1124:1 1126:1 2506:1 3074:1 3449:1 3450:1 3451:1 3452:1 3453:1 3454:1 3455:1
-1 	|BT| (S (NP (NNP Dovitinib)) (VP (VBZ demonstrates) (NP (JJ antitumor) (JJ antimetastatic) (NN activity) (NN xenograft) (NN model) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255|ES| 19:1 72:1 265:1 303:1 304:1 399:1 2244:1 2245:1 2541:1 3449:1
-1 	|BT| (S (NP (NP (NN Downregulation) (JJ tumor-suppressor) (NN miR-16)) (PP (IN via) (NP (JJ progestin-mediated) (JJ oncogenic) (NN signaling)))) (VP (VBZ contributes) (NP (NN breast) (NN cancer) (NN development)))) |ET| |BS|69:G02.111.087.800 85:G02.111.087.225 206:G05.360.340.024.340.375.249 279:D27.888.569.100 981:D27.505.696.399.472.858|ES| 18:1 19:1 23:1 35:1 195:1 296:1 596:1 845:1 953:1 1156:1 3456:1 3457:1
-1 	|BT| (NP (NP (NN Down-regulation) (NN tumor) (NN suppressor) (NN A) (NN kinase) (NN anchor) (NN protein) (CD 12) (JJ human) (NN hepatocarcinogenesis) (JJ epigenetic) (NN mechanism))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 206:G05.360.340.024.340.375.249 671:G05.355.315.203 823:D08.811.913.696.620.682.700.150.125|ES| 4:1 7:1 19:1 36:1 69:1 162:1 470:1 700:1 900:1 1120:1 1603:1 3458:1 3459:1
-1 	|BT| (S (VP (VBN Dysregulated) (SBAR (S (NP (JJ Kruppel-like) (NN factor) (CD 4) (NN vitamin) (NN D) (NN receptor) (NN signaling)) (VP (VBP contribute) (NP (NN progression) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|16:C23.550.291.656 69:G02.111.087.800 104:C04.557.470.200.025.255 982:D12.776.826.535|ES| 19:1 48:1 185:1 186:1 195:1 303:1 304:1 318:1 319:1 450:1 2591:1 2592:1 3460:1
-1 	|BT| (S (NP (NNS Effects)) (VP (VBP magnolol) (NP (NP (JJ UVB-induced) (NN skin) (NN cancer) (NN development) (NN mouse)) (JJ possible) (NN mechanism) (NN action)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 742:G03.787|ES| 18:1 19:1 35:1 52:1 162:1 1359:1 2013:1 2319:1 2526:1 2752:1 3461:1
-1 	|BT| (NP (NP (NNS Effects) (JJ S-adenosylmethionine) (NN methylthioadenosine) (JJ inflammation-induced) (NN colon) (NN cancer) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 232:D02.886.030.676.180 525:C23.550.470|ES| 18:1 19:1 52:1 113:1 1793:1 3461:1 3462:1 3463:1
-1 	|BT| (S (NP (JJ Elevated) (NN expression) (JJ coactivator-associated) (NN arginine) (NN methyltransferase) (CD 1)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)))) |ET| |BS||ES| 19:1 98:1 115:1 169:1 900:1 1128:1 1350:1 2655:1 3464:1 3465:1
-1 	|BT| (NP (NP (NP (VBN Enhanced) (NN liver) (NN tumor) (NN promotion) (NN liver) (NN initiation) (NN activity)) (NP (NN rat) (VBN subjected) (JJ combined) (NN administration) (NN omeprazole) (NN beta-naphthoflavone)))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 983:D03.383.663.283.266.450.175.100 984:D02.886.640.074.500|ES| 7:1 19:1 164:1 399:1 637:1 836:1 849:1 2337:1 2575:1 3267:1 3466:1 3467:1 3468:1
-1 	|BT| (NP (NP (JJ Epigenetic) (NN identification) (NN ubiquitin) (JJ carboxyl-terminal) (NN hydrolase) (NN L1) (JJ functional) (NN tumor) (NN suppressor) (NN biomarker) (JJ hepatocellular) (NN carcinoma) (JJ digestive) (NN tumor))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 206:G05.360.340.024.340.375.249 244:C04.588.274.476 374:F01.393.446 985:D08.811.277.352.897.850 986:C04.588.274|ES| 7:1 19:1 303:1 304:1 415:1 700:1 885:1 1201:1 3469:1 3470:1 3471:1 3472:1 3473:1 3474:1
-1 	|BT| (FRAG (NP (NP (NN ErbB2) (NN ErbB3) (NN receptor) (NN tyrosine) (NN kinase)) (NP (VBN associated) (NN development) (JJ human) (NN colon) (NN cancer)) (, ,) (NP (NN expression) (NN receptor) (JJ high) (NN HT-29) (NN cell)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 792:A11.251.210.190.475 987:D08.811.913.696.620.682.725.400|ES| 2:1 18:1 19:1 35:1 36:1 94:1 113:1 115:1 169:1 178:1 186:1 470:1 1705:1 2341:1 2782:1 3475:1
-1 	|BT| (NP (NP (JJ Essential) (NN contribution) (NN chemokine)) (, ,) (NP (NN CCL3)) (, ,) (NP (NN receptor)) (, ,) (NP (NN CCR1)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN progression))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 313:D12.644.276.374.200|ES| 2:1 19:1 48:1 186:1 303:1 304:1 1360:1 3476:1 3477:1 3478:1 3479:1
-1 	|BT| (NP (NP (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD investigated) (NP (NP (NP (NN effect) (JJ novel) (NN farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ human) (NN liver) (NN cancer) (NN cell) (NN line))) (, ,) (NP (NN HepG2) (NN Huh7)) (, ,) (NP (NN animal) (NN model) (NN hepatocarcinogenesis)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 204:E05.581.500 205:E05.581.500 259:D12.776.395.240.150.500 285:E05.598 988:D08.811.913.225.431 989:D08.811.913.225.437 990:C22.232|ES| 2:1 18:1 19:1 36:1 46:1 72:1 75:1 94:1 104:1 131:1 244:1 264:1 380:1 403:1 689:1 690:1 836:1 891:1 900:1 1307:1 2538:1 3480:1 3481:1 3482:1
-1 	|BT| (NP (NP (NP (NN Expression) (NP (JJ ets-related) (JJ transcriptional) (NN factor)) (NN E1AF) (VBN associated) (NN tumor) (NN progression) (NN over-expression) (NN matrilysin)) (NP (JJ human) (JJ gastric) (NN cancer)))) |ET| |BS|8:C04 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 166:D12.776.930 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 18:1 19:1 36:1 48:1 86:1 169:1 185:1 316:1 559:1 1013:1 3289:1 3483:1 3484:1
-1 	|BT| (S (NP (NN Expression) (NN glutathione) (NN peroxidase) (CD 2)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)) (ADVP (RB also)) (NP (JJ late) (NN stage) (NN metastasis)))) |ET| |BS|113:C04.697.650 991:D08.811.682.732.500|ES| 5:1 19:1 148:1 169:1 316:1 806:1 900:1 1128:1 1129:1 2649:1 2744:1 3485:1
-1 	|BT| (S (NP (NN Expression) (NN protein) (NN kinase) (NN C)) (VP (NNS isoenzymes) (NP (JJ colorectal) (NN cancer) (NN tissue) (JJ differential) (NN activation) (JJ different) (NN bile) (NN acid)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 98:A10 992:D08.811.913.696.620.682.700.725 993:D08.811.348 994:D04.808.105|ES| 4:1 17:1 18:1 19:1 225:1 272:1 316:1 414:1 470:1 1275:1 1621:1 1677:1 1955:1 3486:1
-1 	|BT| (NP (NP (NP (NNP Farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ potent) (NN liver) (NN cancer) (JJ chemopreventive) (NN agent)))) |ET| |BS|988:D08.811.913.225.431 989:D08.811.913.225.437|ES| 2:1 18:1 19:1 22:1 380:1 728:1 836:1 1946:1 2538:1 3487:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1
1 	|BT| (NP (NP (NN AIM) (: :)) (S (S (VP (TO To) (VP (VB elucidate) (S (NP (JJ anticancer) (NN mechanism) (NNP Huqi) (NNP San)) (VP (VBG assessing) (NP (NN expression) (NN G-6-Pase))))))) (, ,) (NP (NP (NN SDH)) (, ,) (NP (NN ATPase) (NN AFP) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (NN rat))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 893:D08.811.277.040.025 894:D08.811.277.040.025|ES| 2:1 19:1 104:1 115:1 162:1 828:1 849:1 900:1 959:1 1196:1 1697:1 1880:1 2762:1 2765:1 2766:1 3630:1 3632:1 3634:1 3957:1
1 	|BT| (S (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ therapeutic) (NN effect) (JJ potential) (NN mechanism) (JJ natural) (NN flavonoid) (NN quercetin-3-O-beta-D-glucuronide)) (PRN (-LRB- -LRB-) (NP (NN Q3GA)) (-RRB- -RRB-))) (VP (NN lipid) (NP (NP (NN metabolism) (NN disorder) (JJ free) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FFA)) (-RRB- -RRB-)))))))) (: -) (VP (VBN induced) (NP (NN fatty) (NN liver)) (ADVP (FW vivo) (FW vitro)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 1132:C18.452.584 1133:D10.251.310|ES| 10:1 14:1 19:1 75:1 104:1 162:1 216:1 378:1 409:1 459:1 541:1 827:1 828:1 836:1 959:1 1275:1 1886:1 2007:1 2070:1 2333:1 2401:1 3163:1 3958:1 3959:1 3960:1 3961:1
1 	|BT| (NP (NP (NN Alcohol) (JJ well-established) (NN risk) (NN factor) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN mechanism) (NN alcohol) (NN liver) (NN cancer) (NN complex))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 751:D02.033.375 822:D02.033|ES| 2:1 18:1 19:1 162:1 171:1 185:1 303:1 304:1 695:1 836:1 1770:1 3710:1 3962:1
1 	|BT| (NP (NP (NP (JJ Altered) (NN gene) (NN expression) (NN DNA) (NN repair)) (: -) (NP (NP (NN cell) (JJ proliferation-associated) (NNS proteins/enzymes)) (VP (VBN examined) (NP (NN process) (JJ tamoxifen-induced) (NN hepatocarcinogenesis) (JJ female) (JJ Sprague-Dawley) (NN rat)))))) |ET| |BS|155:G05.355.310 640:D02.455.426.559.389.150.700.900 642:M01.975 730:D08.811 769:B01.050.150.900.649.865.635.505.700.750 1134:G02.111.087.219 1135:D12.776.543|ES| 9:1 19:1 94:1 115:1 324:1 638:1 666:1 849:1 900:1 971:1 1404:1 2707:1 3963:1 3964:1 3965:1 3966:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (JJ Chronic) (NN alcohol) (NN drinking)) (VP (VBZ accelerates) (NP (NP (NN liver) (NN fibrosis) (NN patient)) (JJ viral) (NN hepatitis)) (VP (ADVP (RB fully)) (VBD explained) (NP (JJ ethanol-enhanced) (NN liver) (NN damage)))))) |ET| |BS|50:M01.643 242:A03.620 676:C06.552.630 751:D02.033.375 904:F01.145.317.269 1136:B04.450|ES| 19:1 104:1 120:1 529:1 836:1 889:1 949:1 1046:1 1777:1 1778:1 1848:1 2048:1 3710:1 3967:1 3968:1 3969:1 3970:1 3971:1
1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NN Alcohol) (NN consumption)) (VP (VBZ promotes) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 904:F01.145.317.269|ES| 10:1 14:1 19:1 104:1 298:1 303:1 304:1 441:1 1046:1 2387:1 3962:1
1 	|BT| (S (NP (NP (NP (NN BACKGROUND) (: :)) (NP (NP (JJ Chemopreventive) (NN effect) (JJ selective) (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN inhibitor) (NN JTE-522) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis)) (VP (VBD evaluated) (NP (NNP Wistar) (NN rat)))) |ET| |BS|225:E05.337 349:D27.505.519.389.310.500 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900|ES| 10:1 14:1 19:1 61:1 75:1 76:1 104:1 380:1 409:1 780:1 849:1 900:1 1046:1 1749:1 1875:1 1952:1 2603:1 3972:1 3973:1
1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (JJ Chronic) (NP (NP (NN ethanol) (NN consumption) (NN increase) (NN risk) (JJ hepatic) (NN cirrhosis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 904:F01.145.317.269|ES| 10:1 14:1 19:1 40:1 104:1 171:1 303:1 304:1 441:1 838:1 1046:1 1199:1 2387:1 3440:1 3967:1
1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (S (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (ADVP (RB rapidly)) (VP (VBG increasing) (NP (NP (NN cancer)) (WHNP (WHNP (WP$ whose) (JJ known) (NN risk) (NN factor)) (NP (JJ chronic) (NN ethanol) (NN abuse))) (, ,) (NP (JJ viral) (NN hepatitis) (NN infection)) (, ,) (NP (NN aflatoxin) (NN exposure)))))) |ET| |BS|104:C04.557.470.200.025.255 409:E05.318.740.600.800.725 1137:D03.383.663.283.119 1138:C02.440.420 1139:C25.775.100.250 1140:C06.552.380 1141:C02|ES| 2:1 10:1 14:1 18:1 19:1 104:1 171:1 185:1 304:1 441:1 556:1 715:1 919:1 1046:1 1790:1 1953:1 2048:1 2151:1 2214:1 2362:1 3424:1 3440:1 3969:1 3974:1
1 	|BT| (NP (NP (NP (NN BACKGROUND)) (: :) (NP (NP (JJ Prolonged) (JJ high) (NN intake) (JJ dietary) (NN selenium)) (VP (VBN shown) (VP (VBP induce) (NP (JJ gestational) (NN diabetes) (NN rat) (NN hyperinsulinemia) (NN pig))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 935:D01.268.185.850 1053:C18.452.394.968 1142:B01.050.150.900.649.077.880.399 1143:B01.050.150.900.649.077.880 1144:C13.703.170|ES| 19:1 104:1 178:1 237:1 243:1 849:1 1046:1 2009:1 2563:1 2594:1 3284:1 3670:1 3975:1 3976:1 3977:1
1 	|BT| (S (NP (NP (NP (JJ Carcinogenic) (NN risk) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN liver) (JJ tumor-promoting) (NN activity)) (NN copper) (NN gluconate)))) (, ,) (NP (JJ additive) (JJ functional) (NN food)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (NP (NN rat) (JJ medium-term) (NN liver) (NN carcinogenicity) (NN bioassay) (NN protocol)) (PRN (-LRB- -LRB-) (NP (NN Ito) (NN test)) (-RRB- -RRB-))) (ADJP (ADJP (JJ 2-week)) (ADJP (JJ short-term))) (NN administration) (NN experiment)))))) |ET| |BS|12:Z01.542.049 61:E05.318.740.600.800 106:E05.091 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 515:C04.588.274.623 849:G08.686.785.760.769.490.500 914:L01.178 1145:D02.241.081.844.322 1146:D27.720.368 1147:C17.800.621|ES| 2:1 10:1 14:1 19:1 161:1 162:1 171:1 350:1 399:1 403:1 415:1 435:1 836:1 849:1 1418:1 2470:1 2575:1 2632:1 2931:1 3022:1 3215:1 3216:1 3266:1 3583:1 3776:1 3801:1 3978:1 3979:1 3980:1 3981:1
1 	|BT| (NP (NP (JJ Chronic) (JJ excessive) (NN alcohol) (NN consumption) (NN lead) (NN development)) (NP (NP (JJ alcoholic) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN ALD)) (-RRB- -RRB-))) (S (VP (ADVP (RB greatly)) (VB increase) (NP (NN risk) (NN liver) (NN cancer))))) |ET| |BS|61:E05.318.740.600.800 86:D01.268.556.435 650:C06.552 904:F01.145.317.269 1148:M01.066|ES| 10:1 14:1 18:1 19:1 35:1 40:1 171:1 254:1 836:1 998:1 2387:1 2880:1 3710:1 3967:1 3982:1 3983:1 3984:1
1 	|BT| (S (NP (JJ Chronic) (NN exposure) (NN toxaphene)) (VP (VBD resulted) (NP (NN increase) (NN liver) (NN tumor) (NN B6C3F1) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 7:1 19:1 40:1 52:1 594:1 836:1 1953:1 3967:1 3985:1 3986:1
1 	|BT| (SINV (NP (NP (JJ Hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (CD one) (JJ common) (NN cancer)) (ADVP (RB worldwide)) (, ,) (VP (VBD caused)) (NP (NP (NP (NNP Hepatitis) (NNP C) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HCV)) (-RRB- -RRB-))) (NN hepatotoxin))) |ET| |BS|104:C04.557.470.200.025.255 550:B04.450.410|ES| 2:1 10:1 14:1 18:1 19:1 304:1 441:1 655:1 1010:1 1422:1 1938:1 1954:1 1955:1 2151:1 2506:1 3987:1 3988:1
1 	|BT| (NP (NP (NP (NN Mouse) (JJ nongenotoxic) (NNS hepatocarcinogens)) (SBAR (S (NP (JJ phenobarbital) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-)) (NN chlordane)) (VP (VBP induce) (ADVP (RB hepatomegaly)) (VP (VBN characterized) (NP (NN hypertrophy) (NN hyperplasia)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 510:C23.550.444 756:D03.383.742.698.253.650 1150:D02.455.526.439.180 1151:C06.552.416 1152:C23.300.775|ES| 10:1 14:1 19:1 243:1 985:1 1795:1 2127:1 2685:1 3340:1 3496:1 3989:1 3990:1 3991:1 3992:1
1 	|BT| (NP (NP (NP (NNS OBJECTIVES)) (: :) (NP (NP (NP (NP (DT The) (JJ chemopreventive) (JJ potential) (NN Tephrosia) (NN purpurea) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN TPE)) (-RRB- -RRB-))) (NN N-nitrosodiethylamine) (-LRB- -LRB-) (NN NDEA) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ Wistar) (NN rat)) (VP (VBN assessed))))))))) |ET| |BS|104:C04.557.470.200.025.255 415:F01.658.500 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890|ES| 10:1 14:1 19:1 104:1 303:1 304:1 409:1 441:1 691:1 827:1 849:1 1946:1 2496:1 2602:1 2603:1 3823:1 3993:1 3994:1 3995:1 3996:1 3997:1
1 	|BT| (S (NP (PRP$ Our) (JJ prior) (NN work)) (VP (VBD showed) (NP (NP (NP (JJ brief) (NN exposure) (JJ pregnant) (NN C3H) (NN mouse) (JJ inorganic) (JJ arsenic-induced) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN formation) (JJ adult) (JJ male) (NN offspring))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 445:I03.946 1154:B01.050.050.199.520.520.388 1155:G08.686.340 1156:F01.829.263.065 1157:E05.916.039 1158:D01.268.513.249|ES| 10:1 14:1 19:1 43:1 52:1 132:1 303:1 304:1 355:1 441:1 658:1 1402:1 1546:1 1953:1 3174:1 3998:1 3999:1 4000:1 4001:1 4002:1 4003:1
1 	|BT| (NP (NP (NP (NNP Phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (NN orphenadrine) (-LRB- -LRB-) (NN ORPH) (-RRB- -RRB-) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (NP (NN 2B) (NN inducer) (NN liver) (JJ tumor-promoting) (NN effect) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1159:D02.092.471.600 1160:D27.505.389.249|ES| 10:1 14:1 19:1 75:1 836:1 849:1 2549:1 3496:1 3776:1 3788:1 3789:1 3791:1 4004:1 4005:1 4006:1 4007:1
1 	|BT| (S (NP (NN Rat) (NN liver) (NN tumor)) (VP (VBD initiated) (NP (NP (NP (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD followed) (S (NP (NP (NN promotion) (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NP (NP (NP (VBN examined) (NN expression) (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF) (NN beta)) (-RRB- -RRB-))) (NP (NN type) (CD I) (, ,) (NP (QP (CD II) (CD III))) (NP (NN receptor))))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 554:D02.654.442.200 756:D03.383.742.698.253.650 1161:D12.644.276.374.687.100|ES| 2:1 7:1 10:1 14:1 19:1 102:1 115:1 186:1 324:1 543:1 836:1 1116:1 1772:1 1773:1 1875:1 1900:1 1972:1 2281:1 2337:1 2350:1 2602:1 2685:1 3130:1 3496:1 4008:1 4009:1
1 	|BT| (S (NP (NP (DT The) (JJ key) (NN event) (JJ responsible) (NN mouse) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (NN pesticide)) (PRN (-LRB- -LRB-) (NP (NP (NN viz.)) (, ,) (NP (NN pronamide))) (-RRB- -RRB-))))) (VP (VBD investigated) (NP (S (NP (NN series) (NN study)) (VP (VBG employing) (ADJP (ADJP (JJ molecular)) (, ,) (ADJP (JJ biochemical)) (, ,) (ADJP (JJ cellular))))) (, ,) (NP (JJ apical) (NN endpoint))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 515:C04.588.274.623 913:D27.720.031.700|ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 159:1 161:1 205:1 403:1 412:1 691:1 836:1 1689:1 1807:1 2132:1 3074:1 3214:1 3323:1 4010:1 4011:1 4012:1 4013:1
1 	|BT| (S (NP (DT The) (JJ objective) (NN study)) (VP (VBD determine) (SBAR (S (NP (NP (NP (NP (JJ chemopreventive) (NN activity) (JJ Korean) (JJ red) (NN ginseng) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN KRG)) (-RRB- -RRB-))) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD induced) (NP (NN hepatocarcinogenesis) (NN rat))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 415:F01.658.500 554:D02.654.442.200 1162:B01.650.940.800.575.100.087.500|ES| 10:1 14:1 19:1 74:1 131:1 399:1 412:1 691:1 849:1 900:1 1634:1 1875:1 1946:1 1952:1 2496:1 2916:1 4014:1 4015:1 4016:1
1 	|BT| (S (NP (DT The) (JJ present) (NN study)) (VP (VBN designed) (VP (VB determine) (SBAR (IN whether) (S (NP (NN alteration) (NN expression) (NN RXRalpha) (NN retinoid) (NN receptor) (NN RARalpha) (NN RARbeta)) (VP (VBN involved) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG using) (NP (NP (NP (CD 3) ('' ') (: -) (NN methyl-4-dimethylaminoazobenzene) (-LRB- -LRB-) (CD 3) ('' ') (: -)) (NP (NN MeDAB) (-RRB- -RRB-) (: -))) (VP (VBN induced) (NP (NN rat) (NN liver) (NN carcinogenesis) (NN model)))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1163:D02.092.146.325.500 1164:D12.776.826.701|ES| 10:1 14:1 19:1 72:1 74:1 115:1 131:1 186:1 207:1 221:1 350:1 409:1 691:1 774:1 836:1 849:1 900:1 951:1 1307:1 1683:1 2573:1 4017:1 4018:1 4019:1 4020:1 4021:1
1 	|BT| (S (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN undertaken))) (VBP investigate) (NP (NP (NN effect) (JJ dietary) (NN supplementation) (NN nimesulide) (NN eugenol) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN initiated) (NP (JJ early) (NN hepatocarcinogenesis) (NN F344) (JJ male) (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 554:D02.654.442.200 590:B01.050.050.199.520.760.200 595:G07.203.650.240 1165:D02.241.223.200.054.500|ES| 10:1 14:1 19:1 75:1 131:1 459:1 691:1 849:1 900:1 1128:1 1307:1 1402:1 1875:1 2567:1 2594:1 2602:1 3185:1 3186:1 4022:1 4023:1 4024:1
1 	|BT| (S (NP (NP (DT The) (JJ preventive) (NN effect)) (VP (VP (VBN processed) (NP (NP (NP (NP (NNP Aloe) (NN vera) (NN gel)) (PRN (-LRB- -LRB-) (NP (NN PAG)) (-RRB- -RRB-))) (NN colon) (NN carcinogenesis)) (VP (VBN examined) (S (VP (VBG using) (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-)))))))) (: -) (VP (VBN initiated) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))))) (: -) (VP (VBD promoted) (NP (NN mouse) (NN colon) (NN carcinogenesis) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080|ES| 10:1 14:1 19:1 52:1 72:1 75:1 113:1 207:1 324:1 350:1 406:1 407:1 674:1 691:1 1883:1 1993:1 1994:1 3300:1 3306:1 4024:1 4025:1 4026:1 4027:1 4028:1 4029:1
1 	|BT| (S (NP (NP (NP (DT The) (NN process) (NN hepatocarcinogenesis) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (JJ initiation/phenobarbital) (-LRB- -LRB-) (NN PB) (-RRB- -RRB-) (NN promotion) (NN mouse) (NN model)) (VP (VBZ involves) (NP (NP (JJ selective) (JJ clonal) (NN outgrowth) (NN cell) (NN harboring) (NN oncogene) (NN mutation) (NN Ctnnb1)) (, ,) (S (NP (JJ spontaneous) (JJ DEN-only-induced) (NN tumor)) (ADVP (RB often)) (NP (NP (NN Ha-ras)) (: -) (NP (JJ B-raf-mutated))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 9:G05.360.340.024.340.375.500 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 41:A11 216:Z01.107.084.900.425 278:D08.811.913.696.620.682.700.559.842.374 301:A11.251.353 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 2:1 7:1 10:1 14:1 19:1 24:1 34:1 52:1 72:1 94:1 283:1 632:1 638:1 691:1 900:1 1069:1 1304:1 1673:1 1749:1 1875:1 1952:1 2337:1 3496:1 4030:1 4031:1 4032:1 4033:1 4034:1 4035:1
1 	|BT| (S (NP (NP (NP (DT The) (JJ tumour-promoting) (NN effect) (NN beta-naphthoflavone)) (PRN (-LRB- -LRB-) (NP (NN BNF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ novel) (NN aryl) (NN hydrocarbon) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN AhR)) (-RRB- -RRB-))) (NN agonist)) (, ,)) (VP (VBN investigated) (S (VP (VBG using) (NP (JJ medium-term) (NN hepatocarcinogenesis) (NN model) (NN rat)))))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 259:D12.776.395.240.150.500 849:G08.686.785.760.769.490.500 914:L01.178 969:D12.776.260.643.715 983:D03.383.663.283.266.450.175.100|ES| 2:1 10:1 14:1 19:1 72:1 75:1 186:1 350:1 403:1 691:1 849:1 891:1 900:1 3215:1 3228:1 3417:1 3418:1 3468:1 4036:1 4037:1 4038:1
1 	|BT| (S (NP (EX There)) (NP (JJ abundant) (JJ epidemiological) (NN evidence) (JJ heavy) (NN alcohol) (NN intake)) (VP (VBZ contributes) (NP (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development)))) |ET| |BS|104:C04.557.470.200.025.255 651:H02.403.720.500 904:F01.145.317.269|ES| 10:1 14:1 19:1 35:1 38:1 303:1 304:1 441:1 767:1 845:1 1798:1 2563:1 3217:1 3710:1 4039:1
1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ validates) (NP (NP (NP (NN utility) (NN Gum) (JJ Arabic-conjugated) (NN gold) (NNS nanoparticles)) (PRN (-LRB- -LRB-) (NP (NNS GA-AuNPs)) (-RRB- -RRB-))) (SBAR (S (NP (NN laser)) (VP (VBP induce) (NP (JJ photothermal) (NN inhibition) (NN hepatocarcinogenesis)))))) (, ,) (PP (IN via) (S (VP (VBG employing) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (FRAG (: -) (NP (VBN mediated) (JJ hepatocellular) (NN carcinoma) (NN model))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 104:C04.557.470.200.025.255 554:D02.654.442.200 1166:Z01.058.290.190.300 1167:D05.750.078.739.500 1168:J01.637.512.600 1169:D01.268.556.322 1170:E07.632.490|ES| 2:1 10:1 14:1 19:1 72:1 103:1 131:1 243:1 303:1 304:1 596:1 807:1 900:1 1875:1 1952:1 2194:1 4011:1 4040:1 4041:1 4042:1 4043:1 4044:1 4045:1 4046:1 4047:1 4048:1
1 	|BT| (NP (NP (S (VP (TO To) (VP (VB clarify) (S (VP (VBG modifying) (NP (NP (NN effect) (NN N-Acetyl-L-Cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (JJ antioxidative) (NN ability)) (, ,) (NP (NN hepatocarcinogenesis)) (VP (VBD promoted) (SBAR (S (NP (NP (NP (NP (NN fenofibrate)) (PRN (-LRB- -LRB-) (NP (NN FF)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PPAR)) (-RRB- -RRB-))) (NN alpha)) (NP (NN agonist))) (, ,) (NP (NP (JJ male) (NN F344/N) (NN rat)) (VP (VBN administered) (NP (NP (NP (ADJP (JJ single) (JJ intraperitoneal)) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN initiator))))) (VP (VBD followed) (NP (NN administration) (NN diet) (VBG containing) (CD 3,000) (NN ppm) (NN FF) (CD 16) (NN week))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 385:F02.784.629.131 536:D12.776.826.239.500 554:D02.654.442.200 590:B01.050.050.199.520.760.200 596:E02.642.249 791:D02.886.030.230.259 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 916:D02.241.081.114.968.500.625 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 75:1 186:1 286:1 783:1 785:1 828:1 849:1 900:1 1300:1 1402:1 1801:1 1836:1 1875:1 1887:1 1912:1 2191:1 2336:1 2575:1 2644:1 2846:1 3130:1 3193:1 3221:1 3222:1 3223:1 3224:1 3225:1 3226:1 3227:1 3228:1 3229:1 3230:1 3231:1 3232:1 3233:1 3234:1
1 	|BT| (S (VP (TO To) (VP (VB clarify) (NP (NP (JJ possible) (NN mechanism) (JJ non-genotoxic) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (NP (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ male) (NN F344) (NN rat)) (VP (VBN administered) (S (NP (NN i.p))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 590:B01.050.050.199.520.760.200 967:D01.248.497.158.490 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 162:1 412:1 828:1 849:1 900:1 1359:1 1402:1 2336:1 3185:1 3193:1 3777:1 3778:1 4049:1 4050:1 4051:1
1 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (JJ protective) (NN effect) (NN bilberry) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN BBE)) (-RRB- -RRB-))) (NP (NP (NP (ADJP (RB enzymatically) (VBN modified)) (NN isoquercitrin)) (PRN (-LRB- -LRB-) (NP (NN EMIQ)) (-RRB- -RRB-))) (NP (NP (JJ hepatocarcinogenic) (NN process)) (VP (VBG involving) (NP (NP (JJ oxidative) (NN stress) (NN response)) (, ,) (VP (VBN used) (S (NP (NP (JJ two-stage) (NN hepatocarcinogenesis) (NN model) (JJ N-diethylnitrosamine-initiated) (NN piperonyl) (NN butoxide)) (PRN (-LRB- -LRB-) (NP (NN PBO)) (-RRB- -RRB-))))))))))))) (: -) (VP (VBD promoted) (NP (NN rat)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 1077:D03.383.246.118.600|ES| 2:1 10:1 14:1 19:1 72:1 75:1 459:1 476:1 493:1 494:1 638:1 828:1 849:1 900:1 2335:1 2372:1 2496:1 2522:1 2583:1 2971:1 3773:1 3774:1 3777:1 3778:1 4029:1 4050:1 4052:1 4053:1 4054:1 4055:1 4056:1
1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (S (NP (NN effect) (NN liver) (NN damage)) (VP (VBD induced) (NP (NN flutamide) (JJ primary) (NN rat) (NNS hepatocytes)) (S (VP (VBG using) (NP (NP (NN liver)) (NP (JJ microfluidic) (NN biochip)))))))))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 1171:E05.830.666 1172:D02.065.199.420|ES| 19:1 75:1 344:1 350:1 403:1 412:1 836:1 843:1 849:1 894:1 1848:1 4057:1 4058:1 4059:1
1 	|BT| (NP (NP (JJ 2-Amino-1-methyl-6-phenylimidazo) (PRN (-LRB- -LSB-) (ADJP (JJ 4,5-b)) (-RRB- -RSB-)) (NN pyridine) (NN increase) (NN number) (NN tumor)) (, ,) (NP (JJ cystic) (NN crypt) (JJ aberrant) (NN crypt) (NN focus) (JJ multiple) (JJ intestinal) (NN neoplasia) (NN mouse))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 555:C04.182 744:D03.383.725 824:C04.834.020|ES| 2:1 7:1 19:1 40:1 52:1 109:1 640:1 646:1 649:1 1373:1 1378:1 1431:1 1725:1 2639:1 2640:1 2913:1 4060:1 4061:1
1 	|BT| (S (NP (NP (JJ 2-Nitrobenzo) (-LRB- -LSB-) (-RRB- -RSB-) (NN pyrene) (NN 6-nitrochrysene)) (VP (VBD induced) (NP (NP (JJ high) (NN incidence) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (CD 91-100) (NN %)) (-RRB- -RRB-))) (, ,) (PP (VBG remaining) (NP (NN test) (NN compound))))) (VP (VBP induce) (NP (NN tumor) (NN rate)) (NP (RB significantly) (JJR higher) (JJ solvent) (NN control)))) |ET| |BS|8:C04 434:E05.318.308.985.525.375 515:C04.588.274.623 1173:D02.455.426.559.847.799 1174:D27.720.844|ES| 2:1 7:1 10:1 14:1 19:1 41:1 124:1 170:1 178:1 243:1 289:1 369:1 412:1 836:1 1373:1 1378:1 1418:1 1511:1 2433:1 4062:1 4063:1 4064:1 4065:1 4066:1 4067:1
1 	|BT| (S (NP (DT A) (JJ diethylnitrosamine-induced) (NN liver) (NN cancer) (NN model)) (VP (VBD used) (VP (VB evaluate) (NP (NN role) (NN Myc) (NN hepatocarcinogenesis))))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 554:D02.654.442.200|ES| 18:1 19:1 31:1 69:1 72:1 476:1 836:1 890:1 900:1 1786:1 2732:1
1 	|BT| (S (ADVP (RB Additionally)) (, ,) (VP (VBD reported) (SBAR (S (NP (NN tamoxifen)) (VP (MD may) (VP (VB cause) (NP (NP (NP (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN NAFLD)) (-RRB- -RRB-))) (NP (JJ human) (JJ experimental) (NN animal))))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 577:C06.552.241.519 640:D02.455.426.559.389.150.700.900 1175:B01.050.050.199|ES| 2:1 10:1 14:1 19:1 36:1 46:1 263:1 491:1 836:1 993:1 998:1 1779:1 2069:1 2070:1 2371:1 2609:1 4068:1
1 	|BT| (S (NP (NP (NP (NNP Administration) (NN acetaminophen) (NN Jnk)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN mouse)) (VP (VBD produced) (NP (NP (JJR greater) (NN level) (NN liver) (NN injury)) (VBN observed) (NP (NP (NN Jnk1)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN control) (NN mouse)) (, ,) (NP (VBN based) (NN level) (NN serum) (NN marker) (JJ microscopic) (JJ histologic) (NN analysis) (NN liver) (NN tissue)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 98:A10 242:A03.620 333:D01.045 426:E01.370.350.515 661:D02.065.199.092.040 1176:D23.101|ES| 2:1 10:1 14:1 19:1 52:1 134:1 249:1 261:1 272:1 289:1 534:1 661:1 836:1 1992:1 2204:1 2346:1 2412:1 2414:1 2415:1 2416:1 2741:1 4069:1 4070:1 4071:1
1 	|BT| (FRAG (PP (IN After) (NP (NP (JJ 3-month) (NN recovery) (NN period) (JJ tamoxifen-treated) (NN rat) (JJ large) (NN liver) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN diameter) (CD 3) (NN cm)) (-RRB- -RRB-))))) |ET| |BS|8:C04 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 640:D02.455.426.559.389.150.700.900 776:G01.910.645 1151:C06.552.416|ES| 7:1 10:1 14:1 19:1 836:1 849:1 862:1 1408:1 1409:1 2722:1 2724:1 2725:1 3265:1 4072:1 4073:1
1 	|BT| (S (NP (NN AIRmax)) (ADVP (RB also)) (NP (JJ susceptible) (NN AIRmin) (NN colon) (NN cancer)) (VP (VP (VBD induced) (NP (NP (QP (CD 2) (CD 7)) (JJ weekly) (NNS dos)) (ADJP (ADJP (JJ 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-)))) (, ,) (S (VP (VBG showing) (NP (NP (ADJP (RB significantly) (JJR higher)) (NN number) (JJ colonic) (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NP (CD 150) (NN day) (NN DMH) (NN treatment))))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (ADJP (RB significantly) (JJR higher)) (NN number) (NN tumor) (VBG affecting) (NP (NP (JJR larger) (JJ intestinal) (NN area)) (CD 300-475) (NN day)))) |ET| |BS|8:C04 46:A03.556.124.526.356 52:E02 292:Z01 433:F01.470.047 824:C04.834.020 1177:A03.556.124.526|ES| 2:1 5:1 7:1 10:1 14:1 18:1 19:1 109:1 113:1 124:1 148:1 170:1 311:1 315:1 412:1 546:1 581:1 646:1 677:1 899:1 988:1 1431:1 1725:1 2201:1 2530:1 2642:1 2643:1 2653:1 2913:1 2914:1 4074:1 4075:1 4076:1 4077:1 4078:1 4079:1 4080:1 4081:1
1 	|BT| (NP (NP (NN Amelioration) (JJ free) (NN fatty) (JJ acid-induced) (NN fatty) (NN liver) (NN quercetin-3-O-beta-D-glucuronide) (NN modulation) (NN peroxisome) (JJ proliferator-activated) (JJ receptor-alpha/sterol) (JJ regulatory) (JJ element-binding) (JJ protein-1c) (NN signaling))) |ET| |BS|69:G02.111.087.800 242:A03.620 533:D03.383.663.283.266.450.284.777 536:D12.776.826.239.500 576:D12.776.260.103.500.750.500 1133:D10.251.310|ES| 19:1 195:1 836:1 1801:1 1817:1 1887:1 1945:1 2070:1 2599:1 3958:1 3960:1 4082:1 4083:1 4084:1 4085:1
1 	|BT| (NP (JJ Arsenic) (VP (VBN induced) (NP (NP (NP (JJ dose-related) (NN increase) (NN lung) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN sex)) (-RRB- -RRB-))) (, ,) (NP (NP (NN gallbladder) (NN tumor)) (PRN (-LRB- -LRB-) (NP (NN male)) (-RRB- -RRB-))) (, ,) (NP (JJ uterine) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 265:C04.557.470.200 1158:D01.268.513.249 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810 1182:C04.588.274.120.401 1183:A05.360.319.679|ES| 2:1 7:1 10:1 14:1 19:1 40:1 255:1 303:1 304:1 328:1 412:1 1402:1 4086:1 4087:1 4088:1 4089:1 4090:1
1 	|BT| (S (NP (NN beta-Naphthoflavone)) (VP (VBZ enhances) (NP (NP (JJ oxidative) (NN stress) (NN response)) (NN induction) (JJ preneoplastic) (NN lesion) (JJ diethylnitrosamine-initiated) (NN hepatocarcinogenesis) (NN model)) (ADVP (RB partially)) (VP (VBD hepatectomized) (NP (NN rat))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 716:G03.495.710 983:D03.383.663.283.266.450.175.100|ES| 19:1 72:1 494:1 736:1 849:1 900:1 1131:1 1351:1 1356:1 1438:1 2522:1 2583:1 4091:1 4092:1 4093:1
1 	|BT| (NP (NP (NN Cell) (NN expression) (NN pattern) (NN CD147) (JJ N-diethylnitrosamine/phenobarbital-induced) (NN mouse) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 41:A11 104:C04.557.470.200.025.255 554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 19:1 52:1 115:1 260:1 303:1 304:1 4094:1 4095:1 4096:1
1 	|BT| (S (S (NP (NN Cell) (NN proliferation) (NN hepatocarcinogenesis) (NN rat)) (VP (VBD initiated) (SBAR (S (NP (NN diethylnitrosamine)) (VP (VBD promoted) (NP (NN phenobarbital))))))) (: :) (NP (NP (JJ potential) (NN role) (JJ early) (NN DNA) (NN damage) (NN liver) (NN metallothionein) (NN expression)))) |ET| |BS|15:F01.829.316.616 183:G04.299.233.750 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 526:G05.355.180 554:D02.654.442.200 756:D03.383.742.698.253.650 777:D12.776.556.670|ES| 19:1 31:1 104:1 115:1 299:1 666:1 827:1 836:1 849:1 900:1 1128:1 1848:1 1900:1 1912:1 1952:1 2685:1 2731:1 4094:1
1 	|BT| (NP (NP (NNP Chemoprevention) (NNP Diethylnitrosamine-Initiated) (NNP Phenobarbital-Promoted) (NNP Hepatocarcinogenesis) (NNP Rats) (NNP Sulfated) (NNP Polysaccharides) (NNP Aqueous) (NN Extract) (NNP Ulva) (NN lactuca))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 253:E02.319.162 554:D02.654.442.200 756:D03.383.742.698.253.650 803:D01.248.497.158.845 804:D09.698 1184:B01.650.940.150.900|ES| 19:1 1959:1 2842:1 3664:1 4097:1 4098:1 4099:1 4100:1 4101:1 4102:1 4103:1 4104:1
1 	|BT| (NP (NP (JJ Chemopreventive) (NN evaluation) (NN Tephrosia) (NN purpurea) (JJ N-nitrosodiethylamine-induced) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))) |ET| |BS|225:E05.337 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1153:B01.650.940.800.575.100.401.890|ES| 19:1 849:1 900:1 2503:1 2603:1 2948:1 3972:1 3994:1 3995:1
1 	|BT| (S (NP (JJ Chronic) (NN ethanol) (NN feeding)) (VP (VBZ accelerates) (NP (JJ hepatocellular) (NN carcinoma) (NN progression) (JJ sex-dependent) (NN manner)) (NP (NN mouse) (NN model) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 751:D02.033.375 1178:F01.145.802.188 1179:F01.393.446.250 1180:F01.145.802 1181:G08.686.810|ES| 19:1 48:1 52:1 72:1 303:1 304:1 529:1 900:1 1668:1 2942:1 3440:1 3967:1 4105:1
1 	|BT| (S (S (NP (JJ Chronic) (JJ inorganic) (JJ arsenic) (NN exposure)) (VP (VBZ induces) (NP (JJ hepatic) (JJ global) (JJ individual) (NN gene) (NN hypomethylation)))) (: :) (NP (NN implication) (JJ arsenic) (NN hepatocarcinogenesis))) |ET| |BS|6:G05.360.340.024.340 197:A01.456.505.420 493:M01 1158:D01.268.513.249|ES| 9:1 19:1 85:1 104:1 214:1 660:1 838:1 900:1 1953:1 2512:1 3174:1 3967:1 4106:1 4107:1
1 	|BT| (S (NP (NN Colitis)) (VP (VBD induced) (NP (NP (NN knockout)) (, ,) (NP (NP (NP (JJ transgenic) (, ,) (NN control)) (PRN (-LRB- -LRB-) (NP (NN C57BL/B6)) (-RRB- -RRB-))) (NP (NP (NN mouse) (NN administration) (NN dextran) (NN sulfate) (NN sodium)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (, ,) (NP (NP (NN mouse)) (VP (VBN given) (NP (NN azoxymethane))))) (VP (VBP induce) (NP (JJ colorectal) (NN carcinogenesis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 131:D09.698.365.272.300 132:D02.172.080 352:B01.050.050.136 593:B01.050.050.199.520.520.420|ES| 2:1 10:1 14:1 17:1 19:1 29:1 52:1 71:1 207:1 243:1 285:1 289:1 406:1 407:1 412:1 1993:1 2575:1 3300:1 3306:1 4108:1 4109:1
1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (NP (DT These) (VBP result) (NP (VBN suggested) (NN TFA) (VBD protected) (ADJP (NN mouse) (JJ CCl4-induced) (ADJP (NN liver) (NN injury) (JJ antioxidant)) (NN stress) (JJ antiinflammatory)) (NN effect)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217|ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1
1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN In) (NP (NNS hepatocytes))) (, ,) (NP (NN JNK1) (NN JNK2)) (VP (VP (VBP appear) (NP (NP (JJ combined) (NN effect)) (VP (VBG protecting) (NP (NN mouse) (NN CCl4))))) (: -) (NP (JJ acetaminophen-induced) (NN liver) (NN injury)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 242:A03.620 262:A11.436.348 661:D02.065.199.092.040|ES| 2:1 19:1 52:1 75:1 104:1 164:1 239:1 244:1 836:1 894:1 2251:1 2357:1 2416:1 4110:1 4111:1 4112:1 4113:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (S (NP (VBN truncated) (NN PPARalpha) (NN splice) (JJ variant) (NN function)) (NP (NP (JJ endogenous) (NN inhibitor) (JJ proliferative) (JJ pro-inflammatory) (NN gene)) (SBAR (S (NP (JJ human) (NN cell) (NN absence) (NN mouse)) (VP (MD may) (VP (VB explain) (NP (JJ species-specific) (NN difference) (JJ fibrate-induced) (NN hepatocarcinogenesis))))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 55:B01.050.150.900.649.801.400.112.400.400 536:D12.776.826.239.500 1185:D12.125.072.401.623 1186:G16.824|ES| 9:1 19:1 33:1 36:1 52:1 94:1 104:1 239:1 380:1 491:1 658:1 793:1 796:1 900:1 990:1 1534:1 1674:1 3870:1 4114:1 4115:1 4116:1 4117:1 4118:1 4119:1 4120:1 4121:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NN Silibinin) (NN target) (NN beta-catenin) (NN IGF-1Rbeta) (NN pathway) (JJ chemopreventive) (NN efficacy) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937|ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1
1 	|BT| (S (NP (JJ Concurrent) (NN administration) (JJ ascorbic) (NN acid)) (VP (VBZ enhances) (NP (NP (NN liver) (JJ tumor-promoting) (NN activity)) (JJ kojic) (NN acid) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1187:D02.241.081.844.107|ES| 19:1 399:1 836:1 849:1 1275:1 1356:1 2575:1 3776:1 4122:1 4123:1 4124:1
1 	|BT| (S (NP (JJ Considerable) (NN attention)) (VP (VBD focused) (NP (NP (JJ peroxisome) (JJ proliferator-induced) (JJ hepatocellular) (NN carcinoma)) (, ,) (SBAR (S (NP (NN phenomenon)) (VP (VBD noted) (NP (NN man)))))) (, ,) (SBAR (IN whereas) (S (NP (JJ limited) (NN study)) (VP (VBP examine) (VP (VBZ fibrates) (SBAR (S (NP (JJ therapeutic) (NN drug)) (VP (VBP induce) (NP (NP (NN cholestasis)) (, ,) (NP (JJ common) (NN finding) (JJ human)))))))))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 67:D26 104:C04.557.470.200.025.255 275:C23.888 879:C06.130.120.135 905:F02.830.104.214 912:D27.888.569.100.675 1188:D02.241.081.114.968.500 1189:M01.390|ES| 2:1 19:1 36:1 131:1 191:1 243:1 303:1 304:1 372:1 541:1 655:1 927:1 960:1 1887:1 2131:1 2310:1 3198:1 4125:1 4126:1 4127:1 4128:1 4129:1 4130:1 4131:1
1 	|BT| (S (NP (NNP Cyclooxygenase) (CD 2) (NN Prostaglandin) (NN E2)) (VP (VBN Involved) (NP (JJ N-Nitrosodiethylamine-Initiated) (JJ Early) (NN Rat) (NN Hepatocarcinogenesis)))) |ET| |BS|24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1118:D10.251.355.255.550.250.200|ES| 19:1 148:1 1959:1 3432:1 3909:1 4008:1 4132:1 4133:1 4134:1 4135:1
1 	|BT| (NP (NP (NN DESIGN) (: :)) (NP (NP (NP (JJ Spontaneous) (JJ experimental) (NN fibrogenesis)) (SBAR (S (NP (ADJP (RB well) (JJ diethylnitrosamine-induced)) (NN hepatocarcinogenesis)) (VP (VBD investigated) (NP (NP (JJ lecithin-retinol) (NN acyltransferase)) (PRN (-LRB- -LRB-) (NP (NN LRAT)) (-RRB- -RRB-))))))) (: -) (NP (JJ deficient) (NN mouse) (NN lack) (JJ retinoid-containing) (NN lipid) (NN droplet) (NNS HSCs)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393|ES| 10:1 14:1 19:1 52:1 104:1 263:1 403:1 690:1 787:1 900:1 2401:1 2732:1 3381:1 3383:1 3937:1 4136:1 4137:1 4138:1 4139:1 4140:1 4141:1 4142:1
1 	|BT| (S (NP (NP (NN Dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (VP (VBN given) (S (VP (VBP induce) (NP (NP (NP (NN colitis) (NN C57/BL6)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-))) (NN mouse)))) (, ,) (NP (ADVP (RB well)) (NP (NP (NN mouse) (NN disruption) (NN hydroxyprostaglandin) (NN dehydrogenase) (CD 15) (NN gene)) (PRN (-LRB- -LRB-) (NP (JJ 15-PGDH-knockout) (NN mouse)) (-RRB- -RRB-))) (, ,) (NP (NP (NN Yap1) (NN gene)) (PRN (-LRB- -LRB-) (NP (JJ YAP-knockout) (NN mouse)) (-RRB- -RRB-))) (, ,) (NP (JJ double-knockout) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 53:C06.405.205.265 131:D09.698.365.272.300|ES| 2:1 9:1 10:1 14:1 19:1 29:1 52:1 143:1 243:1 289:1 406:1 407:1 787:1 1602:1 3085:1 3306:1 4143:1 4144:1 4145:1 4146:1 4147:1 4148:1 4149:1 4150:1
1 	|BT| (S (NP (NN Diethylnitrosamine) (NN initiation)) (VP (VBP alter) (NP (ADJP (JJ clofibric) (JJ acid-induced)) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 1190:D02.241.081.114.968.500.500|ES| 19:1 637:1 849:1 900:1 2599:1 4151:1 4152:1 4153:1
1 	|BT| (S (NP (JJ Diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (VP (VBD suppressed) (NP (NP (JJ heterozygous) (JJ NRDC-deficient) (NN mouse)) (VP (VBN compared) (NP (JJ wild-type) (NNS littermates)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 554:D02.654.442.200|ES| 8:1 19:1 50:1 52:1 307:1 786:1 900:1 1355:1 2569:1 4154:1
1 	|BT| (S (NP (NNS Effects)) (VP (VBD baked) (S (NP (NP (NP (NN PP)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 20) (NN %)) (NN wt/wt)) (-RRB- -RRB-))) (NN colon) (NNS CSCs)) (ADVP (RB also)) (VP (VBN tested) (NP (FW vivo) (NN mouse) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 556:C11.768.175 1126:Z01.639.760.590.715|ES| 5:1 10:1 14:1 19:1 52:1 78:1 113:1 369:1 378:1 1870:1 1966:1 2533:1 2988:1 3461:1 3941:1 3942:1 4155:1
1 	|BT| (S (NP (VBN Enhanced) (NP (NN liver)) (NN tumor) (NN promotion) (NN activity) (NN rat)) (VP (VBN subjected) (NP (JJ combined) (NN administration) (JJ phenobarbital) (NN orphenadrine)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1159:D02.092.471.600|ES| 7:1 19:1 164:1 399:1 836:1 849:1 2337:1 2575:1 2685:1 3267:1 3466:1 4005:1
1 	|BT| (S (S (NP (NP (NN Ethanol)) (VBD diminished) (JJ hepatic) (NN function)) (VP (VBD increased) (NP (NN liver) (NN damage)))) (, ,) (S (NP (NP (NN ethanol)) (ADVP (RB alone))) (VP (VBP induce) (NP (JJ hepatic) (NN foci/HCC) (NN formation))))) |ET| |BS|20:G03.495 104:C04.557.470.200.025.255 242:A03.620 751:D02.033.375|ES| 2:1 19:1 33:1 43:1 47:1 241:1 243:1 836:1 838:1 1848:1 3178:1 3440:1 4156:1 4157:1
1 	|BT| (NP (NP (NP (NN Evaluation) (JJ chemopreventive) (NN effect)) (NP (NNP Fumaria) (NN indica) (NN N-nitrosodiethylamine) (JJ CCl4-induced) (JJ hepatocellular) (NN carcinoma) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750|ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1
1 	|BT| (NP (NP (NN Evolution) (JJ genomic) (NN instability) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 1191:C23.550.362 1192:G05.355.044|ES| 19:1 52:1 900:1 910:1 1299:1 2732:1 4158:1
1 	|BT| (NP (NP (NP (NP (NN Expression) (NN analysis) (NN group) (NN IIA) (JJ secretory) (NN phospholipase) (NN A)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (NN mouse) (JJ differential) (NN susceptibility) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 192:D08.811.277.352.100.680.750.937.750 401:C23.550.291.687 829:M01.686|ES| 10:1 14:1 19:1 52:1 69:1 78:1 113:1 148:1 316:1 643:1 644:1 661:1 1353:1 1677:1 2222:1 2300:1 2533:1
1 	|BT| (S (S (NP (NN Expression) (NN retinoid) (NN X) (NN receptor) (NN alpha)) (VP (VBD decreased) (NP (CD 3) ('' ')))) (: -) (FRAG (NP (JJ methyl-4-dimethylaminoazobenzene-induced) (JJ hepatocellular) (NN carcinoma) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 941:D12.776.826.701.500.500 1193:D02.092.146.325|ES| 19:1 186:1 202:1 303:1 304:1 316:1 849:1 929:1 1836:1 2573:1 4159:1
1 	|BT| (S (PP (VBG Following) (NP (NP (JJ initial) (CD 14) (NN day)) (JJ dietary) (NN dose) (NN range-finding) (NN study) (JJ male) (NN mouse))) (, ,) (ADJP (NP (NP (JJ mechanistic) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (CD 0) (, ,) (CD 3) (, ,) (CD 32) (, ,) (CD 320) (NN ppm) (NN toxaphene) (NN diet) (CD 7)) (, ,) (NP (CD 14)) (, ,) (NP (ADJP (CD 28) (NN day)) (NN treatment))) (-RRB- -RRB-))) (VBN performed)) (VP (VBP examine) (SBAR (S (NP (JJ potential) (NN mechanism) (NN toxaphene)) (VP (VBD induced) (NP (NN mouse) (NN liver) (NN tumor))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 275:C23.888 515:C04.588.274.623 595:G07.203.650.240 596:E02.642.249 1149:D02.455.526.439.913|ES| 2:1 7:1 10:1 14:1 19:1 52:1 131:1 162:1 412:1 458:1 546:1 827:1 836:1 862:1 960:1 988:1 1401:1 1402:1 1440:1 1890:1 2191:1 2301:1 2546:1 2594:1 3233:1 3985:1 4078:1 4160:1 4161:1 4162:1 4163:1 4164:1
1 	|BT| (S (PP (IN For) (NP (FW vivo) (NN study))) (, ,) (NP (JJ 1,2-dimethylhydrazine) (NN dihydrochloride) (-LRB- -LRB-) (NN DMH) (-RRB- -RRB-) (NN s.c.)) (VP (VBD injected) (VP (VBP induce) (NP (NP (NP (NN colon) (NN cancer) (NN PPARgamma)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NN PPARgamma) (PRN (-LRB- -LRB-) (CC +) (: /) (: -)))) (-RRB- -RRB-) (NP (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 719:D12.776.826.239.588|ES| 2:1 10:1 14:1 18:1 19:1 44:1 51:1 52:1 113:1 131:1 243:1 378:1 2588:1 2642:1 2643:1 3489:1 3586:1 4165:1 4166:1
1 	|BT| (S (NP (JJ Garlic) (NN oil)) (VP (VBD attenuated) (NP (NP (JJ nitrosodiethylamine-induced) (NN hepatocarcinogenesis)) (VP (VBG modulating) (NP (JJ metabolic) (NN activation) (NN detoxification) (NN enzyme)))))) |ET| |BS|554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811|ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1
1 	|BT| (NP (NP (NP (NN Glutathione) (NN S-transferase) (JJ placental) (-LRB- -LRB-) (NN GST-P) (-RRB- -RRB-)) (: -) (NP (NP (JJ negative) (JJ hepatocellular) (JJ altered) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN HAF)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (NN HCA)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBD generated) (NP (NP (NP (NP (CD two) (JJ initiation-promotion) (NN model) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN NDEN)) (-RRB- -RRB-))) (NP (NN peroxisome) (NNS proliferators))) (, ,) (NP (NN Wy-14,643) (NN clofibrate)))))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 780:D08.811.913.225.500 783:A16.710 910:D02.241.081.114.968.500.500.195 912:D27.888.569.100.675 1194:C04.557.470.035.120|ES| 2:1 10:1 14:1 19:1 42:1 72:1 73:1 303:1 304:1 441:1 693:1 933:1 1431:1 1887:1 2446:1 2602:1 2743:1 2745:1 3058:1 3200:1 4167:1 4168:1 4169:1 4170:1 4171:1 4172:1 4173:1
1 	|BT| (NP (NP (NP (NN GP73)) (PRN (-LRB- -LRB-) (PRN (: -) (: /) (: -)) (-RRB- -RRB-))) (, ,) (NP (NN GP73) (PRN (-LRB- -LRB-) (CC +) (: /) (: -)) (-RRB- -RRB-) (, ,) (NP (NP (NN GP73) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-)) (NN mouse)) (VP (VBN given) (NP (NN injection) (NN diethylnitrosamine))))) (S (VP (VBP induce) (NP (NN liver) (NN injury))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 242:A03.620 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 29:1 44:1 45:1 51:1 52:1 243:1 785:1 836:1 1952:1 2416:1 4174:1
1 	|BT| (S (NP (NN GT-094) (JJ first) (NN nitrate)) (VP (VBD reported) (VP (VB reduce) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 45) (NN %)) (-RRB- -RRB-))) (NP (VBN administered) (NN carcinogen) (NN standard) (NN azoxymethane) (NN rat) (NN model) (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 824:C04.834.020 1195:D01.248.497.158.606|ES| 10:1 14:1 17:1 18:1 19:1 72:1 369:1 816:1 849:1 993:1 1431:1 1725:1 1993:1 2125:1 2336:1 2361:1 2913:1 4175:1 4176:1 4177:1 4178:1
1 	|BT| (S (ADVP (RB Hence)) (, ,) (NP (NN chloroform)) (VP (VBD prevented) (SBAR (S (NP (NN hypomethylation)) (VP (VBD increased) (NP (NP (NN mRNA)) (NN expression) (NN c-myc) (NN gene) (NN promotion) (NN liver) (NN tumor) (NN DCA)) (, ,) (S (VP (VBG enhancing) (NP (JJ DCA-promotion) (NN kidney) (NN tumor))))))))) |ET| |BS|111:D13.444.735.544 155:G05.355.310 274:C04.588.945.947.535 515:C04.588.274.623 1196:D02.455.526.439.224|ES| 2:1 7:1 9:1 19:1 47:1 115:1 325:1 455:1 836:1 1717:1 1943:1 1944:1 2337:1 2527:1 4107:1 4179:1 4180:1 4181:1
1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NN diethylnitrosamine) (JJ hepatic) (NN deletion) (NN PTEN)))) |ET| |BS|306:G05.355.600.800 554:D02.654.442.200|ES| 19:1 412:1 838:1 1059:1 1936:1 1952:1 1959:1
1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (ADJP (JJ diethylnitrosamine/phenobarbital) (PRN (-LRB- -LRB-) (NP (NN DEN/PB)) (-RRB- -RRB-))))) |ET| |BS|554:D02.654.442.200 756:D03.383.742.698.253.650|ES| 10:1 14:1 19:1 412:1 1959:1 4182:1 4183:1
1 	|BT| (S (NP (NN Hepatocarcinogenesis)) (VP (VBD induced) (NP (NP (JJ male) (NP (NP (JJ Sprague-Dawley) (NN rat) (JJ chronic) (NN feeding) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN 2-AAF)) (-RRB- -RRB-))) (NN dose) (ADJP (CD 0.05) (NN %)) (JJ basal) (NN diet)) (NP (JJ daily) (CD 5) (NN day) (NN week))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 595:G07.203.650.240 596:E02.642.249 767:D02.065.064.150 769:B01.050.150.900.649.865.635.505.700.750 881:D02.065.064.150|ES| 10:1 14:1 19:1 369:1 412:1 578:1 783:1 849:1 1402:1 1790:1 1959:1 2191:1 2301:1 2696:1 2707:1 2942:1 3271:1 3849:1 4078:1 4184:1 4185:1
1 	|BT| (NP (NP (JJ Hepatocarcinogenic) (NN susceptibility) (NN fenofibrate) (JJ possible) (NN mechanism) (NN carcinogenicity) (JJ two-stage) (NN hepatocarcinogenesis) (NN model) (NN rasH2) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 401:C23.550.291.687 916:D02.241.081.114.968.500.625|ES| 19:1 52:1 72:1 162:1 900:1 1353:1 1359:1 2971:1 3225:1 3583:1 4186:1 4187:1
1 	|BT| (S (NP (JJ Hepatocellular) (NN carcinoma)) (VP (VBD found) (NP (CD four) (CD five) (NN rat) (CD 12) (NN month) (NN tamoxifen) (NN treatment)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900|ES| 19:1 37:1 304:1 546:1 770:1 849:1 1120:1 2151:1 2371:1 2723:1 4188:1
1 	|BT| (S (NP (NN Hepatocyte) (JJ nuclear) (NN factor) (CD 4) (NN alpha) (NN deletion)) (VP (VBZ promotes) (S (NP (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)) (ADJP (JJ rodent))))) |ET| |BS|104:C04.557.470.200.025.255 306:G05.355.600.800 514:B01.050.150.900.649.865 554:D02.654.442.200 1197:D12.776.260.262.968|ES| 19:1 185:1 298:1 303:1 304:1 319:1 1059:1 1256:1 1836:1 2173:1 2349:1 2732:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBN conducted) (S (NP (NP (NP (CD two) (NN stage) (NN hepatocarcinogenesis) (NN study) (NN rat)) (VP (VBN exposed) (S (VP (VBG initiating) (NP (NP (NN agent) (NN nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))))) (, ,) (NP (NP (JJ hepatotoxic) (NN compound) (NN thioacetamide)) (PRN (-LRB- -LRB-) (NP (NN TAA)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN methapyrilene)) (PRN (-LRB- -LRB-) (NP (NN MP)) (-RRB- -RRB-))) (VP (NN acetaminophen) (S (-LRB- -LRB-) (NP (NN APAP) (-RRB- -RRB-) (CD 1-2) (NP (NN week))) (VP (VBD followed) (NP (NP (NN liver) (NN tumor) (NN promoter) (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))))))))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 296:D02.065.064.786 554:D02.654.442.200 600:D27.888.569.100 661:D02.065.199.092.040 756:D03.383.742.698.253.650 876:F01.145 1198:D02.092.782.258.368.500|ES| 2:1 7:1 10:1 14:1 19:1 83:1 131:1 400:1 728:1 783:1 836:1 849:1 900:1 933:1 1035:1 1129:1 1875:1 2019:1 2412:1 2433:1 2685:1 2862:1 3100:1 3102:1 3130:1 3496:1 4189:1 4190:1 4191:1 4192:1 4193:1 4194:1
1 	|BT| (SINV (ADVP (RB Here)) (, ,) (VP (VBN examined) (NP (NP (NP (JJ chemopreventive) (JJ potential) (NN Acteoside)) (PRN (-LRB- -LRB-) (NP (NN ACT)) (-RRB- -RRB-))) (, ,) (NP (NP (NN plant)) (VP (VBN derived) (NP (NP (JJ phenylethanoid) (NN glycoside) (JJ environmental) (JJ dietary) (NN carcinogen)) (, ,) (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (S (: -) (VP (VBN induced) (NP (NN rat) (NN hepatocarcinogenesis)))))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 328:B01.650 554:D02.654.442.200 595:G07.203.650.240 1199:D04.808.155.580 1200:G16.500.275 1201:D09.408|ES| 2:1 10:1 14:1 19:1 324:1 400:1 409:1 827:1 849:1 900:1 1098:1 1721:1 1875:1 1946:1 1952:1 2125:1 2594:1 3446:1 4195:1 4196:1 4197:1 4198:1
1 	|BT| (S (S (ADVP (RB Here)) (, ,) (VP (VBD identified) (SBAR (S (NP (JJ novel) (NN mechanism) (NN alcohol)) (VP (VBZ accelerates) (NP (NN liver) (NN fibrosis))))))) (: :) (NP (NP (NN inhibition) (JJ antifibrotic) (NN effect)) (SBAR (S (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (VP (NN cell) (NP (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-)))))))) |ET| |BS|43:F01.145.544 259:D12.776.395.240.150.500 676:C06.552.630 751:D02.033.375 822:D02.033 1033:D12.644.276.374.440.893 1202:A11.118.637.555.567.537|ES| 2:1 10:1 14:1 19:1 75:1 94:1 103:1 104:1 162:1 400:1 529:1 623:1 836:1 891:1 949:1 2333:1 2885:1 3710:1 4199:1 4200:1 4201:1 4202:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NN level) (NN MT-1) (NN MT-2A)) (ADVP (RB drastically)) (VP (VBD reduced) (NP (JJ primary) (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NNS HCCs)) (-RRB- -RRB-))) (JJ diethylnitrosamine-induced) (NN liver) (NN tumor) (NN mouse)) (, ,) (NP (ADVP (RB primarily)) (JJ due) (NP (JJ transcriptional) (NN repression))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 208:F01.393.821 209:G02.111.087.847 515:C04.588.274.623 554:D02.654.442.200|ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 249:1 303:1 304:1 344:1 400:1 417:1 452:1 559:1 706:1 836:1 1132:1 1970:1 2732:1 2851:1 4203:1 4204:1 4205:1
1 	|BT| (S (ADVP (RB Herein)) (NP (ADJP (NN report) (JJ concurrent)) (NP (NN increase) (NN liver) (NN progenitor) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNS LPCs)) (-RRB- -RRB-))) (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (VP (NN diethylnitrosamine) (S (-LRB- -LRB-) (NP (NN DEN) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN rat) (NN hepatocarcinogenesis) (JJ cirrhotic) (NN liver) (NN HCC) (NN patient)))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 503:D12.644.276.374.687 554:D02.654.442.200|ES| 10:1 14:1 19:1 40:1 94:1 102:1 120:1 409:1 417:1 428:1 441:1 836:1 849:1 900:1 1772:1 1773:1 1774:1 1875:1 1952:1 2968:1 4206:1 4207:1 4208:1
1 	|BT| (S (ADVP (RB Herein)) (VP (VBP show) (SBAR (S (NP (JJ global) (NN loss) (NN ERRalpha)) (VP (VBZ accelerates) (NP (NP (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (: -) (S (VP (VBN induced) (NP (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|104:C04.557.470.200.025.255 197:A01.456.505.420 554:D02.654.442.200|ES| 10:1 14:1 19:1 32:1 35:1 303:1 304:1 409:1 428:1 429:1 529:1 660:1 1875:1 1952:1 4209:1
1 	|BT| (S (NP (ADVP (RB Herein)) (, ,) (JJ first) (NN time)) (, ,) (VP (VBP investigate) (NP (FW vivo) (NN efficacy) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910|ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1
1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (NP (NN MMP10) (NN expression) (NN function)) (JJ human) (JJ hepatocellular) (NN carcinoma) (-LRB- -LRB-) (NN HCC) (-RRB- -RRB-) (NN diethylnitrosamine) (-LRB- -LRB-) (NN DEN) (-RRB- -RRB-) (: -)) (VBN induced) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 33:1 36:1 52:1 115:1 303:1 304:1 403:1 409:1 428:1 441:1 900:1 1875:1 1952:1 4210:1
1 	|BT| (NP (NP (JJ High-saturate-fat) (NN diet) (NN delay) (NN initiation) (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 694:G07.203.650.240.267|ES| 19:1 136:1 303:1 304:1 637:1 2191:1 2732:1 4211:1
1 	|BT| (NP (NP (ADVP (RB However)) (PRN (, ,) (NP (JJ Ptk6-null) (NN mouse)) (ADVP (RB also)) (NP (JJ resistant) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis))))) |ET| |BS|29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 2:1 5:1 19:1 52:1 78:1 113:1 427:1 433:1 2533:1 4212:1
1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NNP Sorafenib) (NN treatment)) (ADVP (RB transiently)) (VP (VBD inhibited) (SBAR (S (NP (NN cell) (NN cycle) (NN progression)) (VP (VBD resulted) (SBAR (S (NP (JJ mitotic) (NN catastrophe)) (VP (VBD enhanced) (NP (JJ non-apoptotic) (NN liver) (NN injury) (NN regeneration)))))))))) |ET| |BS|16:C23.550.291.656 39:G04.299.139.160 52:E02 122:C14.280.383 353:G04.299.134 925:G10.261.326.520|ES| 2:1 19:1 48:1 94:1 365:1 385:1 433:1 546:1 594:1 601:1 720:1 836:1 2416:1 2833:1 3210:1 3260:1 3614:1 4213:1
1 	|BT| (FRAG (ADVP (RB However)) (, ,) (NP (NP (NN action) (NN compound) (JJ ethanol-induced) (NN liver) (NN injury)) (ADJP (RB still) (JJ unknown)))) |ET| |BS|242:A03.620 751:D02.033.375|ES| 2:1 19:1 433:1 776:1 836:1 2013:1 2182:1 2416:1 2433:1 2674:1
1 	|BT| (S (NP (NN HTHQ)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN carcinogenesis) (CD two) (NN stage) (NN colon) (NN carcinogenesis) (NN model)) (S (VP (VBG using) (NP (NP (NP (NN 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-))) (NN initiator))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725|ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1
1 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN GEN-27)) (VP (VBD protected) (FRAG (NP (NP (NN mouse) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (: /) (FRAG (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (: -) (NP (NP (VBN induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (VBD reduced) (NN mortality)) (, ,) (NP (NN tumor) (NN number) (NN tumor) (NN volume))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 695:E05.318.308.985.550 1203:E05.041.124.892|ES| 2:1 7:1 10:1 14:1 19:1 52:1 113:1 207:1 406:1 407:1 409:1 452:1 646:1 1993:1 1994:1 2413:1 2511:1 2651:1 3305:1 3306:1 3589:1 4214:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN mouse) (NNP Diethylnitrosamine) (NN model) (NN hepatocarcinogenesis)) (VP (VBN observed) (NP (JJ strong) (NN induction) (NN CXCR7) (NN CXCL11) (NN transcript)) (, ,) (S (VP (VBG confirming) (NP (NN CXCR7/CXCL11) (NN up-regulation) (VBN conserved) (JJ human) (NN mouse) (NN liver) (NN cancer)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 554:D02.654.442.200|ES| 2:1 18:1 19:1 36:1 52:1 72:1 244:1 261:1 468:1 736:1 836:1 896:1 900:1 937:1 3578:1 4151:1 4215:1 4216:1 4217:1 4218:1 4219:1
1 	|BT| (S (PP (IN In) (NP (NP (JJ experimental) (NN mouse) (NN model) (NN hepatocarcinogenesis)) (PRN (-LRB- -LRB-) (NP (JJ diethylnitrosamine-induced)) (-RRB- -RRB-)))) (, ,) (NP (NN tumor)) (VP (VBD showed) (NP (NP (VBN increased) (NN activation) (NN TGF-beta) (NN pathway)) (VBD enhanced) (NN CXCR4) (NN level)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 95:E05.599 503:D12.644.276.374.687 554:D02.654.442.200 1204:D12.776.543.750.100.160.500.400|ES| 2:1 7:1 10:1 14:1 19:1 47:1 52:1 72:1 132:1 225:1 244:1 249:1 263:1 383:1 385:1 900:1 1774:1 2732:1 4220:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (NN dioscin) (NN show) (JJ excellent) (JJ protective) (NN effect)) (JJ ethanol-induced) (NN liver) (NN injury)) (S (VP (VBG ameliorating) (NP (NP (JJ ethanol-induced) (JJ oxidative) (NN stress)) (, ,) (NP (JJ mitochondrial) (NN function)) (, ,)) (NP (NP (JJ inflammatory) (NP (NN cytokine)) (NN production)) (, ,) (NP (NN apoptosis) (NN liver) (NN steatosis)) (, ,))))) (VP (VBD developed) (NP (JJ new) (NN drug) (NN treatment) (JJ ethanol-induced) (NN liver) (NN injury) (NN future)))) |ET| |BS|39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241|ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1
1 	|BT| (FRAG (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (CD three) (CD 18) (NN vinyl) (JJ carbamate-induced) (NN liver) (NN tumor)) (, ,) (NP (CD one) (CD 18) (JJ TCDD-induced) (NN liver) (NN tumor)) (, ,) (NP (CD two) (CD 22) (JJ spontaneous) (NN liver) (NN neoplasm) (NN mutation) (NN beta-catenin)))) |ET| |BS|18:G05.365.590 23:D12.776.091.249 491:D27.505.259.500 515:C04.588.274.623 1096:D03.383.231.900|ES| 2:1 7:1 19:1 34:1 60:1 244:1 283:1 482:1 836:1 933:1 1010:1 1193:1 1392:1 1523:1 3714:1 4221:1 4222:1 4223:1
1 	|BT| (S (PP (IN In) (NP (JJ medium-term) (NN carcinogenesis) (NN test) (NN rat))) (, ,) (NP (NP (ADJP (CD 2.0) (NN %)) (NN KA)) (VP (ADVP (RB orally)) (VBN given) (NP (NN F344/DuCrj) (NN rat) (CD 4) (NN week) (NN initiation) (NN period))) (, ,)) (VP (VBD followed) (NP (NP (NN combination) (JJ partial) (NN hepatectomy) (NN treatment) (NN hepatocarcinogenesis) (NN promoter)) (, ,) (NP (NP (NN phenobarbital)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-)))))) |ET| |BS|52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200 756:D03.383.742.698.253.650 776:G01.910.645 849:G08.686.785.760.769.490.500 914:L01.178 928:E04.210.556 1205:E05.940.150|ES| 2:1 10:1 14:1 19:1 29:1 83:1 207:1 244:1 319:1 369:1 530:1 546:1 637:1 783:1 849:1 900:1 1418:1 2685:1 2725:1 3130:1 3215:1 3272:1 3273:1 3496:1 4224:1 4225:1 4226:1 4227:1
1 	|BT| (FRAG (PP (IN In) (NP (NN mouse) (NN fed) (NN bezafibrate) (CD 1) (NN year))) (, ,) (NP (NP (JJ preneoplastic) (NN focus)) (, ,) (NP (NP (NP (NN adenoma) (JJ hepatocellular) (NN carcinoma)) (VP (VBN found))) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NN mouse)) (, ,) (NP (NP (JJ single) (JJ microscopic) (NN adenoma)) (VP (VBD found) (S (NP (NP (CD one)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 104:C04.557.470.200.025.255 426:E01.370.350.515 663:C16.320.565.398.500.330.500 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 909:D02.065.277.067|ES| 2:1 10:1 14:1 19:1 37:1 42:1 45:1 51:1 52:1 98:1 244:1 303:1 304:1 1010:1 1431:1 1438:1 1452:1 2426:1 2846:1 3201:1 4071:1
1 	|BT| (SINV (PP (IN In) (NP (NN order))) (VP (VBP prepare)) (NP (NP (JJ human) (NN trial) (NN inhibition) (NN colon) (NN carcinogenesis)) (, ,) (NP (NP (VBN conducted) (NN study) (JJ green) (NN tea) (NNS polyphenols)) (VP (JJ preventive) (VP (NN agent) (NP (NN azoxymethane) (S (-LRB- -LRB-) (NP (NN AOM) (-RRB- -RRB-) (: -)) (VP (VBN induced) (NP (NN rat) (NN colon) (NN cancer) (NN model)) (S (VP (VBG using) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN end) (NN point)))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 43:F01.145.544 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 375:Z01.639.100 824:C04.834.020 841:E05.318.760.250.500 876:F01.145|ES| 2:1 10:1 14:1 18:1 19:1 36:1 72:1 103:1 113:1 131:1 154:1 207:1 244:1 350:1 409:1 728:1 849:1 1431:1 1725:1 1883:1 1993:1 1994:1 2121:1 2379:1 2834:1 2913:1 2914:1 2989:1 3100:1 3192:1 4228:1 4229:1
1 	|BT| (FRAG (PP (IN In) (NP (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN model) (NN colon) (NN cancer))) (, ,) (NP (NP (NN addition) (NN K-ras) (NN mutation)) (, ,) (VP (VBN shown) (S (NP (ADJP (ADJP (JJ wild-type)) (PRN (-LRB- -LRB-) (ADJP (JJ WT)) (-RRB- -RRB-))) (NN Ras)) (VP (VBD activated) (NP (NP (JJ upstream) (NN pathway)) (, ,) (S (VBG including) (, ,) (PP (FW e.g.)) (, ,) (VP (VBG signaling) (NP (NN ErbB) (NN receptor)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 69:G02.111.087.800 132:D02.172.080 563:D08.811.913.696.620.682.725.400.009|ES| 2:1 8:1 10:1 14:1 18:1 19:1 34:1 72:1 113:1 163:1 186:1 195:1 237:1 244:1 383:1 468:1 561:1 1121:1 1775:1 1993:1 1994:1 1995:1 1996:1 1997:1 1998:1
1 	|BT| (S (PP (IN In) (NP (JJ azoxymethane-treated) (NN rat) (NN model) (JJ experimental) (NN colon) (NN carcinogenesis))) (, ,) (NP (NN sulindac) (NN treatment)) (ADVP (RB markedly)) (VP (VBD induced) (NP (NP (NNP Csk) (JJ corresponding) (NN increase) (JJ inhibitory) (NN phosphorylation) (NN Src)) (PRN (-LRB- -LRB-) (NP (NN Tyr) (PRN (-LRB- -LRB-) (CD 527) (-RRB- -RRB-)) (-RRB- -RRB-)))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 52:E02 95:E05.599 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 251:D02.455.426.559.847.486.875 634:D12.125.072.050.875 972:G02.111.087.677 1206:D08.811.682.690.708.125.500|ES| 2:1 10:1 14:1 19:1 40:1 72:1 113:1 207:1 244:1 263:1 412:1 546:1 849:1 869:1 2396:1 2429:1 2793:1 3426:1 3674:1 4230:1 4231:1 4232:1 4233:1
1 	|BT| (FRAG (PP (IN In) (ADJP (JJ present) (SBAR (S (NP (NP (NN paper)) (, ,) (NP (NP (JJ ethanol-induced) (JJ acute) (JJ chronic) (NN liver) (NN damage) (NN rat) (NN model)) (VP (VBN used))) (, ,)) (VP (VBP result) (VP (VBD showed) (SBAR (S (NP (NN dioscin)) (ADVP (RB significantly)) (VP (VBD alleviated) (SBAR (S (NP (NP (NN liver) (NN steatosis)) (, ,) (NP (VBN reduced) (NN level) (NN alanine) (NN aminotransferase)) (, ,) (NP (NN aspartate) (NN aminotransferase)) (, ,) (NP (NP (JJ total) (NN triglyceride)) (PRN (-LRB- -LRB-) (NP (NN TG)) (-RRB- -RRB-))) (, ,) (NP (JJ total) (NN cholesterol) (NN malondialdehyde)) (, ,)) (VP (VBD increased) (NP (NP (NN level) (JJ high-density) (NN lipoprotein)) (, ,) (NP (NN superoxide) (NN dismutase)) (, ,) (NP (NN glutathione) (NN glutathione) (NN peroxidase)))))))))))))))) |ET| |BS|58:D08.811.682.881 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 655:D04.808.247.222.284 751:D02.033.375 753:C06.552.241 991:D08.811.682.732.500 1207:D08.811.913.477.700.225 1208:D12.644.456.448 1209:D10.532.432 1210:D02.047.700 1211:J01.637.650 1212:D10.351.801|ES| 2:1 10:1 14:1 19:1 47:1 72:1 90:1 101:1 124:1 132:1 146:1 147:1 244:1 249:1 452:1 476:1 836:1 849:1 1307:1 1790:1 1848:1 2392:1 2393:1 2403:1 2672:1 2674:1 2678:1 2744:1 3132:1 3485:1 4234:1 4235:1 4236:1 4237:1 4238:1 4239:1 4240:1 4241:1
1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN shown) (NP (NP (JJ myrtenal) (, ,) (JJ natural) (NN monoterpene)) (, ,) (NP (VP (VBP act) (SBAR (S (NP (JJ antineoplastic) (NN agent) (NN diethylnitrosamine)) (VP (VBD induced) (NP (JJ phenobarbital) (VBN promoted) (NP (JJ experimental) (JJ hepatocellular) (NN carcinoma))))))))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575|ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1
1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (S (VP (VBG using) (NP (FW vivo) (NN model) (NN rat) (NN hepatocarcinogenesis)))) (VP (VP (VBD induced) (NP (NN 2-acetylaminofluorene))) (, ,) (VP (VBD found) (NP (JJ extensive) (NN alteration) (JJ cellular) (NN iron) (NN metabolism) (JJ preneoplastic) (NN stage) (NN liver) (NN carcinogenesis))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 41:A11 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 881:D02.065.064.150 895:D01.490.600 896:D01.268.556.412 898:G03.495|ES| 2:1 19:1 37:1 72:1 131:1 207:1 244:1 350:1 378:1 412:1 836:1 849:1 900:1 951:1 1129:1 1307:1 1438:1 3074:1 3162:1 3163:1 3271:1 4242:1
1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBP demonstrate) (NP (NP (JJ altered) (NN gene) (NN expression) (JJ various) (NNS proteins/enzymes)) (VP (VBN involved) (NP (NP (NN DNA) (NN repair)) (, ,) (NP (NP (NN cell) (NN growth) (NN cell) (NN cycle) (NN process)) (JJ tamoxifen-induced) (NN hepatocarcinogenesis))))))) |ET| |BS|41:A11 45:G07.700.320.249 353:G04.299.134 640:D02.455.426.559.389.150.700.900 730:D08.811 1134:G02.111.087.219 1213:D12.776|ES| 2:1 9:1 19:1 94:1 102:1 115:1 131:1 244:1 502:1 513:1 601:1 638:1 666:1 693:1 774:1 900:1 1096:1 1307:1 3965:1 3966:1
1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN shown) (NN diosmin)) (VP (VBZ attenuates) (SBAR (S (NP (NP (NN 2-AAF)) (VP (VBD induced) (NP (NP (NP (JJ hepatic) (NN toxicity) (JJ early) (NN tumor) (NN promotion) (NN marker)) (PRN (-LRB- -LRB-) (NP (NP (NN ODC)) (, ,) (NP (NN PCNA) (NN Ki67))) (-RRB- -RRB-))) (, ,) (NP (JJ chemopreventive) (NN efficacy) (NN DEN))))) (VP (VBD initiated) (NP (JJ 2-AAF) (VBN promoted) (NN hyper-proliferation) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))))) |ET| |BS|376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740|ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1
1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN investigated) (S (NP (NP (NN role) (NN IDO) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NP (NP (NN IDO-knockout)) (PRN (-LRB- -LRB-) (NP (NN KO)) (-RRB- -RRB-))) (NN mouse)))))))) |ET| |BS|15:F01.829.316.616 29:B01.050.050.136.500.500 554:D02.654.442.200|ES| 2:1 10:1 14:1 19:1 31:1 52:1 131:1 244:1 350:1 403:1 409:1 900:1 1307:1 1875:1 1952:1 2849:1 4243:1 4244:1
1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD investigated) (SBAR (S (NP (NP (NP (JJ chemopreventive) (NN efficacy) (NN PEITC) (NN DBM) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (PRN (: -) (VP (VBN initiated) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-)))) (: -))) (VP (VBD promoted) (SBAR (S (NP (NN colon) (NN cancer) (NN mouse) (NN model)) (VP (VBP compare) (NP (NP (JJ potential) (FW vivo) (NN mechanism)) (VP (VBG leading) (NP (NN chemoprevention)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 86:D01.268.556.435 131:D09.698.365.272.300 132:D02.172.080 253:E02.319.162|ES| 2:1 10:1 14:1 18:1 19:1 52:1 72:1 113:1 131:1 162:1 244:1 378:1 403:1 406:1 407:1 639:1 827:1 870:1 1946:1 1993:1 1994:1 2304:1 3300:1 3306:1 4024:1 4029:1 4245:1 4246:1 4247:1
1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (NP (VBN characterized) (NN cell) (NN signaling) (NN event)) (VP (VBD evoked) (NP (NN decorin) (NN deficiency) (CD two) (JJ experimental) (NN model) (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NN thioacetamide) (NN diethyl) (NN nitrosamine) (NN carcinogen)))))) |ET| |BS|69:G02.111.087.800 87:C18.654.521 95:E05.599 279:D27.888.569.100 296:D02.065.064.786 554:D02.654.442.200 708:D12.776.395.650.750.625|ES| 2:1 19:1 72:1 94:1 131:1 195:1 205:1 244:1 253:1 263:1 350:1 900:1 933:1 985:1 1514:1 2125:1 2901:1 4190:1 4248:1 4249:1
1 	|BT| (SINV (PP (IN In) (NP (NN study))) (, ,) (VBD evaluated) (FRAG (NP (NN susceptibility) (NNP Vparp)) (: -) (: /) (: -) (NP (NN Tep1) (: -) (: /) (: -) (NN mouse) (JJ dimethylhydrazine-induced) (NN colon) (NN tumorigenesis) (JJ urethane-induced) (NN lung) (NN tumorigenesis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 182:A04.411 225:E05.337 401:C23.550.291.687 1214:D02.241.081.251.944|ES| 2:1 19:1 52:1 78:1 113:1 131:1 244:1 328:1 780:1 1353:1 4250:1 4251:1 4252:1 4253:1
1 	|BT| (S (PP (IN In) (NP (JJ wild-type) (NN mouse))) (, ,) (NP (CD 200) (NN ppm) (NN cyproconazole)) (VP (VBD caused) (NP (NP (NP (NP (NN liver) (NN hypertrophy)) (, ,) (NP (VBD increased) (NN liver) (NN weight) (NN cell) (NN proliferation)) (, ,)) (JJ single-cell) (NN necrosis) (JJ fat) (NN vacuolation)) (, ,) (NP (NP (NP (NN effect)) (ADJP (RB generally) (JJ similar))) (VP (VBN caused) (NP (CD 850) (NN ppm) (NN phenobarbital))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 183:G04.299.233.750 242:A03.620 756:D03.383.742.698.253.650 805:F01.829.263.315.500.725 806:F01.829.263.315.500.725 1151:C06.552.416 1215:C23.888.144.243.926 1216:C23.550.717|ES| 2:1 8:1 19:1 47:1 52:1 75:1 94:1 244:1 299:1 332:1 836:1 2399:1 2425:1 2506:1 2685:1 3233:1 3364:1 3992:1 4254:1 4255:1 4256:1 4257:1 4258:1 4259:1
1 	|BT| (NP (NP (NN indica)) (NP (NP (-RRB- -RRB-) (NN extract) (-LRB- -LRB-) (NN FIE) (-RRB- -RRB-) (NN N-nitrosodiethylamine) (NN CCl)) (FRAG (-LRB- -LRB-) (NP (NP (CD 4) (-RRB- -RRB-) (: -)) (VBN induced) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))) |ET| |BS|554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900 1217:A02.513.514.100|ES| 10:1 14:1 19:1 319:1 409:1 849:1 900:1 2496:1 2601:1 2602:1 2603:1 4260:1 4261:1
1 	|BT| (S (NP (NN Inhibition) (JJ retinoic) (NN acid) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NN N-nitrosomorpholine) (NN expression) (NN myc) (NN oncogene) (NN protein) (JJ Sprague-Dawley) (NN rat)))) |ET| |BS|43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500|ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1
1 	|BT| (S (NP (NP (NN Inhibition) (JJ azoxymethane-induced) (JJ colorectal) (NN cancer) (NN CP-31398)) (, ,) (NP (NN TP53) (NN modulator)) (, ,) (ADVP (RB alone)) (NP (NN combination) (JJ low) (NNS dos))) (VP (VBP celecoxib) (NP (JJ male) (NN F344) (NN rat)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 132:D02.172.080 590:B01.050.050.199.520.760.200 684:D02.065.884.247|ES| 2:1 17:1 18:1 19:1 241:1 530:1 531:1 849:1 1018:1 1402:1 1607:1 2533:1 2653:1 2703:1 2807:1 3047:1 3185:1
1 	|BT| (NP (NP (JJ Inhibitory) (NN effect) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 75:1 78:1 113:1 2533:1 2534:1 2635:1 2713:1
1 	|BT| (S (NP (NP (VBN injected) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP induce) (NP (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 554:D02.654.442.200|ES| 10:1 14:1 19:1 243:1 303:1 304:1 1875:1 1952:1 3586:1
1 	|BT| (S (NP (NP (NN Injection) (NN carcinogen)) (, ,) (NP (NN diethylnitrosamine)) (, ,)) (VP (VBD induced) (SBAR (S (NP (ADJP (RB significantly) (JJR larger)) (NN liver) (NN tumor) (NN HCV) (JJ transgenic) (NN mouse)) (VP (VBP overexpress) (NP (NP (NN PP2Ac)) (VBN compared) (NN control) (NN mouse))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 99:B01.050.050.136.500 226:E02.319.267.530 279:D27.888.569.100 550:B04.450.410 554:D02.654.442.200 1151:C06.552.416|ES| 2:1 7:1 19:1 50:1 52:1 124:1 285:1 289:1 412:1 836:1 1938:1 1952:1 2125:1 2513:1 4079:1 4262:1 4263:1
1 	|BT| (NP (NP (NP (NN Involvement) (NN Mouse) (JJ Constitutive) (NN Androstane) (NN Receptor) (JJ Acifluorfen-Induced) (NN Liver)) (NP (NNP Injury) (JJ Subsequent) (NN Tumor) (NN Development)))) |ET| |BS|8:C04 242:A03.620|ES| 19:1 1218:1 2059:1 2127:1 2721:1 3399:1 4264:1 4265:1 4266:1 4267:1 4268:1 4269:1
1 	|BT| (S (NP (PRP It)) (VP (VBD suggested) (SBAR (S (NP (NN CYP2E1)) (ADVP (RB completely)) (VP (VBZ participates) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (, ,) (SBAR (S (NP (JJ high) (NP (NN frequency)) (NN tumor) (JJ wild-type) (NN mouse)) (VP (MD could) (VP (VBN associated) (NP (VBN increased) (NN apoptosis))))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 554:D02.654.442.200 1218:D08.244.453.300|ES| 2:1 7:1 8:1 19:1 47:1 52:1 89:1 169:1 178:1 900:1 908:1 925:1 1247:1 1327:1 2732:1 4270:1 4271:1 4272:1
1 	|BT| (S (NP (PRP It)) (ADVP (RB also)) (VP (VBD nominated) (NP (NP (JJ dichloroacetic) (NN acid)) (VP (VBN studied) (NP (NP (JJ representative) (NN class) (JJ haloacetic) (NN acid)) (NP (VBN shown) (NN cause) (NN liver) (NN tumor) (NN rat) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 1062:D01.029 1219:D02.241.081.018.214.500|ES| 5:1 7:1 19:1 52:1 237:1 401:1 836:1 849:1 1017:1 1275:1 1327:1 1779:1 2814:1 4273:1 4274:1 4275:1
1 	|BT| (NP (NP (NN JNK) (NN protein)) (VP (VBN activated) (PP (IN via) (NP (NN phosphorylation) (NN response) (NN acetaminophen)))) (FRAG (: -) (NP (NP (NN carbon) (NN tetrachloride)) (PRN (-LRB- -LRB-) (NP (NN CCl4)) (-RRB- -RRB-))) (: -) (NP (NP (VBN induced) (NN liver) (NN damage)) (: ;) (S (NP (NN level) (NN activation)) (VP (VBP correlate) (NP (NN degree) (NN injury))))))) |ET| |BS|7:D12.776 242:A03.620 661:D02.065.199.092.040 972:G02.111.087.677 1220:D02.455.526.439.150|ES| 4:1 10:1 14:1 19:1 163:1 217:1 225:1 249:1 409:1 494:1 596:1 836:1 1848:1 2416:1 2806:1 3426:1 4276:1 4277:1 4278:1 4279:1 4280:1 4281:1
1 	|BT| (S (NP (NN Liver) (NN fibrosis)) (VP (VBD induced) (NP (NP (NN carbon) (NN tetrachloride)) (, ,) (NP (NN bile) (NN duct) (NN ligation)) (, ,) (NP (NP (NN disruption) (JJ multidrug-resistance) (NN transporter) (CD 2) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN Mdr2)) (-RRB- -RRB-)))))) |ET| |BS|227:D12.776.157.530 676:C06.552.630 1220:D02.455.526.439.150 1221:G05.360.340.024.340.361 1222:A03.159.183 1223:E04.426|ES| 2:1 9:1 10:1 14:1 19:1 148:1 412:1 779:1 949:1 1602:1 1621:1 1622:1 2721:1 4278:1 4279:1 4282:1 4283:1 4284:1
1 	|BT| (S (NP (NN Liver) (NN tumor) (NN formation) (JJ female) (NN rat)) (VP (VBD induced) (NP (NN fluopyram) (JJ mediated) (NN CAR/PXR) (JJ nuclear) (NN receptor) (NN activation)))) |ET| |BS|20:G03.495 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 642:M01.975|ES| 7:1 19:1 43:1 186:1 225:1 412:1 437:1 849:1 1256:1 1404:1 2721:1 4285:1 4286:1
1 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN etofenprox) (NN rat) (JJ possible) (NN mechanism) (NN action)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 742:G03.787|ES| 7:1 19:1 75:1 162:1 849:1 881:1 1359:1 2013:1 2721:1 4287:1
1 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBG promoting) (NP (NP (NN effect) (NN orphenadrine) (NN rat) (JJ possible) (NN mechanism) (NN action)) (PP (VBG including) (NP (NN CAR) (NN activation) (JJ oxidative) (NN stress)))))) |ET| |BS|139:J01.937.500.100 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 716:G03.495.710 742:G03.787 1159:D02.092.471.600|ES| 7:1 19:1 75:1 162:1 225:1 421:1 561:1 849:1 881:1 1359:1 2013:1 2522:1 2583:1 2721:1 4005:1
1 	|BT| (S (NP (NN Liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ male) (NNP Fischer) (NN F344) (NN rat) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))))) |ET| |BS|515:C04.588.274.623 554:D02.654.442.200 590:B01.050.050.199.520.760.200|ES| 7:1 10:1 14:1 19:1 412:1 849:1 1402:1 1875:1 1952:1 2721:1 3185:1 4288:1
1 	|BT| (S (NP (NN Loss) (NN hepatocyte) (NN growth) (NN factor/c-Met) (NN signaling) (NN pathway)) (VP (VBZ accelerates) (SBAR (S (NP (JJ early) (NN stage) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) |ET| |BS|45:G07.700.320.249 69:G02.111.087.800 126:G02.111.087.800 262:A11.436.348 554:D02.654.442.200|ES| 19:1 102:1 195:1 383:1 412:1 529:1 900:1 1128:1 1129:1 1788:1 1909:1 2602:1 4289:1
1 	|BT| (S (S (NP (NP (JJ Low) (JJ dietary) (NN folate) (NN intake)) (VP (VBN associated))) (VP (VBD increased) (NP (NN risk) (NN colon) (NN cancer))) (: ;)) (S (ADVP (RB however)) (, ,) (NP (JJ relevant) (JJ genetic) (NN animal) (NN model)) (VP (VBG lacking)))) |ET| |BS|19:B01.050 61:E05.318.740.600.800 224:D03.438.733.631.400 285:E05.598 595:G07.203.650.240 1109:E05.599.395.397|ES| 2:1 18:1 19:1 46:1 47:1 72:1 113:1 169:1 171:1 217:1 376:1 778:1 864:1 865:1 1387:1 2563:1 2594:1 3615:1
1 	|BT| (S (S (NP (NNP Lycopene)) (VP (VBZ modulates) (SBAR (S (NP (NN initiation) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) (: :) (S (NP (NP (NN study) (JJ chromosomal) (NN abnormality)) (, ,) (NP (NN membrane) (NN fluidity) (JJ antioxidant) (NN defense) (NN system))))) |ET| |BS|554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260|ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1
1 	|BT| (S (NP (JJ Male) (NN F344) (NN rat)) (VP (VBN treated) (S (NP (NP (CD one) (JJ powerful) (NNP Valerian) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN Valeriana) (NN sitchensis)) (-RRB- -RRB-))) (VP (VBZ dos) (NP (CD 0) (, ,) (CD 50) (, ,) (NP (NP (CD 500) (CD 5000) (NN ppm) (NN drinking) (NN water) (NN initiation) (NN hepatocarcinogenesis) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))))) |ET| |BS|52:E02 554:D02.654.442.200 590:B01.050.050.199.520.760.200 857:B01.650.940.800.575.100.955.888 858:B01.650.940.800.575.100.955.888 1060:D01.045.250.875.300 1224:E05.318.740.872 1225:F01.658.780|ES| 2:1 10:1 14:1 19:1 368:1 637:1 849:1 900:1 1010:1 1099:1 1875:1 1952:1 2355:1 2653:1 3057:1 3185:1 3233:1 3635:1 3968:1 4163:1 4290:1 4291:1 4292:1 4293:1 4294:1 4295:1
1 	|BT| (NP (NP (NP (JJ Male) (NN Malat1)) (: -) (: /) (: -)) (NP (S (NP (NN mouse) (JJ wild-type) (-LRB- -LRB-) (JJ WT) (-RRB- -RRB-) (NNS littermates)) (VP (VBD studied) (NP (NP (CD one) (NN year)) (NP (NP (NN treatment) (JJ genotoxic) (NN agent) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-)))))) (, ,) (NP (JJ potent) (NN inducer) (NN liver) (NN cancer)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 554:D02.654.442.200 775:E02.760.058|ES| 2:1 8:1 10:1 14:1 18:1 19:1 22:1 52:1 401:1 546:1 728:1 836:1 1010:1 1355:1 1452:1 1875:1 1952:1 1995:1 3329:1 3635:1 3791:1 4296:1
1 	|BT| (NP (NP (NP (JJ Mechanistic) (NN Investigation) (NNP Toxaphene)) (NP (VBN Induced) (NN Mouse) (NN Liver) (NNS Tumors)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 225:E05.337 515:C04.588.274.623 1149:D02.455.526.439.913|ES| 19:1 53:1 2127:1 2721:1 4297:1 4298:1 4299:1 4300:1
1 	|BT| (S (NP (JJ Mechanistic) (NN study) (NN liver) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN flutamide) (NN rat)))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 1172:D02.065.199.420 1226:E01.370.372.460|ES| 7:1 19:1 75:1 131:1 836:1 849:1 881:1 4057:1 4297:1
1 	|BT| (S (NP (NNP Melatonin)) (VP (VBZ Activates) (NP (NP (JJ Endoplasmic) (NN Reticulum) (NN Stress) (NN Apoptosis) (NNS Rats)) (NP (JJ Diethylnitrosamine-Induced) (NN Hepatocarcinogenesis))))) |ET| |BS|39:G04.299.139.160 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 707:D03.438.473.914.481 1071:G04.434|ES| 19:1 1959:1 2738:1 3291:1 3664:1 4301:1 4302:1 4303:1 4304:1 4305:1
1 	|BT| (S (NP (NN Melatonin)) (VP (VBZ prevents) (NP (NN deregulation) (NN sphingosine) (NN kinase/sphingosine) (NN 1-phosphate) (NN signaling) (NN pathway) (NN mouse) (NN model) (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 469:D08.811.913.696 554:D02.654.442.200 707:D03.438.473.914.481 1227:D01.029.260.700.675.374 1228:D02.705.400|ES| 19:1 52:1 72:1 195:1 303:1 304:1 383:1 402:1 2718:1 2732:1 2738:1 4306:1 4307:1 4308:1
1 	|BT| (S (NP (NN Metformin)) (VP (VBZ inhibits) (NP (JJ early) (NN stage) (JJ diethylnitrosamineinduced) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 784:D02.078.370.141.450|ES| 19:1 615:1 849:1 900:1 1128:1 1129:1 2746:1 2747:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (DT A) (JJ Solt-Farber) (JJ two-step) (NN test) (NN model) (NN hepatocarcino) (NN genesis)) (VP (VBD established) (S (NP (NP (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN AAF)) (-RRB- -RRB-))) (NN rat)) (VP (VBP investigate) (S (VP (VBG modifying) (NP (NP (NP (NN effect) (NN expression) (NN 6-glucosephosphatase)) (PRN (-LRB- -LRB-) (NP (NN G-6-Pase)) (-RRB- -RRB-))) (, ,) (NP (NN succinodehydrogenase) (-LRB- -LRB-) (NN SDH) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NN adenosine) (NN triphosphatase)) (PRN (-LRB- -LRB-) (NP (NN ATPase)) (-RRB- -RRB-))) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250|ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1
1 	|BT| (FRAG (NP (NNS METHODS) (: :)) (NP (NN Liver) (NN fibrosis)) (VBD induced) (NP (NN mouse)) (VBG receiving) (NP (NP (NN bile) (NN duct) (NN ligation)) (PRN (-LRB- -LRB-) (NP (NN BDL)) (-RRB- -RRB-))) (NP (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NP (NN CCl) (PRN (-LRB- -LRB-) (CD 4) (-RRB- -RRB-) (-RRB- -RRB-)) (NN administration)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 168:E05.581 676:C06.552.630 1217:A02.513.514.100 1220:D02.455.526.439.150 1222:A03.159.183 1223:E04.426|ES| 10:1 14:1 19:1 52:1 104:1 319:1 412:1 548:1 565:1 949:1 1621:1 1622:1 2575:1 2721:1 4261:1 4278:1 4279:1 4282:1 4309:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (CD Twenty-four) (JJ Sprague-Dawley) (NN rat) (VBN treated) (NN diethylnitrosamine) (NN phenobarbital)) (VP (VBP induce) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 168:E05.581 554:D02.654.442.200 756:D03.383.742.698.253.650 769:B01.050.150.900.649.865.635.505.700.750|ES| 19:1 104:1 243:1 303:1 304:1 565:1 849:1 1099:1 1952:1 2685:1 2707:1 4310:1
1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG developing) (NP (NP (JJ diethylnitrosamine-induced) (JJ hepatocellular) (NN carcinoma)) (VP (VBN subjected) (NP (JJ hydrodynamic) (NN gene) (NN delivery)))))) (VP (VBP overexpress) (NP (NN Gas1) (NN liver)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 242:A03.620 554:D02.654.442.200 1229:E04.520.252 1230:G01.342|ES| 9:1 19:1 303:1 304:1 583:1 590:1 836:1 2513:1 2732:1 3267:1 4311:1 4312:1 4313:1
1 	|BT| (NP (NP (NNP Mode) (NN action) (NN analysis) (JJ synthetic) (NN pyrethroid) (JJ metofluthrin-induced) (NN rat) (NN liver) (NN tumor)) (: :) (NP (NN evidence) (JJ hepatic) (NN CYP2B) (NN induction) (NN hepatocyte) (NN proliferation))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 262:A11.436.348 515:C04.588.274.623 1231:D02.455.849.575.812|ES| 7:1 19:1 38:1 104:1 299:1 661:1 736:1 836:1 838:1 849:1 1909:1 2013:1 3218:1 4314:1 4315:1 4316:1 4317:1
1 	|BT| (NP (NP (NN Modulation) (NN energy) (JJ metabolic) (NN enzyme) (NN expression) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis) (JJ Chinese) (NN herb)) (, ,) (NP (NNP Huqi) (NNP San))) |ET| |BS|554:D02.654.442.200 730:D08.811 788:H01.158.273.118.598.500|ES| 2:1 19:1 115:1 900:1 2006:1 2388:1 2760:1 2761:1 2762:1 2763:1 2764:1 2765:1 2766:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN mouse) (NN model) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis)) (, ,) (S (NP (NN rimonabant)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ aberrant) (NN crypt) (NN focus)) (PRN (-LRB- -LRB-) (NP (NN ACF)) (-RRB- -RRB-))) (NN formation)))) (, ,)) (VP (VBZ precedes) (NP (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 20:G03.495 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 824:C04.834.020|ES| 2:1 10:1 14:1 17:1 18:1 19:1 43:1 52:1 72:1 113:1 124:1 202:1 207:1 622:1 1431:1 1725:1 2533:1 2831:1 2913:1 2914:1 4318:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN mechanism) (NNS fibrates)) (VP (VBP induce) (NP (NN hepatocyte) (NN proliferation) (NN cholestasis)) (ADVP (RB still)) (VP (ADVP (RB fully)) (VBN understood)))) |ET| |BS|239:F02.463.188.357 262:A11.436.348 879:C06.130.120.135 1188:D02.241.081.114.968.500|ES| 2:1 19:1 162:1 243:1 299:1 622:1 776:1 889:1 979:1 1909:1 4130:1 4131:1
1 	|BT| (S (NP (NN N-acetyl-L-cysteine)) (VP (VBD blocked) (SBAR (S (NP (NN EGFR) (NN activation)) (VP (VBD reduced) (NP (JJ N-nitrosodiethylamine-initiated) (NN hepatocarcinogenesis) (NN level) (NNP Cre-Ctrl) (NN mouse))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 122:C14.280.383 554:D02.654.442.200 791:D02.886.030.230.259|ES| 19:1 52:1 187:1 225:1 249:1 452:1 900:1 2776:1 2777:1 2778:1 2779:1
1 	|BT| (S (NP (JJ Nonalcoholic) (NN steatohepatitis)) (VP (VBD induced) (SBAR (S (NP (JJ high-fat) (NN diet)) (VP (VBZ promotes) (NP (JJ diethylnitrosamine-initiated) (JJ early) (NN hepatocarcinogenesis) (NN rat))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 509:C06.552.241.519 554:D02.654.442.200 694:G07.203.650.240.267|ES| 19:1 298:1 412:1 849:1 900:1 1128:1 1791:1 2191:1 2507:1 4092:1 4319:1
1 	|BT| (S (NP (ADJP (RB Orally) (VBN administered)) (NN lycopene)) (VP (VBZ attenuates) (NP (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN rat)) (VP (VBG modulating) (NP (NP (NN Nrf-2)) (: /) (NP (NN HO-1) (NN Akt/mTOR) (NN pathway))))))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 378:D08.811.913.696.620.682.700.755 554:D02.654.442.200 799:D12.776.260.615.249 800:Z01.107.169.534|ES| 19:1 383:1 849:1 900:1 2336:1 2423:1 2435:1 2566:1 2732:1 2817:1 2818:1 2819:1
1 	|BT| (NP (NP (PRP$ Our) (S (VP (VBP result) (S (VP (VBP provide) (NP (NP (ADJP (NN clue) (JJ molecular)) (NN event)) (VP (VBN involved) (NP (NN mechanism) (NN action) (JJ HCB-induced) (NN hepatocarcinogenesis)))))))))) |ET| |BS|742:G03.787 1232:D02.455.426.559.389.261.400|ES| 19:1 101:1 161:1 162:1 205:1 658:1 711:1 774:1 900:1 1142:1 2013:1 4320:1
1 	|BT| (NP (PRP$ Our) (VP (VBP result) (NP (NP (NN show) (NNS HCCs)) (VP (VBG developing) (FRAG (X (SYM AOX)) (: -) (NP (NP (: /) (: -) (NN mouse) (NN share) (NN number)) (VP (VBN deregulated) (FRAG (-LRB- -LRB-) (NP (RP up) (: -) (VBN down-regulated) (-RRB- -RRB-) (NN gene) (JJ ciprofibrate-induced) (NN liver) (NN tumor)))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 142:I01.880.604 351:A17.360 515:C04.588.274.623|ES| 7:1 9:1 10:1 14:1 19:1 52:1 101:1 429:1 590:1 646:1 658:1 836:1 1132:1 1283:1 1965:1 4321:1 4322:1 4323:1 4324:1
1 	|BT| (S (NP (JJ Overall) (NN finding)) (VP (VBP substantiate) (SBAR (S (NP (NN artesunate)) (VP (VBZ promotes) (SBAR (S (NP (JJ anti-tumour) (, ,) (JJ anti-proliferation) (NN apoptosis) (NN nitrosodiethylamine)) (VP (VBD mediated) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|8:C04 39:G04.299.139.160 104:C04.557.470.200.025.255 554:D02.654.442.200 696:V02.270.500|ES| 2:1 19:1 89:1 298:1 303:1 304:1 437:1 927:1 2434:1 2858:1 2859:1 2860:1 2861:1 2862:1
1 	|BT| (S (NP (NP (NN Overdose) (NN acetaminophen)) (PRN (-LRB- -LRB-) (NP (NN APAP)) (-RRB- -RRB-))) (VP (VBP cause) (NP (NN liver) (NN injury) (JJ human) (NN animal)))) |ET| |BS|19:B01.050 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 242:A03.620 661:D02.065.199.092.040 1233:C25.775.383|ES| 10:1 14:1 19:1 36:1 46:1 836:1 1779:1 2412:1 2416:1 4193:1 4325:1
1 	|BT| (NP (NP (NP (JJ Partial) (JJ hepatectomized) (NN rat)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (QP (CD 11) (CD 12))))) (-RRB- -RRB-))) (VP (VBN fed) (NP (NN diet) (VP (VBG containing) (S (CD 0) (, ,) (NP (CD 0.03) (, ,) (CD 0.06) (, ,) (CD 0.125) (ADJP (CD 0.25) (NN %)) (NN BNF)) (NP (NP (CD 6) (NN week) (JJ intraperitoneal) (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP initiate) (NP (NN hepatocarcinogenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 554:D02.654.442.200 595:G07.203.650.240 663:C16.320.565.398.500.330.500 917:E02.319.267.530.490|ES| 2:1 10:1 14:1 19:1 286:1 369:1 580:1 581:1 783:1 785:1 849:1 900:1 1057:1 1120:1 1875:1 2191:1 2426:1 3230:1 3231:1 3529:1 3595:1 4037:1 4093:1 4163:1 4326:1 4327:1 4328:1 4329:1 4330:1
